{"title": "PDF", "author": "PDF", "url": "www.idipaz.es/ficheros/files/prensa/IdiPAZ%20Scientific%20Report%202018.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Scientific Report Scientific Report Index 2 1 2 3 4 3 1 2 3 4 5 6 13 23 27 40 43 68 95 106 108 110 111 1 2 3 4 113 114 135 161 212 278 327 1 2 3 4 351 Introd uction Executive summary Information Groups by Area Associated Clinicians2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe Institutional Projects 2.11 Internationalization 2.12 3.2 Cardiovascular Area 3.3 Infectious Diseases and Immunity Area 3.4 Large System Pathologies Area 3.5 Cancer and Human Molecular Genetics Area 3.6 Surgery, Transplant and Health Technologies AreaScientific Report 1 2 3 4Executive summary 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians3 3Information Groups by Area 1Introduction 2 Executive summary Associated Clinicians 4 Dr. Eduardo L\u00f3pez-Collazo Scientific Director of IdiPAZ Dr. Rafael P\u00e9rez-Santamarina Feij\u00f3o Managing Director of HULP Chairman of the Board of FIBHULPThe Hospital La Paz Institute for Health Research (Instituto de Investi - gaci\u00f3n Sanitaria del Hospital Universitario La Paz)-IdiPAZ was created in 2009, as a result of the relationship that has been forged over the years between La Paz University Hospital (HULP), the Autonomous University of Madrid (UAM), and the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP). Recently, we have incorporated Fuenla - brada University Hospital to our structure, and we are also very excited with the upcoming incorporation of Getafe University Hospital and the European University of Madrid. Since its establishment, IdiPAZ has promoted the configuration several facets of translational re - search, with the mind always focused on the generation of innovation and the transfer of results to the healthcare system. Over the years, we have maintained a progressive growth of our scientific activity, which is organi - zed into six research areas: neurosciences, cardiovascular, infectious disea - ses and immunity, cancer and human molecular genetics and transplants and health technologies. The increasing scientific contributions performed by our research groups over the last years have placed IdiPAZ amongst the top three health research Institutes with the best scientific evaluation of Spain. The Scientific Report of IdiPAZ provides us an opportunity to recognize these achievements of our researchers, and reflects the effort of the 55 research groups that currently constitute IdiPAZ, as well as the associated position in clinical research is evidenced by its scien - tific performance figures. Particularly regarding scientific production, we published more than 1,200 articles in 2018, of which 928 were original papers. In addition, the overall impact factor reached almost 5,600 points, exceeding for the first time the 5,000 points threshold. There has been also a consolidation in the quality of the source journals, and more than 514 of the manuscripts were published in journals in the first quartile of their subject area. 2018 Scientific Report 1 2 3 4Introduction4 1 2 3 4Executive summary 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe 2018 Scientific Report also shows data reflecting the com - mitment of IdiPAZ to biomedical research training. The involve - ment of the university in most of the research groups has resul - ted in a high participation in graduate programs, generating 34 Doctoral Theses in 2018; 5 of them being qualified with an In - ternational Mention. Additionally, in our attempt to promoting research and science in the society, we hosted many scientific activities as: the European Researchers' Night, the Science and Innovation Week, the International Day of Woman and Girl in Science, and other several events of scientific dissemination, all organized with the aim of actively involving citizens in science, technology and innovation, contributing gender effort to promote IdiPAZ brand and collaborations both national and For in workshops relationships with new partners to increase our visibility and current potential, while improving our the taking the aspects. our innovation we must highlight the fact that at December 31 2018, our Innovation Support Unit (UAI) had 184 innovation projects or ideas in active state, 26 of which were in the capture phase, 65 in the evaluation phase, 12 in development, 49 in transfer and 32 in the market. IdiPAZ researchers and groups work in research involve we done an effort to continue and improve our translational research with a direct application to the care of our patients; and in this strategic process, 371 new contracts for clinical trials were signed in 2018. The excellence of our research institute is based on the cons - tant struggle of our human capital to improve patient's health; therefore, we would like to enable IdiPAZ to continue advancing towards a promising future. There have been many achievements and we are con - fident that we will achieve many more. Our human potential and desire to continue progressing represent the best guaran - tee of continued We are especially grateful to all our researchers, members of the Governing Council, the Executive Committee, Board, the and all the professionals involved in the day-to-day work of the Institute, for the magnificent performed work during these years and the achieved results. In we celebrating the 10th IdiPAZ, thus it represents a pretty special occasion to show and dissemi - nate our strengths and the achievements we have accomplis - hed over this decade. Proudly, we can show to the scientific community and the civilian society all those merits that have allowed our Institution to be national and internationally re - cognized as a Center of Excellence, and be on a par with the best scientific institutes worldwide. Hospital Universitario La Paz Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Scientific Report 1 2 3 4Introduction 3 Information Groups by Area 1Introduction 2 Executive summary Associated Clinicians 45 1 2 3 4Information Groups by Area 1 2 3 4 Associated Cell 2.11 Internationalization Communication 2.2 Research 2.3 Committee 2.3.2 Courses 2.1.1 Scientific Analysis 2.1.2 Annual Accounts 2.8 Scientific Production 2.8.1 Journal Analysis 2.8.2 High Impact PublicationsScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 6 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.1 Global Analysis In 2018, the scientific production of IdiPAZ inclu - ded more than 1,200 publications that reached, for the first time, almost 5,600 points of total im - pact factor. Of the total of publications, 46.7% are documents belong to IdiPAZ, so the author the first, the last or the corresponding author of the publication is a researcher Scientific AnalysisScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 7 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.1 Global Analysis In 2018, the scientific production of IdiPAZ included more than 1,200 publications that reached, for the first time, almost 5,600 points of total impact factor. Of the total publi - cations, 46.7% are documents belong to IdiPAZ, so author the first, the last or the corresponding author of the publication is a researcher of the institute. TOTAL IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018 MEAN IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 8 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.1 Global Analysis 2.1 Global Analysis Considering originals published by IdiPAZ researchers, 928 articles, we keep the trend of the last years, exceeding the 4,000-point threshold (4,360.7 points). Moreover, about 18% of the originals published in this year were in first-decile journals of their subject area, journals. IdiPAZ evidenced their participation in national and international scientific networks, with near 85% of the total documents published in collaboration, which 88.6% of the originals collaboration, for all manuscripts and for originals. TOTAL IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018MEAN IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018 PAPERS WITH INTERNTATIONAL COLLABORATION BETWEEN 2009-2018 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 9 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.1 Global Analysis 2.1 Global Analysis IdiPAZ researchers evidenced their participation in national and international scientific networks, with near 85% of the total documents published in collaboration, which 88.6% of the originals publications. In addition, IdiPAZ - percentage of intramural collaboration, originals. OWNED BETWEEN 2009-2018 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 10 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.1.2 Annual Accounts2.1 Global Analysis 2.1 Global Analysis In accordance with the Law 19/2013, of December 9th, of transparency, access to public information and good governance, the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) makes their information public, with the objective http://www.idipaz.es/PaginaDinamica.aspx?IdPag=550&Lang=ES In 2018, the FIBHULP received a Nominative Grant of the Consejer\u00eda de Sanidad de la Comunidad de Madrid in favor of charging the 312D program \"Biomedical Research Foundations\", to fund the and personal of support of the I3, I3SNS, Miguel Servet II and Juan Rod\u00e9s Programs. of health professionals. scientific cul- ture. Accreditations of the research activity. Support to the T echnical Units or Platforms for Research and Mana - gement I+D+i.ECONOMIC INCOME 2018 ECONOMIC INCOME OVERHEAD- 2018 Economic 2018 Summary Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 11 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.1 Global Analysis 2.1 Global Analysis Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 12 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.1 Global Analysis 2.1 Global Analysis Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 13 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure Scientific Director Eduardo L\u00f3pez-Collazo Scientific Assistant Director Ignacio Zapardiel Guti\u00e9rrez Technical Assistant Director Paloma G\u00f3mez Campelo Executive Committee Chairman Rafael Feij\u00f3o. Chairman of the of FIBHULP; permanent delegation to Rodolfo \u00c1lvarez-Sala Walther Members Juan Antonio Vargas N\u00fa\u00f1ez. Dean of UAM Medical School Eduardo L\u00f3pez-Collazo. Scientific Director IdiPAZ Francisco Garc\u00eda R\u00edo. HULP Representative Francisco Arnalich Fern\u00e1ndez. UAM Representative Secretary Ana Coloma Zapatero. Director of FIBHULPGoverning Council Chairman Ana D\u00e1vila-Ponce de Le\u00f3n Mundo. Health Care Vice Councillor CM Deputy Chairman Rafael Garesse Alarc\u00f3n. Chancelor of UAM Rafael Feij\u00f3o. the Board of FIBHULP \u00c1lvarez-Sala Walther. FIBHULP Patron T eresa Chavarr\u00eda Gim\u00e9nez. FIBHULP Patron Jos\u00e9 Mar\u00eda Mu\u00f1oz y Ram\u00f3n. FIBHULP Patron Juan Antonio Vargas N\u00fa\u00f1ez. FIBHULP Patron Eduardo L\u00f3pez-Collazo. Scientific Director of IdiPAZ Almudena Castro Conde. FIBHULP Patron Exuperio D\u00edez T ejedor. FIBHULP Patron Fernando Rodr\u00edguez Artalejo. UAM Representative Amparo Cano Garc\u00eda. UAM Representative Francisco Javier Garc\u00eda-Samaniego Rey. FIBHULP Patron Secretary Ana Coloma Zapatero. Director of FIBHULP Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 14 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure External Scientific Committee Juan Tamargo Men\u00e9ndez. Professor. of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- Complutense University of Madrid. Madrid Reiner Albert Veitia. Professor G\u00e9nomique fonctionnelle Universit\u00e9 Denis Diderot, Paris the Molecular Oncology and Ovarian Pathologies, l'Institut Jacques Monod. Paris Joaqu\u00edn Arribas L\u00f3pez. Principal investigator. Vall d\u00b4Hebron Hospital. Barcelona Jacinta Cecilia Bustamante. Associate Professor. Paris Descartes Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris Carlos Belmonte Mart\u00ednez. Professor. Miguel Hern\u00e1ndez University. Institute of Neuroscienciences. Alicante Isabel Fabregat Romero. Centre d\u00b4Oncologia Molecular. L\u00b4Hospitalet, IDIBELL- Bellvitge Biomedical Research Institute. Barcelona Carmen Maroto Vela. Professor. Chief of Microbiology. Clinical Hospital University of Granada. Granada Santiago Moreno Guill\u00e9n. Chief of Infectious diseases Service. Ram\u00f3n y Cajal Hospital. Professor. Alcal\u00e1 University. Madrid Juan Pedro Bola\u00f1os Hern\u00e1ndez. Departament of Biochemistry and Molecular Biology. University of Salmanca. Institute of Functional Biology and Genomics. Salamanca. Santiago Rodr\u00edguez de C\u00f3rdoba. Professor. Cellular and Molecular Medicine Department. Center of Biological Research. CSIC. Madrid Governing Council Chairman Eduardo L\u00f3pez Collazo, Scientific Director Secretary Inmaculada Ib\u00e1\u00f1ez de C\u00e1ceres. Jonay Ojeda Feo, Comitee Paloma G\u00f3mez Campelo Ignacio Zapardiel Guti\u00e9rrez HULP representatives Francisco Garc\u00eda R\u00edo Antonio P\u00e9rez Mart\u00ednez Jaime Feliu Batlle Jos\u00e9 Luis Merino Mar\u00eda Guti\u00e9rrez Fern\u00e1ndez Nuria Vilaboa D\u00edaz Nora Butta Coll Blanca Fuentes Gimeno Inmaculada Ib\u00e1\u00f1ez de C\u00e1ceres Mar\u00eda Auxiliadora Bajo Rosario Perona Abell\u00f3n UAM representatives Amparo Cano Garc\u00eda Guillermo Reglero Rada Fernando Rodr\u00edguez Artalejo Mercedes Salaices S\u00e1nchez Francisco Arnalich Fern\u00e1ndez Bel\u00e9n P\u00e9rez Gonz\u00e1lez in training representatives PhD: Alejandro Mart\u00edn Quir\u00f3s Predoctoral: Karla Marina Montalb\u00e1n Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 15 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure Research Ethics Committee President Almudena Castro Conde. Head of Section of Cardiology Department Vicepresesident Jes\u00fas Fr\u00edas Iniesta. Head Department. of Research Committee Technical of the Secretary Members Jos\u00e9 Manuel A\u00f1\u00f3n Elizalde. Head of Section of Intensive Medicine Department Jos\u00e9 Ignacio Bernardino de la Serna. Assistant Physician-Internal Medicine Department Antonio Bu\u00f1o Soto. Head of Clinical Laboratory Department Nora Butta Coll. Head of Research Laboratory of Coagulopathies and Alterations of Haemostasis. Researcher of the IdiPAZ Fernando Caba\u00f1as Gonz\u00e1lez. Head of Pediatrics and Neonatology. Quiron Salud Madrid University Hospital. Researcher of the IdiPAZ Filiberto Chuli\u00e1 Fern\u00e1ndez. Lawyer, Head of the legal Department Mariana D\u00edaz Almiron. Data analyst. Biostatistics Platform Representative Department Filomena Trocoli Gonz\u00e1lez. Elena Villama\u00f1\u00e1n Gracia Garc\u00eda. Assistant Mar\u00eda Isabel Arribas \u00c1lvarez. Administrative Animal Welfare Organ Carmen Fern\u00e1ndez Criado. Director of the Veterinary Office of the Faculty of Medicine of the UAM. Specialist in Animal Health and Welfare as an external Internal of the animal Service HULP Experimental Surgery Specialist in Animal Coordinator Jos\u00e9 Jonay Ojeda Feo Members Blanca Fuentes Gimeno Alberto Mart\u00edn Vega Mar\u00eda Luisa D\u00edaz Mart\u00ednez Margarita Rodrigo Angulo Gema Vall\u00e9s P\u00e9rez Paloma G\u00f3mez Campelo Mar\u00eda Dolores P\u00e9rez Garre Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 16 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Training Committee Coordinator B\u00e1rbara Mart\u00ednez de Miguel Members Ana Mar\u00eda Briones Alonso Mar\u00eda Fern\u00e1ndez Velasco Juli\u00e1n Nevado Blanco Alejandro Mart\u00edn Quir\u00f3s Alberto Borobia P\u00e9rez Paloma G\u00f3mez Campelo Inmaculada Ib\u00e1\u00f1ez de C\u00e1ceres Beatriz Vila Cordero Mar\u00eda Isabel S\u00e1nchez P\u00e9rez Roc\u00edo Rosas Alonso V\u00edctor Manuel T oledano Real Mercedes Ruiz Balibrea Luc\u00eda Medina Royo Silvia G\u00f3mez Senent Pilar S\u00e1nchez-Corral G\u00f3mez Equality and Diversity Committee Members Mar\u00eda Quintanar Jaime Paloma G\u00f3mez Campelo Nora Butta Coll Francisco Gil Gadea Jos\u00e9 Avenda\u00f1o Ortiz Technical Secretary Mercedes Ruiz Balibrea Lucia Medina Royo Documentation Service Ra\u00fal Rom\u00e1n Ca\u00f1izaresFIBHULP Director Ana Coloma Zapatero Human Reesources Manager Head: Ana Gloria Herrera Puerta Mar\u00eda Quintanar Jaime Private Projects Manager Head: Francisco Gil Gadea Nathalia Garc\u00eda Quero Clinical Trial Manager Head: Sara Moral \u00c1lamo Desir\u00e9e Hern\u00e1ndez L\u00f3pez Public Projects Manager Head: Silvia Arce Santamar\u00eda Raquel Carmona del Mazo Institutional Projects Manager Jos\u00e9 Luis Narro Villanueva Marisa T ejedor BotelloInternational Projects Manager Santiago Rello Varona Marta Mar\u00edn Barba Contracting Manager and Head of Legal Department Sara Fern\u00e1ndez Morata Accountants: Head: Laura L\u00f3pez Revuelta M\u00f3nica Garc\u00eda L\u00f3pez Researcher Reception and Attention Carmen Garc\u00eda Artiaga2.2 Research Structure Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 17 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Neuroscience Area GROUP DIRECTOR Psychiatry and Mental Health Consuelo de Dios Perrino Neurology and Diseases Exuperio D\u00edez in CentralNervous System PathologiesFrancisco Zafra G\u00f3mezCoordinator: Exuperio D\u00edez Tejedor Cardiovascular Area GROUP DIRECTOR on Clinical Cardiology - ICCI-PazJos\u00e9 of V\u00edctor Jim\u00e9nez Yuste Vascular Pharmacology Mercedes Salaices S\u00e1nchez Vascular Pharmacology and Metabolism (FARMAVSM) Carlos F. S\u00e1nchez Ferrer Cardiolog\u00eda HUFAlejandro L\u00f3pez-Send\u00f3n Hentschel2.2 Research and Human Molecular Genetics Area Pathology AreaNeuroscience AreaScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 18 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure Large System Pathology Area GROUP Diseases F\u00e9rnandez Organic Dysfunction and Failure in Aggression Abelardo Garc\u00eda de Lorenzo y Mateos Respiratory Diseases Francisco Garc\u00eda R\u00edo Regulation of Gene Expression and by Hypoxia Luis del Peso Ovalle Nephrology Rafael Selgas Guti\u00e9rrez Neonatology Adelina Pellicer Mart\u00ednez Aging and Fragility in the ElderlyJuan Ignacio Gonz\u00e1lez Montalvo Molecular Hepatology Paloma Jara Vega Diagnosis and Treatment of Allergic Diseases Santiago Quirce Gancedo Gynecologic Oncology Ignacio Zapardiel Guti\u00e9rrez Patient Blood Management Manuel Quintana D\u00edaz Endocrine Diseases Lucrecia Herranz de la Morena Urology Luis Mart\u00ednez-Pi\u00f1eiro Lorenzo Health Care Nurses Research Jes\u00fas Castro Toro Maternal and Fetal Medicine Jos\u00e9 Luis Bartha Rasero Emergency and Critical Pathology Alejandro Mart\u00edn Quir\u00f3sCoordinator: Francisco Garc\u00eda R\u00edoInfectious and Immunity Area GROUP DIRECTOR AIDS and Infectious Diseases Jos\u00e9 Ram\u00f3n Arribas L\u00f3pez Molecular Therapy P\u00e9rez Intestinales HUFFernando Bermejo San Jos\u00e9 Coordinator: Eduardo L\u00f3pez-CollazoScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 19 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure Surgery, Transplant and Health Technologies Area GROUP DIRECTOR Congenital Leopoldo Mart\u00ednez Cellular Jes\u00fas Osteoarticular Luis Rehabilitaci\u00f3n HUFJuan Carlos Miangolarra PageCoordinator: Leopoldo Mart\u00ednez Mart\u00ednezCancer and Human Molecular Genetics Area GROUP DIRECTOR INGEMM- Institute of Medical and Molecular Genetics Pablo Lapunzina Inmaculada Ib\u00e1\u00f1ez de C\u00e1ceres and Cell Models for Detection and Characterization of Leukemic Stem and of Function by Phosphoinositides Francesc Oncolog\u00eda HUF Manuel Hidalgo MedinaCoordinator: Amparo Cano Garc\u00edaScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 20 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure PUBLIC RESEARCH CONTRACTS Ram\u00f3n y (I3) - CM Karen Elise Heath. INGEMM - Institute of Medical and Molecular Genetics Group Jes\u00fas Mingorance Cruz. Molecular Microbiology Group Rebeca P\u00e9rez de Diego. Innate Response Group Fresno Vara. Translational Oncology Group \u00c1ngel Campos Barros. INGEMM - Institute of Medical and Molecular Genetics Group Mar\u00eda Paz de Miguel Gonz\u00e1lez. Cellular Engineering Group Eduardo L\u00f3pez-Collazo. Innate Immune Response Group Juan Rey Herranz. Group Berta Rod\u00e9s Soldevila. AIDS and Infectious Diseases Group Pilar S\u00e1nchez-Corral G\u00f3mez. Diagnosis and Treatment of Diseases Associated with Abnor - malities of the Complement System Group Mar\u00eda Rosa T orres Jim\u00e9nez. Metabolic-Vascular Unit Group David Vicent L\u00f3pez. Molecular Hepatology Group Nuria Vilaboa D\u00edaz. Bone Pathophysiology Coagulopathies and Alterations of Haemostasis Group Mar\u00eda Ib\u00e1\u00f1ez de C\u00e1ceres. Experimental Therapies and Biomarkers in Cancer Group Rosa Mar\u00eda Rodr\u00edguez P\u00e9rez. Diagnosis and Treatment of Allergic Diseases Group Miguel Servet Contracts Type I - ISCIII Mar\u00eda Dolores Guti\u00e9rrez Fern\u00e1ndez (MS15/00069). Neurology and Cerebrovascular Diseases Group Carolina Cubillos Zapata (MS18/00208). Respiratory Diseases Group Miguel Servet Contracts Type Ram\u00f3n Arribas L\u00f3pez. AIDS and Rosa Guti\u00e9rrez 2020. European Union Elie Dahdouh. Molecular Microbiology Group Juan de la Cierva Contracts - Ministry of Science, Innovation and Universities Laura Otero Ortega (IJCI-2017-33505). Neurology and Cerebrovascular Cantos (FI17/00192). AIDS and Infectious Diseases Group Mar\u00eda del Carmen G\u00f3mez de Frutos (FI17/00188). Neurology and Cerebrovascular Diseases Group Fernando Laso Garc\u00eda (FI18/00026). Neurology and Cerebrovascular Diseases Group Predoctoral Contract - Ministry Science, Innovation and Universities Francisca D\u00edaz Gonz\u00e1lez (FPU17/04055). INGEMM - Institute of Medical and Molecular Genetics 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 21 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.2 Research Structure Bioinformatics Technician Sol\u00eds (CA18/00033). INGEMM - Institute of Medical and Molecular Genetics Youth Guarantee Contracts - CM Graduate Alba Pinto Garc\u00eda (PEJ-2017-AI/SAL-5716). Psychiatry and Mental Health Predoctoral Marta Cadenas Mart\u00edn (PEJD-2018-PRE/BMD-8872). Cellular Engineering Group Paramio (PEJD-2018-PRE/BMD-7965). Health Technical Support Virginia Rufo Rabad\u00e1n (PEJ-2017-TL/BMD-6201). INGEMM - Institute of Me - dical and Molecular Genetics Sonia Jim\u00e9nez Rodr\u00edguez (PEJ-2017-TL/BMD-6939). Molecular Microbiology Group C\u00e9sar V\u00e9lez Casanova (PEJ-2017-TL/BMD-6873). Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Artur Mart\u00edn Franklin (PEJ-2017-TL/BMD-5831). AIDS and Infectious Diseases Programme Organisation Total Ram\u00f3n CM 3 Miguel Servet T echnical Support CM 3 TOTAL ESTABLISHED 20 Miguel Servet Contracts CP Type 1 ISCIII 2 Miguel Servet Contracts CP ISCIII 2 Marie Skodowska-Curie Actions EU 1 Juan de ContractsMinistry and 1 Y TOTAL 50 Plattforms ISCIII 7 FIS Projects ISCIII 9 European Projects EU 9 Research Network ISCIII 6 Research Network CM 5 SAF/MAT MINECO 1 Commercial clinical trials EECC Promoters 36 Private Pharmaceutical Industry 67 In-house Projects FIBHULP 6 RETOS MINECO 3 Spin-off CM 1 TOTAL EMPLOYEES DEPENDET ON RESEARCH PROJECTS 150 Private projects Pharmaceutical Industry 10 TOTAL FELLOWS DEPENDET ON RESEARCH PROJECTS 10 TOTAL STAFF DEPENDENT ON RESEACRH PROJECTS 160 T echnical Unit Staff FIBHULP 15 TOTAL TECHNICAL UNIT 15 TOTAL 225Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 22 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians RESEARCHER PROFILE This researchers in this Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 23 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.3 Training Report and Teaching 2.3.1 Training Committee One of the main priorities of IdiPAZ Research Institute is to encourage and develop training programs for researchers, with special attention to the scientific training in research methodology. IdiPAZ's Training Committee is responsible for designing, planning and evaluating the training ac - tivities given by the Institute, as well as ensuring the development of a global Training Plan that meets the proposed objectives. The main objective of IdiPAZ's Training Committee is to draw up, promote and evaluate the training plan, aimed at maintaining or different structures of IdiPAZ and guarantees the representation of all the different types of IdiPAZ members, as well as the correct coordi - nation between all the training activities that make up the plan. IdiPAZ's Training Plan includes the HULP training offer, the UAM offer and the implementation of the Institute's own training offer in line with its strategic objectives and linked to the detection of new training needs not covered by the existing training offers from each of those entities. The objective of the Institute's own training offer is to complement the training provided by both HULP and UAM. The design of the plan includes, as origin and addressees, healthcare professionals with research activity as of training arises as a result of communication with area coordinators and group directors, analysis the Needs As - sessment Surveys submitted by members of the Institute, reception proposals suggestions proposals made within the Continuing Medical Training Committee that meet the requirements of interest in research, analysis of new training proposals by IdiPAZ'S Training Committee itself and other study techniques. Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 24 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.3 Training Report and Teaching Adapting Researh Areas Area Coordinators Research Groups Groups Director Aimed at basic and clinical researchesResearch Area activities Title Hours Curso de ingl\u00e9s cient\u00edfico Sim\u00f3n Bartlett13th-16th november 15 12 An\u00e1lisis de datos biom\u00e9dicos con SPSS: Nivel b\u00e1sicoRosario Madero Jarabo21st-24th may21 12 Investigaci\u00f3n cl\u00ednica y lectura cr\u00edtica. B\u00fasqueda y recuperaci\u00f3n de la literatura cient\u00edficaJuan Jos\u00e9 R\u00edos Blanco10th-13th december- 12Title de C\u00e1ceres 13th november Antonio P\u00e9rez Mart\u00ednez 16th november Eduardo L\u00f3pez Collazo Al otro lado del laboratorio: Jornada de puertas abiertas y visita guiada al edificio IdiPAZ y los laboratorios8th november Gema Vall\u00e9s P\u00e9rez V\u00edctor Toledano Real Mar\u00eda Teresa Vallejo Cremades Irene Cuevas Gordo13th november 16tth november Ven a conocer la gen\u00e9tica del futuro: Jornada de puertas abiertas y visita guiada al Instituto de Gen\u00e9tica del Hospital Universitario La Paz-INGEMM6th november Juli\u00e1n Nevado Blanco 13th november Jornada de puertas abiertas y visita guiada a la UCICEC y Biobanco15th novemberAlberto Borobia P\u00e9rez Paloma G\u00f3mez Campelo Marina Arranz \u00c1lvarez Jornada de puertas abiertas al laboratorio de Microbiolog\u00eda y charla con el investigador Elie Dahdouh16th november Elie Dahdouh Impresi\u00f3n 3D en el \u00e1mbito hospitalario: Plataforma de Ingenier\u00eda Tisular e Impresi\u00f3n 3D (PITI3D)15th novemberDaniel Cerme\u00f1o Pampliega Carlos Biec Amigo Mario Ju\u00e1rez Rodr\u00edguez D\u00eda Internacional de la Mujer y la Ni\u00f1a en la ciencia Fast Meeting: 5 cient\u00edficas en investigaci\u00f3n11th febraryInmaculada Ib\u00e1\u00f1ez de C\u00e1ceres, Dolores Diestro Tejada \u00c1ngela del Pozo Mat\u00e9 Dolores P\u00e9rez Garr\u00e9 Olga Vera PuenteScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 25 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.3 Training Report and una Universidad Aut\u00f3noma de Madrid: 2018(21/06/2018). Directors: Cachafeiro S\u00e1nchez SM . Estructura-funci\u00f3n del transportador neuronal de glicina GlyT2:localizaci\u00f3n del inhibici\u00f3n[dissertation]. Madrid: de Madrid: 2018(30/11/2018). Director: L\u00f3pez Corcuera B Bravo Lubjetic L . Experiencia en el manejo del rabdomiosarcoma orbitario en el hospital universitario La Paz, 1982-2015[dissertation]. Madrid: 2018(15/06/2018). Director: Peralta Calvo J Celaya Pu\u00e9rtolas A . Papel del IGF-1 en la protecci\u00f3n frente a la p\u00e9rdida auditiva inducida por el ruido [dissertation]. Madrid: UAM: 2018(12/11/2018). Director: Varela Nieto I Chinea B. Importancia de la leche humana y sus caracter\u00edsticas nutricionales. Efec - tos a corto, medio y largo plazo[dissertation]. Madrid: UCM: 2018(21/03/2018). Director: Saenz Pipaon Marcos M Corral S\u00e1nchez D . Producci\u00f3n de c\u00e9lulas Natural Killer activadas con inter - lequina-15 para uso cl\u00ednico en pacientes pedi\u00e1tricos con c\u00e1ncer[dissertation]. Madrid: UAM: 2018(22/10/2018). Director: P\u00e9rez Mart\u00ednez A Corvillo Rodr\u00edguez F. Estudio de los mecanismos inmunopatol\u00f3gicos en li - podistrofias adquiridas de tipo parcial y generalizado[dissertation]. Madrid: UAM: 2018(22/06/2018). Director: L\u00f3pez Trascasa M Cruz Castellanos P . Expresi\u00f3n de genes relacionados con la angiog\u00e9nesis como predictores de respuesta al tratamiento combinado (cirug\u00eda y quimio - terapia) en el carcinoma de ovario seroso de alto grado[dissertation]. Madrid: UAM: 2018(19/12/2018). Directors: Mendiola Sabio Francisco Recuero I . Papel de la Aurora quinasa B en la regulaci\u00f3n epige - n\u00e9tica inducida por el virus Sacoto MA . Diabetes gestacional en embarazos m\u00faltiples. Impacto del control metab\u00f3lico materno para el feto. S\u00edndrome metab\u00f3lico y alte - raci\u00f3n de l metabolismo hidro carbonado materno postparto[dissertation]. Madrid: UAM: 2018 (04/04/2018). Director: Herranz de la Morena L Hern\u00e1ndez Oliveros F . Estudio cl\u00ednico experimental del papel del bazo en la prevenci\u00f3n de la enfermedad de injerto contra hu\u00e9sped en el trasplante Isidoro Garc\u00eda L . esteroides sexuales masculinos[dissertation]. Madrid: UAM/UNAM: 2018(17/05/2018). Directors: Role of proteases implicated in the lysosomal pathway I . Indicios de sensibilizaci\u00f3n central en el dolor cr\u00f3nico inespec\u00edfico de cuello con caracter\u00edsticas neurop\u00e1ticas[dissertation]. Madrid: URJC: 2018(27/06/2018). Directors: Fern\u00e1ndez Carnero J; La T ouche Arbizu R Mart\u00ednez del Prado MP . Valor pron\u00f3stico del an\u00e1lisis de marcadores mole - culares mediante prote\u00f3mica dirigida en c\u00e1ncer de mama S . Eficacia de la toxina botul\u00ednica A en el tratamiento de la par\u00e1lisis facial perif\u00e9rica. Comparaci\u00f3n de diferentes escalas en la evaluaci\u00f3n de facial[dissertation]. Madrid: UAM: summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 26 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.3 Training Report and Teaching Moreno Fern\u00e1ndez S . Efecto de un hidrolizado de prote\u00ednas de clara de hue - vo en un modelo de obesidad inducido por dieta. Evaluaci\u00f3n de su eficacia y seguridad en humanos [dissertation]. Madrid: Universidad Aut\u00f3noma de Madrid: 2018(23/10/2018). Garc\u00e9s M Munayco S\u00e1nchez AJ . Gesti\u00f3n de Hospitales de Campa\u00f1a (Cirug\u00eda de Control de Da\u00f1os) para desplazados internos en un teatro de operacio - nes b\u00e9lico. Despliegue y activaci\u00f3n bajo el fuego[dissertation]. Madrid: UAM: 2018(26/10/2018). Directors: Quintana 2018(19/10/2018). Director: Cuadrado Pastor A Pardo Rovira P . Valor pron\u00f3stico de la reversibilidad bronquial en pulmonar obstructiva Director: Garc\u00eda PA . Utilidad de la ecograf\u00eda con contraste en la locali - zaci\u00f3n de lesiones Rubio Caballero C . Changes in gut A Ru\u00edz P\u00e9rez D . Atenuaci\u00f3n del rechazo inmunitario con c\u00e9lulas madre mesen - quimales derivadas de tejido adiposo en un modelo experimental murino de trasplante de pulm\u00f3n[dissertation]. Madrid: UCM: 2018(10/12/2018). Directors: Garc\u00eda R\u00edo F , Largo Aramburu C, \u00c1lvarez G\u00f3mez de Segura I Silva Obreg\u00f3n JA . Fragilidad como predictor de mortalidad en ancianos ingresados en UCI por patolog\u00eda m\u00e9dica. Modelo predictor de mortalidad hospitalaria[dissertation]. Madrid: UAM: 2018(20/12/2018). Directors: Quintana D\u00edaz M, Huerta \u00c1lvarez CTapia Serrano G . Seguridad del paciente neonatal en el uso de productos sanitarios relacionados con la alimentaci\u00f3n[dissertation]. Madrid: UCM: 2018(23/02/2018). Directors: Pacheco del Cerro E, Rivas Paterna AB Tung Chen Y . Utilidad de la ecograf\u00eda en el manejo de fluidos y la terapia de transfusi\u00f3n en la hemorragia digestiva en el \u00e1mbito de urgencias[dissertation]. Madrid: UAM: 2018(03/12/2018). Directors: Quintana D\u00edaz M, Blancas G\u00f3mez Casero R Utrilla Contreras MJ . Estudio de las c\u00e9lulas inmunocompetentes, macr\u00f3fagos, c\u00e9lulas cebadas, de la angiog\u00e9nesis y de la linfangiog\u00e9nesis en la piel de los nucleotide-binding oligomerization domain type I experimental heart failure[dissertation]. Madrid: UAM: 2019(11/01/2018). Director: Fern\u00e1ndez Velasco M Vega Mata N . Diagn\u00f3stico molecular de las anomal\u00edas vasculares cong\u00e9nitas y su repercusi\u00f3n terap\u00e9utica[dissertation]. Oviedo: Universidad de 2018(12/4/2018). L\u00f3pez Guti\u00e9rrez JC Vera Puente O . Regulaci\u00f3n epigen\u00e9tica de la expresi\u00f3n de ARNs no codifi - cantes y su implicaci\u00f3n en la respuesta terap\u00e9utica en c\u00e1ncer de pulm\u00f3n no microc\u00edtico y c\u00e1ncer de ovario[dissertation]. Madrid: UAM: Ferrer Parra M. Villar Lorenzo A . Papel del sustrato del receptor de la insulina 2 en la suscep - tibilidad al da\u00f1o colest\u00e1tico en el h\u00edgado[dissertation]. Aut\u00f3noma de Madrid: 2018(25/10/2018). Mart\u00ednez Valverde AScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 27 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.4 Innovation and Transfer Activities 2.4.1 Innovation and Transfer Activities The Innovation Support Unit (or Innovation Unit) of FIBHULP was created in June 2010 within the framework of the ITEMAS Network -currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting generated, as a step prior to its subsequent transfer to society. Therefore, one of the main commitments of the Innovation Unit is that researchers and health per - sonnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results. ACTIVITIES The main aim of the Innovation Support Unit is to identify the potential transferable research results gener ated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market. Since the Innovation Unit has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have and entrepreneurship within institute by fostering the gene - ration of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives. Actively searching and identifying knowledge and research results within the institute and transferable to the market. Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 28 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Promoting the participation of industry including technology companies as well as indus - trial and financial partners, to develop collaborative projects and to transfer the results to the market. Generating resources that achieve the greatest impact on society, enabling a bet - ter quality health care and at the same time contributing to the sustainability of the National Health System. Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform. In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Its impact in the Hospital has been stren - gthened by the creation of both the Innovation Platform and the Innovation Com - mittee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital's Management order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mis - sion of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. - tion Committee, a decision-making body on the ideas be supported by FIBHULP . Among the greatest achievements of the Innovation Support Unit are the following: 1. The UAI has become one of IdiPAZ's most in-demand and requested plat - as it is responsible for promoting, supporting and managing all inno - vation projects. At December 31 2018, the UAI had 184 innovation projects or ideas in active sta - te, 26 of which were in the capture phase, 65 in the evaluation phase, 12 in develo - pment, 49 in transfer and 32 in the market. According to these data, it follows that 17% of the projects have been successfully exploited and positioned in the market, the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. Among the various types of projects handled by the UAI it is particularly noteworthy the volume of medical device-type pro Although the UAI has more than nine years of experience, most of the activity (157 projects) and its achievements have taken place in the last five years, period 2014-2018. 2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, re -search groups professionals in general who join IdiPAZ's innovation 2014-2018, the (13 Spanish pa - tents, 3 European patents and 1 US patent) and 15 PCT; 10 national or regional phase entry applications were filed (4 at the EPO, 4 at the USPTO and 2 at other patent offices) and 23 patents were granted (20 at the OEPM, 2 at the EPO and 1 at the USPTO). UAI's portfolio of patent families in active reached the of 46 patent families. As for the software, during the period 2014-2018 the UAI registered 18 new computer applications. Special mention should also be made to the UAI trademark portfolio. During the period 2014-2018, 17 trademark applications were filed and 15 were granted. It is important to note these IdiPAZ competitors' products or services, are asso - ciated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks. 3. The UAI has prepared a catalogue of technology offers -based on specifi - IdiPAZ This catalogue aims to promote the transfer IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for tech - nological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalo - gue is updated as the Institute's technology portfolio grows. 4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio. During the period 2014-2018 the succeeded in signing 35 license agreements of intellectual property rights (copyright). On the other hand, during the same period of time the UAI managed to achieve the following values in terms of transfer: patents, software, 16 trademarks in commercial exploi - tation, which meant a significant achievement in terms of economic return. 5. Thanks to UAI's support and management it has been possible to create and consolidate the first technology-based company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid. The spin-off concer - ned, Biomedica Molecular Medicine, exploits the research results in oncolo IdiPAZ. 2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 29 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year its promotional activity has \"La Paz la tridimensionalidad\" Workshop, June 12, 2018 \"La innovaci\u00f3n: un nuevo camino hacia la excelencia en La Paz\" Workshop, October 10, 2018 \"D\u00eda internacional de la mujer y la ni\u00f1a en la ciencia\" Workshop, February 11, 2018 Working meeting between the EPO and the Innovation Support Unit of Idi - PAZ, May 8, 2018 In addition, the UAI has collaborated with important institutions and private enti - ties The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in ITEMAS synergies with the its several by the Unit have been awarded with prestigious awards and aids over the last year: 2nd and 3rd Award obtained in the third edition of the Healthstart Program for two of our innovation projects: STENT -BAND project led by Rosario Ma - Jarabo, former Head of the Biostatistics Service at IdiPAZ; and OSTO - CUTTER project led by Paloma stoma therapy nurse at HULP . Healthstart is the program of the Madrimasd Knowledge Foundation (Madri+d Foundation) and the Medical T echnology Innovation Platform (ITE - MAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the acceleration of technological start-ups of the Community of Madrid in Aid intended to carry out Feasibility Studies granted by the Foundation for Health Innovation and Prospective in Spain (FIPSE) to one of our innovation projects. The innovation project is FACE MIRROR, and is led by Dr. Alfonso Gil Mart\u00ednez.ORGANISATION Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP , as one of the Support Platforms for IdiPAZ research. The Innovation Unit is directed by Dr. Javier de Castro Carpe\u00f1o, M.D. and Ph.D. in Medicine and a member of the Medical Oncology Department of the La Paz University Hospital/ Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ. The Innovation Unit also consists of a team of two experts in fostering innovation and protecting research results and technology transfer: Estela S\u00e1nchez Sim\u00f3n, Law Graduate; and Mar\u00eda Dolores P\u00e9rez Garre, Bachelor of Chemical Sciences. CONTACT Coordinator Javier de Castro Carpe\u00f1o javier.decastro@salud.madrid.org Phone: (+34) 91 34 Members Estela S\u00e1nchez Sim\u00f3n e_sanchez.innovacion@idipaz.es Phone: (+34) 91 207 12 34 Mar\u00eda Dolores maria.dolores.perez@idipaz.es Phone: (+34) 91 207 12 342.4 Innovation Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 30 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.4.2 Patents and trademarks Neuroscience Area Psychiatry and and Cerebrovascular Diseases Group Ballesteros Garc\u00eda P, L\u00f3pez Larrubia P, Dom\u00ednguez Mateo L, Marco Contelles JL, Cerd\u00e1n Garc\u00eda-Esteller S, inventors; Universidad Nacional de Educaci\u00f3n a Distancia, CSIC, assignees. Set of magnetic resonance Moreno prevention of infections and A, Ruh\u00ed Roura R, Montell Bonaventura E, Gar- c\u00eda L\u00f3pez M, J, Egea M\u00e1iquez UAM, assignees. Pastor Innamorato inventors: R, Ma\u00edquez J, Buend\u00eda Abaitua I, Parada P\u00e9rez E, Nava- rro Gonz\u00e1lez de Mesa E , inventors; Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17. Le\u00f3n Mart\u00ednez R, Buend\u00eda Abaitua I, Navarro Gonz\u00e1lez de Mesa E, Michalska P, Gameiro Ros I, L\u00f3pez Vivo A, Egea Ma\u00edquez J, Garc\u00eda L\u00f3pez M, Garc\u00eda Garc\u00eda A, inventors; Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and diseases. P201400810, PCT/ES2015/000139, October 24.2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 31 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansFilgueiras Rama D, L\u00f3pez de S\u00e1 y Areses E, Millet Roig J, Calvo Saiz CJ, in- ventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP , Universidad Polit\u00e9cnica de Valencia, prognosticating neurological performance in patients suffered a car - diac arrest M, Miguel Castro M, L\u00f3pez-Alonso Fandi\u00f1o R, L\u00f3pez-Miranda Gonz\u00e1lez V, Uranga Ocio J , inventors; CSIC, Universidad Rey Juan Carlos, as - signees; of multifunctional bioactive products derived 2013 December Castro M, P\u00e9rez de Vega MJ, Balsera-Paredes B, S Moreno Gonz\u00e1lez-Mu\u00f1iz R, P\u00e9rez de Vega MJ, Miguel M, Balsera-Paredes B, L\u00f3pez-Alonso Fandi\u00f1o R, Sandoval Huertas M Mario Huertas, assignees. Healthy gel or Fandi\u00f1o R, Ramos Gonz\u00e1lez MM, Aleixan- dre de Arti\u00f1ano A , inventors; CSIC, 2005 May 23. Miguel Castro M, L\u00f3pez-Alonso Fandi\u00f1o R, Recio S\u00e1nchez MI, Ramos Gon- z\u00e1lez de Arti\u00f1ano A , inventors; Bioactive pep - tides derived from proteins of egg white by MJ, de Luis Jim\u00e9nez O, P\u00e9rez Boto V, Sanz Gonz\u00e1lez R, Hern\u00e1ndez V\u00e9lez MC, Mas Guti\u00e9rrez JA, Alonso Gordo MJ, Sala\u00edces S\u00e1nchez M, Ros P\u00e9rez M, Coloma Jerez A, Asenjo Barahona A, Sanz Monta\u00f1a JL, Puente Prieto J, Jensen 05. Recio S\u00e1nchez MI; Quir\u00f3s del Bosque A, Hern\u00e1ndez Ledesma B, G\u00f3mez Ruiz JA, Miguel Castro M, Amigo Garrido L, L\u00f3pez Exp\u00f3sito I, Ramos Gonz\u00e1lez MM, Aleixandre de Arti\u00f1ano A, (Contreras G\u00f3mez M) , inventors; CSIC, assignee. Bio active of and Infectious Diseases Group M, Sol\u00e1 Lamoglia R, Gonz\u00e1lez Garc\u00eda JJ , inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundaci\u00f3 Institut Mar D'Investigacions M\u00e8diques, FIBHULP , assignees. Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21. Molecular Microbiology Group Vicente Mu\u00f1oz M, Mingorance Cruz J, Rueda Gonz\u00e1lez MS , inventors; CSIC, assignee. Method for determining cells. P200200370; 2002 February 15. Mingorance Cruz J, Cast\u00e1n Garc\u00eda P, Franco de Sarabia Rosado PM , inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assig - Composition, method and kit Mingorance Cruz J, Cast\u00e1n Garc\u00eda P, Franco de Sarabia Rosado PM , inventors; 2B BLACKBIO S.L., of sequencing. PCT/ES2010/000248; 2010 June 02. Immuno-Rheumatology Group Pascual-Salcedo Pascual MD, March 10. 2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 32 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansFern\u00e1ndez Luna JL, Mart\u00ednez Taboada VM, L\u00f3pez Hoyos M, Torices del Val S, Mu\u00f1oz Cacho P, Varela Egocheaga I, Juli\u00e1 Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP , Fundaci\u00f3n Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla, Servicio C\u00e1ntabro de Salud, Universidad de Cantabria, FUNDACI\u00d3 HOSPITAL UNIVERSITARI VALL D\u00b4HEBRON - INSTITUT P201330768, PCT/ES2014/070434, EP3006570; 2013 of Diseases Associated with Abnormalities of the Complement System Group Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, P\u00e9rez Andr\u00e9s M, Van Zelm MC, Kalina T, Vlkova M, L\u00f3pez varez E, Kienzler Selgas R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, Vaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn , Selgas R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, Vaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FI Ortiz Ardu\u00e1n A ; FIBHULP , Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz. Pharmaceutical composition and its use in the manufac - ture and Therapy Group Vela Cuenca M, Gonz\u00e1lez Navarro P, Valent\u00edn Quiroga J, Escudero L\u00f3pez A, P\u00e9rez Mart\u00ednez A, Fern\u00e1ndez cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13. Large System Pathologies Area Organic Dysfunction and Failure in the Agression Group Herrero Ambrosio A, Ram\u00edrez Garc\u00eda E, Ojeda Feo JJ, P\u00e9- rez Rodr\u00edguez J, Asensio Mart\u00edn MJ, Gonz\u00e1lez S\u00e1nchez ML, Moro Agud M, Lorente Romeo M, L\u00f3pez Nieto M, G\u00f3mez Rioja R , authors; Group Selgas Guti\u00e9rrez R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, Vaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn , Selgas R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, Vaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FI R, Steppan S, Passlickdeetjen J , inventors; Fresenius Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 33 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansL\u00f3pez-Cabrera M, Aguilera Peralta AI, Selgas Guti\u00e9rrez R, Passlickdeetjen J. Buechel J, Steppan S , inventors; Fresenius AG & Co. KGaA, as - signee. Method and kit for diagnosing the peritoneum (EMT -Chip). DE102015115158.8; 2015 September S\u00e1nchez Ni\u00f1o MD, Ortiz Ardu\u00e1n A ; FIBHULP , Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz. Pharmaceutical composition and its use in the manufac - ture January Segovia I\u00f1igo C, Montes Bueno MT , inventors; Segovia I\u00f1igo C, assignee. Positio - ning neonates (Utility model). 31. Diagnosis and Allergic Diseases Quirce Gancedo, 13.083.068; 2014 July 15. S\u00e1nchez Herreros R, Mart\u00ednez Fern\u00e1ndez J, Castro Morera A, Gasset Vega M, Rodr\u00edguez P\u00e9rez RM, Pedrosa Delgado M, Quirce Gancedo S , J, Rodrigo-Mu\u00f1oz JM, Sastre Turri\u00f3n Gancedo S, Ca\u00f1as Ma\u00f1as JA , inventors; Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBER), FIBHULP , Fundaci\u00f3n Conchita R\u00e1bago Santiago Garc\u00eda 2012 June 18. Zapardiel Garc\u00eda J , inventors; FIBHULP Botella Cubells LM, Albi\u00f1ana V, Villar G\u00f3mez de las Heras K , inven - tors; CSIC, Alianza Espa\u00f1ola de Familias de Inhibidores de TGF-\u00df1 y pro - ductores de endoglina para su uso en el tratamiento de 2018 December 12 P , FIBHULP , Instituto de valve for the interruption respiratory mechanics. May 16. Cancer and Human Molecular Genetics Area INGEMM- Institute of Medical and Molecular Genetics Group Friedman S, Li D, Narla G, Martignetti J, Heath K , inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppres - sor GE - N\u00c9TICA M\u00c9DICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 11, 2009 December 10.2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 34 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated 2010 Decem - ber 02, 01, 2011 31. 2010 December 02, 2011 June 01, 2011 May 31. Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, July 05, 2011 July 01. Lapunzina P, Nevado J, Solera J, Vallespin E, Mart\u00ednez P, Mar- t\u00ednez-Gonz\u00e1lez V, 2011 October 27, 2011 May 16. Moreno JC, Moya CM, Vallespin E, Lapunzina Arias Lajara P, J, Dapia Garc\u00eda I, Mu\u00f1oz UAM, name: 2016 September 07. Palomares Bralo M, Vallesp\u00edn Garc\u00eda E, del Pozo Mate A, May 31. Translational Oncology Group Cejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, de Castro Carpe\u00f1o J, Moreno Garc\u00eda V, Burgos Lizalde E, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ , inventors; FIBHULP , UAM, Empresa P\u00fablica Hospital del Genomic finger - print for predicting P201130863, PCT/ES2012/070379; 2011 May 26. Cejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, Gonz\u00e1lez Bar\u00f3n M, de Castro Carpe\u00f1o J, Casado S\u00e1enz E, S\u00e1nchez - nocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04. Cejas Guerrero P, Gonz\u00e1lez Bar\u00f3n M, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ, Perona Abell\u00f3n R , inventors; FIBHULP , UAM, CSIC, Use of trefoil fac - tor family 3 (TFF3) Espinosa Arranz E, Fresno Vara JA, G\u00e1mez Pozo A, L\u00f3pez Vacas R, Berges Soria J, inventors; FIBHULP , assignee. P201430887, 2014 June 09. Espinosa Arranz E, Fresno Vara JA, G\u00e1mez Pozo A, S\u00e1nchez Navarro I , inven 2.4 Innovation Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 35 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansMiranda Utrera N, Castellano D, Villacampa Aub\u00e1 F, Fresno Vara JA, G\u00e1mez in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP16774644.5, US20180346990, CN108174608; 2015 September 23. Moreno Rubio J, Cejas Guerrero P, Feli\u00fa Batlle J, Ram\u00edrez de Molina AI, Regle- ro Rada G, Vargas Alonso T, Molina Arranz to an anticancer S\u00e1nchez A, Hardisson response Experimental Therapies and Biomarkers in Cancer Group Cejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, de Castro Carpe\u00f1o J, Moreno Garc\u00eda V, Burgos Lizalde E, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ, inventors; FIBHULP , UAM, Empresa P\u00fablica Hospital del Norte, Genomic finger - print for predicting the antitumor therapy in colorectal c\u00e1ncer. P201130863, PCT/ES2012/070379; 2011 May 26. Cejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, Gonz\u00e1lez Bar\u00f3n M, de Castro Carpe\u00f1o J, Casado S\u00e1enz E, S\u00e1nchez - nocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04. Cejas Guerrero P, Gonz\u00e1lez Bar\u00f3n M, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ, Perona Abell\u00f3n R , inventors; FIBHULP , UAM, CSIC, Use of trefoil fac - tor family 3 (TFF3) Ib\u00e1\u00f1ez de C\u00e1ceres I, Belda Iniesta C, Pern\u00eda Arias O, Perona Abell\u00f3n R, Cor- t\u00e9s Sempere M ; inventors. FIBHULP , UAM, Hospital Ma - drid, assignees. Method for predicting the de C\u00e1ceres I, de Castro Carpe\u00f1o J, Vera Puente O, Pern\u00eda Arias O, Rodr\u00ed-guez Antol\u00edn C, Gonz\u00e1lez Mu\u00f1oz VM, Mart\u00edn Palma C\u00e1ceres I, Pern\u00eda Arias O, de Castro Carpe\u00f1o J, Vera Puente O, Jim\u00e9nez Hern\u00e1ndez J, Perona Abell\u00f3n R, Rojo Todo F , inventors; FIBHULP , CSIC, Instituto Abell\u00f3n R, Agostini A, Mon- drag\u00f3n Mart\u00ednez L, Moreno Torres M, Mangu\u00e1n Garc\u00eda C, Marcos Mart\u00ednez MD, Soto Camino J, Sancen\u00f3n Galarza F , inventors; Universidad Polit\u00e9cnica de Valencia, CSIC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Bio - materiales y Nanomedicina (CIBER-BBN), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER), assignees. Release 04. Perona Abell\u00f3n R, S\u00e1nchez P\u00e9rez I, Machado Pinilla R, Sastre Garz\u00f3n L, Murgu\u00eda Ib\u00e1\u00f1ez JR , inventors; CSIC, UAM, Universidad Polit\u00e9cnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, can Abell\u00f3n R, Sastre Garz\u00f3n L, Machado Pinilla R, S\u00e1nchez P\u00e9rez I , in- ventors; CSIC, UAM, assignees. Use R, Sastre Garz\u00f3n L, Pintado Berninches L, Carrillo Garc\u00eda J, Molina Pach\u00f3n A, Irradiccio Silva L, Mangu\u00e1n Garc\u00eda C , inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CI - BER), assignees. Peptides derived Elektromedizinische Geraete 2.4 Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 36 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansGmbH, assignee. PCT/US2011/035312; 2010 May P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Mart\u00ednez laboratory animals. P201031720; 2010 November 23. Cobo Parra P, Varela Nieto I, Algovia R reverberating acoustic chamber for hearing test with animals. Procedimiento para dise\u00f1ar una c\u00e1mara ac\u00fastica rever - berante para ensayos auditivos con animales. Cancer A, to an anticancer S\u00e1nchez A, Hardisson of Tumour Progression Group Garc\u00eda JF, Mart\u00edn Moreno AM, Roncador G, Mart\u00ednez Torrecuadra JL, Moreno Bueno G , inventors; Fundaci\u00f3n MD Anderson International Espa\u00f1a, Fundaci\u00f3n Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), August 14. PG, Rojo A, Garc\u00eda JF, Moreno-Bueno G , inventors; UAM, CSIC, Fundaci\u00f3n MD Anderson International Espa\u00f1a, assignees; Gasdermin B2 as a new Puigjaner J, Col\u00e1s Ortega E, Prat D\u00edaz de Losada J, Palacios Calvo J, Abal Posada M, L\u00f3pez L\u00f3pez R, Mo- reno Bueno G, Gil Moreno A , inventors; Institut de Recerca Biom\u00e8dica de Lleida Fundaci\u00f3 Doctor Universitat deLleida, Fundaci\u00f3 Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundaci\u00f3 Institut de Recerca de L'Hospital de la San - ta Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Sa\u00fade, Fundaci\u00f3n MD Anderson International Espa\u00f1a, assignees. Method to predict risk of Casadom\u00e9 D, Moreno Bueno G, Portillo P\u00e9rez F, Cano Garc\u00eda A , inven - tors; UAM, Casadom\u00e9 D, Peinado Selgas H, Portillo P\u00e9rez F, Nieto Toledano MA, Cano Garc\u00eda A , inventors; UAM, assignee. Materials and methods pression of the E-cadherin promoter. US20060003956; 2004 March 03. Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group Campanero Garc\u00eda MR, Molina Privado I , inventors; Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03. Molina Campanero Garc\u00eda MR, Rodr\u00edguez Mart\u00ednez M , inventors; CSIC, P200900651; 09. Zapata Hern\u00e1ndez JM, P\u00e9rez Chac\u00f3n G , inventors; CSIC, UAM, assignees; Use of an indolic compound nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, Metabolic Diseases Group P\u00e9rez Gonz\u00e1lez B, Ruiz Desviat L, Jorge Finnigan A, Ugarte P\u00e9rez M, Mart\u00ednez Ruiz A, Underhaug J, Barnejee R , inventors; UAM, Universidad de Bergen, Uni - versidad de Michigan, assignees; Compounds useful for - malonic aciduria. P201330171; 2013 February 11. P\u00e9rez Gonz\u00e1lez B, G\u00e1mez Abascal A, Yuste Checa P, Arduim Brasil S, Ugar- te P\u00e9rez M, Mart\u00ednez Ruiz A, Underhaug J , inventors; UAM, Universidad FIBHULP , as - October 14.2.4 Innovation Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 37 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSurgery, Transplant and Health Technologies Area Bone Pathophysiology and Biomaterials Group Fabiilli M, Wilson C, Padilla F, Mart\u00edn Saavedra FM , inventors; The regents of the University of Michigan, agents for tissue en - gineering; PCT/US2013/044817, US2013/0330389; 2012 June 08. Gonz\u00e1lez Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodr\u00edguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fern\u00e1ndez Calder\u00f3n MC, Salda\u00f1a Quero L, Gonz\u00e1lez Mart\u00edn ML, P\u00e9rez Giraldo C, Gallardo Moreno AM , inventors; CSIC, Fundaci\u00f3n T ecnalia Research & Innovation, FIBHULP , Universidad de Extremadura, Centro de Investigaci\u00f3n Biom\u00e9dica (CIBER). Moldable, biodegradable, biocom and thereof. P201530683; 2015 May 18. Mart\u00edn Saavedra FM, Vilaboa D\u00edaz NE, Cebri\u00e1n Hernando V, Arruebo Gordo M, Santamar\u00eda J, G\u00f3mez Navascu\u00e9s PCT/ES2014/070484; 2013 June 14. Vilaboa D\u00edaz NE, Calzado Mart\u00edn A, Crespo Garc\u00eda L, Salda\u00f1a Quero L, Moreo P201330040, JL, Multigner Dom\u00ednguez M, Lieblich Rodr\u00edguez M, Mu\u00f1oz Hern\u00e1ndez M, Frutos Torres E, Salda\u00f1a L , inven - tors; NE, Quero and thereof. US 62/495,501; 2016 US HSF F, Royuela MM , inventors; FIBHULP , Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Ram\u00f3n y Ca - jal, Universidad de Alcal\u00e1, Ambrosio A, Ram\u00edrez Garc\u00eda E, Ojeda Feo JJ, P\u00e9- rez Rodr\u00edguez J, Asensio Mart\u00edn MJ, Gonz\u00e1lez S\u00e1nchez ML, Moro Agud M, Lorente Romeo M, L\u00f3pez Nieto M, G\u00f3mez Rioja R , authors; Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 38 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansLapunzina Bad\u00eda P, Borobia P\u00e9rez AM, Carcas Arias Lajara P, Fr\u00edas Dapia Garc\u00eda I, Mu\u00f1oz Surgery Research- GICOA Group Arenas Vara MA, Conde del Campo A, De Damborenea Gonz\u00e1lez JJ, Matykina E, Esteban Moreno J, G\u00f3mez P\u00e9rez-Jorge Peremarch C, P\u00e9rez Tanoira R , inventors; CSIC, Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9 - nez D\u00edaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ ES2011/070342; 2010 14. Transplant Group Hern\u00e1ndez Oliveros F, Nana G\u00f3mez Mayoral N, Raya Gonz\u00e1lez L, Guijarro Fern\u00e1ndez E authors; del Posadas Ma\u00f1anes SJ, Reglero Rada GJ, Largo Aram- buru C, Garc\u00eda Grande A, Merino Mart\u00edn JJ, Caz Bonillo V, Fornari Reale T, tissues from the digestive tract and the breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16. de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodr\u00edguez Garc\u00eda-Risco M, Jaime de Pablo L, Santoyo D\u00edez S, Se\u00f1orans Rodr\u00edguez FJ, Garc\u00eda Grande A, Merino Mart\u00edn J, Caz Bonillo JV, Posadas Ma- \u00f1anes SJ suction. P201031490, PCT/ES2011/002357; 2010 October 07. de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Mar\u00edn Mart\u00edn F, Fornari T, Prodanov Prodanov M, Ruiz Rodr\u00ed- guez A, Ib\u00e1\u00f1ez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodr\u00edguez Garc\u00eda- Risco M, Santoyo D\u00edez S, Gonz\u00e1lez Lorente M, Arranz Guti\u00e9rrez E, Gil Ram\u00edrez A, June 16. Reglero Rada GJ, de Miguel del Campo E, Mar\u00edn Mart\u00edn F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodr\u00edguez A, Largo Aramburu C, Tabernero Urbieta M, Ib\u00e1\u00f1ez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodr\u00edguez Garc\u00eda-Risco M, Santoyo D\u00edez S, Gonz\u00e1lez Lorente M, Arranz Guti\u00e9rrez E, Gil Ram\u00edrez A , CSIC, PCT/ES2012/070443; 2011 June 16. Brian Gahan P, Stroun M, Garc\u00eda del Olmo D, Garc\u00eda Arranz M, Vega Clemente ML, inventors; Peter de Mar\u00eda Pallar\u00e9s P, D\u00edaz A, A, Mart\u00edn de Almagro S; Juli\u00e1n Garc\u00eda Rivera 2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 39 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians F, de la Quintana Jim\u00e9nez P , inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP , assignees. Dispositivo de corte autom\u00e1tico de discos de ostom\u00eda. P201830718. 2018 July 16. Ram\u00edrez de Molina A, Tabernero Urbieta M, Reglero Rada G, Torres Olivares C, Largo Aramburu C, Santamar\u00eda Ramiro M, Polo Paredes G, Ruiz P\u00e9rez D, de Miguel del Campo E, \u00c1lvarez de Segura I , inventors; assignees. Composici\u00f3n para la reducci\u00f3n del declive metab\u00f3lico asociado al envejecimiento y/o el tratamiento de transtor - nos relacionados al metabolismo l\u00edpidico. P201830740; Simulaci\u00f3n y Entrenamiento Cl\u00ednico; ESM 3.567.901-8; 2015 June 22. Associated Clinician G\u00f3mez Candela C, L\u00f3pez Plaza B, Bermejo L\u00f3pez L , authors; FIBHULP , assignee. Brand Alimentos Funcionales; ESM 3.649.812-2; 2017 February 2.4 Innovation and Transfer Activities Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 40 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.5 Quality Committe The vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical research at the national and european level. T o achieve this objective, the institution combines its efforts all its processes, thus ensuring the provision of the best service, research and teaching. IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management team of the IdiPAZ institutions. T o support facilitate quality, Commission itself, three professionals from the IdiPAZ common platforms have been included as members of the Quality Committee. On the other hand, the IdiPAZ management system has been maintained under the requirements of the ISO 9001:2015 and the UNE 166002:2014, including currently in its scope five units/platforms: the Automatic Sequencing laboratory, the Innovation Support Unit, the Central Research and Clinical Trials Unit, the T echnical Secretariat and the Quality Committee itself. A working quality for process to take is a continuously evolving organisation, the Quality activities of our institution has been enriched by the diffe - rent achievements made by its organizations. The Hospital Universitario La Paz, with its accumulative experien - ce about quality of care as the protocols developed or updated in the same In addi tion, the staff members continuously collaborate in committees 2018 hospital departments quality management systems are being integrated in an overall management sys - tem according to the standards ISO 9001:2015, ISO 14001:2015, ISO 22000:2005 and IQNetSR10. The hospital has 26 accredited units within the Spanish National Accreditation System.Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 41 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.5 Quality Committe Protocol / Clinical pathway Status Acompa\u00f1amiento en el bloque quir\u00fargico infantil Review Acompa\u00f1amiento en la unidad de reanimaci\u00f3n de cuidados cr\u00edticos quir\u00fargicos Review Activaci\u00f3n de reanimaci\u00f3n cardiopulmonar en el hospital y su entorno New Actuaci\u00f3n ante casos sospechosos o confirmados de gripe en adultos Review Actuaci\u00f3n ante casos sospechosos o confirmados de gripe/VRS en ni\u00f1os Review Actuaci\u00f3n ante un accidente de trabajo por ca\u00edda o s\u00edncope - UAAN New Actuaci\u00f3n frente a mordeduras de animales Review Alteraciones palpebrales Review Analgosedaci\u00f3n en el Servicio de Medicina Intensiva New Ansiolisis/sedaci\u00f3n en Laboratorio de Ecocardiograf\u00eda New Antiagregaci\u00f3n/anticoagulaci\u00f3n en endoscopia Review Ascitis en urgencias New Asistencia al parto vaginal normal (poco intervencionista) Review Atenci\u00f3n en consulta de alto riesgo por c\u00e1ncer colorrectal y seguimiento de p\u00f3liposReview Biopsia de ganglio centinela en c\u00e1ncer de cavidad oral New Bore grave de colitis ulcerosa Review Cardio-onco-hematolog\u00eda New Cataratas cong\u00e9nitas e infantiles Review Cierre percut\u00e1neo de orejuela New Circuito de insulinizaci\u00f3n al alta New Coledocolitiasis Review Colitis isqu\u00e9mica Review Consulta de alta resoluci\u00f3n de n\u00f3dulo tiroideo (implementaci\u00f3n) Review Control microbiol\u00f3gico en hemodi\u00e1lisis adultos New Control microbiol\u00f3gico en hemodi\u00e1lisis infantil New Creaci\u00f3n y mantenimiento de acceso vasculares para hemodi\u00e1lisis New Detecci\u00f3n y control de pacientes portadores de microorganismos multirresistentes de transmisi\u00f3n por contactoReview Diabetes-II Review Disecci\u00f3n Dislipemia Review Dolor Encefalopat\u00eda urgencias New Enfermedad de Chagas NewProtocol / Clinical pathway Status Enfermedad de Fabry Review Enfermedad del viajero menos prevalentes Review Enfermedad hep\u00e1tica grasa no alcoh\u00f3lica New Enfermedad tromboemb\u00f3lica venosa (tratamiento y profilaxis) Review Enfermedades tropicales m\u00e1s prevalentes Review Esclerosis sist\u00e9mica Review Esofagitis eosinof\u00edlica New Esofagitis por ca\u00fasticos Review Estudio de la hiponatremia New Fatiga cr\u00f3nica Review Gesti\u00f3n de derrames, p\u00e9rdida y/o desaparici\u00f3n de residuos en el Hospital La Paz, H. Cantoblanco, H. Carlos III y CEPsReview Gu\u00eda de antis\u00e9pticos New Gu\u00eda de pr\u00e1ctica cl\u00ednica de insuficiencia cardiaca Review Gu\u00eda de transfusi\u00f3n pedi\u00e1trica New Gu\u00eda obesidad-gestaci\u00f3n y documentaci\u00f3n para el paciente con obesidad, DG, DM preconcepcional y control preconcepcional New Hemorragia digestiva alta no varicosa en urgencias New Hemorragia digestiva alta varicosa en urgencias New Hepatitis aguda alcoh\u00f3lica Review Hipertensi\u00f3n Pulmonar Review Hipertensi\u00f3n Arterial Review Infecci\u00f3n en paciente inmunodeprimido Review Infecci\u00f3n nosocomial Review Ingresos por STEMI (c\u00f3digo infarto) Review Inserci\u00f3n y mantenimiento de cat\u00e9teres vasculares centrales Review Insuficiencia cardiaca Review Insuficiencia hep\u00e1tica aguda Review Limpieza y desinfecci\u00f3n de endoscopios digestivos Review Limpieza y desinfecci\u00f3n de endoscopios ginecol\u00f3gicos Review Limpieza y desinfecci\u00f3n de endoscopios neumol\u00f3gicos Review Limpieza y desinfecci\u00f3n de endoscopios urol\u00f3gicos Review Lupus y s\u00edndrome antifosfol\u00edpido Review Manejo anafilaxia en las consulta de vacunaci\u00f3n New Manejo de contactos de pacientes con tuberculosis NewScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 42 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansProtocol / Clinical pathway Status Manejo de enfermedad inflamatoria intestinal en urgencias Review Manejo de la esofagitis eosinof\u00edlica New Manejo de paciente con enfermedad infecciosa de alto riesgo en la urgencia pedi\u00e1tricaNew Manejo enfermedad perianal enfermedad inflamatoria intestinal con cirug\u00eda Review Manejar de paciente con enfermedad infecciosa de alto riesgo en la urgencia New Mantenimiento del carro de parada Review Microftalm\u00eda y anoftalm\u00eda Review Patolog\u00eda infecci\u00f3n VIH Review Prevenci\u00f3n de endocarditis infecciosa en pacientes portadores de pr\u00f3tesis valvulares cardiacas y dispositivos intravascularesReview Prevenci\u00f3n de la bacteriemia relacionada con la asistencia sanitaria: manejo de dispositivos intravascularesReview Prevenci\u00f3n de la infecci\u00f3n del tracto urinario relacionada con la asistencia sanitariaReview Prevenci\u00f3n de la neumon\u00eda relacionada con la asistencia sanitaria Review Profilaxis antibi\u00f3tica en prequir\u00fargica y predesbridamiento enzim\u00e1tico en el paciente quemadoNew Protocolo de actuaci\u00f3n ante situaciones de obras Review Protocolo de bioseguridad ambiental microbiol\u00f3gica en quir\u00f3fanos y salas TMO Review Protocolo de declaraci\u00f3n de enfermedades de declaraci\u00f3n obligatoria Review Protocolo de gesti\u00f3n de la esterilizaci\u00f3n New Protocolo de gesti\u00f3n de m\u00f3dulos de normohipotermia New Protocolo de limpieza hospitalaria Review Protocolo de recomendaciones de medicina preventiva en la preparaci\u00f3n y conservaci\u00f3n de las f\u00f3rmulas infantiles en polvo y leche maternaNew Protocolo Pie Diab\u00e9tico New Ptosis palpebral Review Queratoplastias en ni\u00f1os Review Reanimaci\u00f3n inicial del paciente quemado Review Recomendaci\u00f3n para la reserva de sangre en cirug\u00eda programada Review Recurrencia de enfermedad inflamatoria intestinal Review Retinopat\u00eda diab\u00e9tica en ni\u00f1os Review Ruta asistencial de atenci\u00f3n a pacientes con dolor New Ruta asistencial disfunci\u00f3n tiroidea (TSH) New Ruta asistencial n\u00f3dulo tiroideo New Sedaci\u00f3n paliativa y para el tratamiento de otros s\u00edntomas en Cuidados Paliativos Pedi\u00e1tricosNewProtocol / Clinical pathway Status Seguimiento de p\u00f3lipo Review S\u00edndrome metab\u00f3lico Review Solicitud de pruebas de ECG, Holter, Rx de isquemia, TC y RM, cateterismoReview TC cardiaco y RM cardiaca Review Toma de muestras endoscopios digestivos Review Toma de muestras endoscopios ginecol\u00f3gicos Review Toma de muestras endoscopios neumol\u00f3gicos Review Toma de muestras endoscopios urol\u00f3gicos Review Transici\u00f3n diabetes (infantil - adulto) New Traslado intrahospitalario en urgencias pedi\u00e1tricas New Tuberculosis en enfermedad inflamatoria intestinal Review Uso de los inmunomoduladores en la enfermedad inflamatoria intestinal New Uso de megadosis vit C en el paciente quemado cr\u00edtico Review Utilizaci\u00f3n de potasio intravenoso Review Utilizaci\u00f3n de sueros de alto riesgo Review Vacunaci\u00f3n del paciente con asplenia New Vacunaci\u00f3n del paciente con hepatopat\u00eda cr\u00f3nica New Vacunaci\u00f3n del paciente con implante coclear New Vacunaci\u00f3n del paciente con insuficiencia renal cr\u00f3nica New Vacunaci\u00f3n del paciente con trasplante de progenitores hematopoy\u00e9ticos New Vacunaci\u00f3n del paciente con trasplante de \u00f3rgano s\u00f3lido New Vacunaci\u00f3n del paciente con trasplante de \u00f3rgano s\u00f3lido New Vacunaci\u00f3n del paciente con tratamiento inmunosupresor New Vacunaci\u00f3n del paciente con VIH New Vasculitis necrotizantes sist\u00e9micas Review V\u00eda biliar en urgencias New V\u00eda cl\u00ednica de atenci\u00f3n al ictus pedi\u00e1trico New V\u00eda cl\u00ednica de gastrostom\u00eda endosc\u00f3pica percut\u00e1nea Review V\u00eda cl\u00ednica de hemorragia digestiva alta con hipertensi\u00f3n portal Review V\u00eda cl\u00ednica de hemorragia digestiva alta sin hipertensi\u00f3n portal Review V\u00eda cl\u00ednica de recuperaci\u00f3n intensificada en cirug\u00eda tor\u00e1cica (RICTO). New V\u00eda cl\u00ednica multiservicio sobre FRA-AKI en unidades de cr\u00edticos Review V\u00eda cl\u00ednica trasplante renal reciente Review2.5 Quality Committe Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 43 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.6 Clinical Trials Acero Pe\u00f1a A. Estudio observacional retrospectivo para evaluar la efectividad de la inyecci\u00f3n intrav\u00edtrea (IVT) de Aflibercept en la pr\u00e1ctica cl\u00ednica en pacientes sin tratamiento previo con degeneraci\u00f3n macular asociada a MJ . Determinantes de la calidad de vida en pacientes de Estudio de extensi\u00f3n abierto y multic\u00e9ntrico para evaluar la seguridad y efi - cacia a largo plazo de Lacosamida como tratamiento complementario para las crisis t\u00f3nico-cl\u00f3nicas generalizadas primarias no controladas en pacientes con epilepsia idiop\u00e1tica . Estudio observacional retrospectivo para determinar el estado de riesgo de pacientes con hipertensi\u00f3n arterial pulmonar en Espa\u00f1a. Type: Estudio multic\u00e9ntrico, descriptivo y transversal para determinar la prevalencia, las caracter\u00edsticas cl\u00ednicas y el tratamiento de la disnea en crisis en pacientes con c\u00e1ncer de pulm\u00f3n avan zado. en fase III, multic\u00e9ntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de uno o m\u00e1s tratamientos intradetrusor con 600 u 800 unidades de Dysport\u00ae para el tratamiento de la carcinoma urotelial no invasivo de alto grado de la vejiga mediante N\u00ba y dosis est\u00e1ndar de instilaciones intravesicales con una dosis Fundaci\u00f3n de La Asociaci\u00f3n Europea de Urolog\u00eda. Signed date: 04/09/2018 Alonso Melgar A . Estudio en fase III multic\u00e9ntrico y abierto de ALXN1210 en ni\u00f1os y adolescentes con s\u00edndrome hemol\u00edtico 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 44 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Alexion Pharmaceutical Inc. Signed date: 10/12/2018 Estudio multic\u00e9ntrico, observacional, no intervencionista, trans - versal y retrospectivo, para evaluar la calidad de vida en condiciones de pr\u00e1ctica cl\u00ednica habitual, en pacientes con psoriasis moderada a severa tratados con Metotrexato en MT . Estudio cl\u00ednico de fase III, prospectivo, aleatorizado y multic\u00e9n - trico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC dirigida a dos concentraciones m\u00ednimas de FVIII distintas en sujetos con hemofilia a grave. . Estudio de fase I/II internacional, abierto y multic\u00e9ntrico de la seguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa un factor VIII con el dominio B (B-DOMAIN DELE - TED FACTOR VIII, BDD-FVIII) en sujetos con hemofilia a grave administrado como infusi\u00f3n \u00fanica por v\u00eda intravenosa. Type: . Estudio epidemiol\u00f3gico transversal para comprender el enfoque actual del tratamiento en la atenci\u00f3n regular de pacientes con hemofilia B en Espa\u00f1a y Portugal. MT . Evaluaci\u00f3n en abierto y multic\u00e9ntrica de la seguridad y la eficacia de la proteina de fusi\u00f3n del factor VIII FC recombinante de la coagulaci\u00f3n (RFIIIFC; BIIB031) en la prevencion y el tratamiento de episodios de sangrado en pacientes con hemofilia a grave. Type: Clinical . Evaluaci\u00f3n en abierto y multic\u00e9ntrico de la seguridad y la efi - cacia de una proteina de fusi\u00f3n del factor IX recombinante de la coagulacion y FC (RFIXFC;BIIB029) en la prevenci\u00f3n y el tratamiento de episodios de sangrado en pacientes con hemofilia B grave. Type: Clinical eficacia de T uroctocog Alfa Pegol (N8-GP) en pacien - tes con hemofilia de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de Delafloxacino intravenoso con cambio a v\u00eda oral en sujetos adultos con neumon\u00eda bacteriana adqui - rida en fase IIB, aleatorizado (estratificado), doble ciego (abierto para promotor), de grupos paralelos, controlado con placebo, de b\u00fasqueda de dosis de Nemiralisib (GSK2269557) a\u00f1adido al est\u00e1ndar de tratamiento frente solo al est\u00e1ndar de tratamiento. Type: Clinical . Estudio observacional transversal grave . Factores de riesgo asociados con la progresi\u00f3n de la insufi - ciencia card\u00edaca (IC) en pacientes con fibrilaci\u00f3n auricular tratados con 06/03/2018 Segura S . Estudio de dosis ascendente \u00fanicas, aleatorizado, doble ciego y con - trolado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocin\u00e9tica de MK-1654 en neonatos prematuros y Segura S . Estudio de dosis ascendente \u00fanicas, aleatorizado, doble ciego y con - trolado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocin\u00e9tica de MK-1654 en neonatos prematuros y Ares Segura S . Estudio de fase III, abierto y aleatorizado para evaluar la eficacia y seguridad de Alectinib adyuvante frente a la quimioterapia adyuvante con un derivado del Platino en pacientes con carcinoma de pulm\u00f3n no microc\u00edtico positivo para la cinasa del linfoma anapl\u00e1sico en estadio IB (tumores 4 CM) A IIIA Type: Armada Maresca F . Influencia de factores cl\u00ednicos y gen\u00e9ticos en la evoluci\u00f3n fun - cional y anat\u00f3mica a largo plazo en una cohorte de pacientes con DMAE h\u00fameda tratados seg\u00fan pr\u00e1ctica cl\u00ednica Arribas L\u00f3pez JR . Estudio de fase 2B aleatorizado, doble ciego, controlado con place - bo para evaluar la actividad antiviral, los resultados cl\u00ednicos, la seguridad, la tolerabili -2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 45 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansdad y farmacocin\u00e9tica de los tratamientos administrados por v\u00eda oral . Estudio de fase III, aleatorizado, multic\u00e9ntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a Dolutegravir m\u00e1s Lamivudina en adultos infectados por el VIH 1 con supre . Estudio de fase III, aleatorizado, multic\u00e9ntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a Dolutegravir m\u00e1s Lamivudina en adultos infectados por el VIH 1 con supre . Estudio fase 3B, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinaci\u00f3n a dosis fija (CDF) de Efavirenz/Emtricitabina/T e - nofovir Disoproxil Fumarato . Estudio fase III, multic\u00e9ntrico, abierto, randomizado, para evaluar el cambio a MK 1439a en pacientes con supresi\u00f3n virol\u00f3gica infectados por el VIH-1 en un r\u00e9gimen de un inhibidor de proteasa potenciado con Ritonavir y dos inhibidores multic\u00e9ntrico, randomizado, con doble enmas - caramiento, controlado, con comparador activo para evaluar la eficacia y seguridad de RO6867461 en pacientes con edema macular Criado A . Ensayo fase 3B, aleatorizado, doble ciego para evaluar la eficacia y seguridad de Abatacept sc en combinaci\u00f3n con Metotrexato comparado con Me - totrexato en monoterapia para conseguir la remisi\u00f3n cl\u00ednica en adultos con artritis reumatoide temprana sin tratamiento previo con Balsa Criado A . Estudio abierto, de 8 semanas, para comparar la comodidad y facilidad de uso de cinco pautas de tratamiento distintas de inyecciones intraarticulares de CNTX5 4975-05 en sujetos con dolor cr\u00f3nico de rodilla por artrosis moderada a grave. Type: Clinical Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Sarilumab en pacientes con arteritis de c\u00e9lulas . Estudio en faseI/III aleatorizado y de grupos paralelos para evaluar la eficacia, la farmacocin\u00e9tica y la seguridad de CT -P13 subcut\u00e1neo y CT -P13 intravenoso en pacientes Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con pla - cebo para evaluar la seguridad, tolerabilidad y eficacia de Secukinumab en pacientes con spondiloartritis axial no radiogr\u00e1fica activa durante un periodo de 2 A . Estudio multic\u00e9ntrico, internacional, aleatorizado, doble ciego, contro - lado con alendronato para determinar la eficacia y seguridad de AMG 785 en el tra - tamiento de mujeres Estudio observacional retrospectivo del tratamiento de la leucemia linfoc\u00edtica cr\u00f3nica (LLC) con Ibrutinib en la pr\u00e1ctica retrospectiva no intervencional posterior a la autori - zaci\u00f3n del uso de Idelalisib en pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) Sanz MPE. Estudio observacional prospectivo para evaluar la carga m\u00e9dica y su asociaci\u00f3n al uso de corticosteroides orales en pacientes con asma grave en Espa\u00f1a. Estudio 08/02/2018 Barrio G\u00f3mez de Ag\u00fcero I . Estudio de extensi\u00f3n, fase III, abierto para evaluar la seguridad y la eficacia del tratamiento a largo plazo con VX 661 en combinaci\u00f3n con 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 46 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansIvacaftor en sujetos a partir de 12 a\u00f1os con fibrosis qu\u00edstica, homocig\u00f3ticos o hetero - cig\u00f3ticos multic\u00e9ntrico, doble ciego, controlado con placebo y grupos paralelos para evaluar la efectividad de la cepa Lactobacillus Saliva - rius V4II-90 en la reducci\u00f3n de la colonizaci\u00f3n por estreptococos del grupo B (GBS) de mujeres embarazadas. Un estudio de prueba de concepto de fase 2A, doble ciego, de gru - po paralelo, aleatorizado y controlado con placebo que eval\u00faa la eficacia, la seguridad y la farmacocin\u00e9tica de OBE022 combinado con Atosiban tras su administraci\u00f3n por v\u00eda oral a mujeres . Estudio piloto para evaluar el efecto de la cepa Lactobacillus Sali - varius PS11610 sobre la microbiota del tracto genital femenino y masculino en parejas con problemas de fecundidad. Type: Producto observacional y retrospectivo de las caracter\u00edsticas cl\u00ednicas y patol\u00f3gicas del carcinoma de c\u00e9lulas de Merkel (CCM) entre 2012 y 2016 en Hu\u00e9rfanos e Signed date: 27/11/2018 Bernardino de La Serna JI . estudio en fase III para evaluar el efecto de la Pitavastatina para prevenir los acontecimientos vasculares en personas con infecci\u00f3n por VIH -1. Type: Clinical Serna JI . Estudio en fase IIIB, multic\u00e9ntrico, abierto, para evaluar el cambio desde una pauta combinada de dosis fija de Elvitegravir/Cobicistat/Emcitra - bina/T enofovir Alafenamida o una pauta que contenga T enofovir Disoproxil Fumarato a una combinaci\u00f3n de dosis fijs de Bictegravir/Emtricitabina/T enofovir Alafenamida en sujetos de edad avanzada, de 65 a\u00f1os de edad, infectados por VIH-1 con Estudio de vida real en pacientes con acontecimientos tromb\u00f3 - ticos o hemorr\u00e1gicos graves siendo tratados con antagonistas de la vitamina K . Ensayo cl\u00ednico, piloto, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes dosis de Tramadol y Tramadol 100 mg por v\u00eda intravenosa en pacientes con dolor mo - derado a intenso tras cirug\u00eda. Type: . Ensayo cl\u00ednico, piloto, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes dosis de Tramadol y Tramadol 100 mg por v\u00eda intravenosa en pacientes con dolor mo - derado a intenso tras cirug\u00eda. Type: MT . BCX7353-204: estudio abierto para evaluar la seguridad a largo plazo de BCX7353 oral diario en pacientes con angioedema hereditario tiposI BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCXS7353 como tratamiento oral para la prevenci\u00f3n de ataques en pacientes con angioedema. Type: Calvo Rey C . Desarrollo neurol\u00f3gico en ni\u00f1os con infecci\u00f3n del SNC por - Calvo Rey C . Estudio de fase IIA sin enmascaramiento en lactantes con infecci\u00f3n de las v\u00edas respiratorias bajas por el virus sincitial respiratorio, seguido de una parte con doble enmascaramiento controlada con placebo, para evaluar la seguridad, la tolera - bilidad, la farmacocin\u00e9tica y el efecto antiv\u00edrico de Trial, phase Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 47 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated C . Estudio en fase II, doble ciego y controlado con placebo para evaluar la actividad antiviral, los resultados cl\u00ednicos, la seguridad, la tolerabilidad y las relaciones entre farmacocin\u00e9tica y farmacodin\u00e1mica de dosis diferentes de JNJ-53718678 en ni - \u00f1os 28 d\u00edas y 3 a\u00f1os de edad con infecci\u00f3n respiratoria aguda debido a la infecci\u00f3n por el virus respiratorio sincitial. Type: . Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Pimodivir en combinaci\u00f3n con la pr\u00e1ctica cl\u00ednica habitual en pacientes adolescentes, adultos y ancianos con gripe A no hospitalizados. Type: Clinical Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Pimodivir en combinaci\u00f3n con la pr\u00e1ctica cl\u00ednica habitual en pacientes adolescentes, adultos y ancianos hospitalizados con gripe A. Type: Clinical y chop (R-CHOP) en pacientes con linfoma difuso de c\u00e9lulas grandes tipo B no tratado anteriormente. Clinical y Chop (R-Chop) en pacientes con linfoma difuso de c\u00e9lulas grandes tipo B no tratado anteriormente. Type: Clinical MA . Ensayo de fase I/IB, multic\u00e9ntrico, sin enmascaramiento para evaluar la seguridad y la farmacocin\u00e9tica de dosis crecientes de BTCT4465A en mono - terapia y en combinaci\u00f3n con Atezolizumab en pacientes con linfoma no Hodgkiniano de linfocitos B y leucemia linfoc\u00edtica Estudio de fase abierto y de dos grupos, de Selinexor (KPT -330) en asociaci\u00f3n con Dexametasona (SEL-DEX) a dosis bajas en pacientes con linfoma difuso de c\u00e9lulas B grandes de fase IB/II, abierto para evaluar la seguridad y la farmacocin\u00e9tica de GDC-0199 (ABT -199) en combinaci\u00f3n con Rituximab (G) m\u00e1s Ciclofosfamida, Doxorrubicina, Vincristina y . Estudio de fase evaluar la seguridad, y acti - vidad antitumoral Polatuzumab Vedotin mab (R) u Obinutuzumab (G) m\u00e1s Bendamustina (B), en pacientes con linfoma folicular o linfoma Canales Albendea MA . Estudio de fase II, abierto, de 2 cohortes y multic\u00e9ntrico de INCB050465, un inhibidor de PI3K, en linfoma de c\u00e9lulas del manto en recidiva o resistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Cita . Estudio de fase II, abierto, de 2 Cohortes y multic\u00e9ntrico de INCB050465, un inhibidor dePI3K, en linfoma de c\u00e9lulas del manto en recidiva o resistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Cita en fase II de TAK-659 en pacientes con linfoma difuso de c\u00e9lulas B grandes recidivante o resistente despu\u00e9s de dos o m\u00e1s l\u00edneas previas de quimioterapia. Type: Clinical Estudio multic\u00e9ntrico, estudio abierto de INCB050465, un inhibidor PI3K, en el tratamiento del Ensayo cl\u00ednico fase IIIB, aleatorizado, abierto, para evaluar el alivio del dolor con Metoxiflurano inhalado, en comparaci\u00f3n con el protocolo actual para el tratamiento del dolor de origen traum\u00e1tico, en adultos atendidos en unidades de urgencias Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab combinado con la quimiorradioterapia de referencia (Cisplatino m\u00e1s radioterapia defi - nitiva) en comparaci\u00f3n con la quimiorradioterapia de referencia en el tratamiento de primera l\u00ednea de pacientes. Type: Clinical Trial, phase III. 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 48 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated of Durvalumab (MEDI4736) plus Tremeli mumab Castelo Fern\u00e1ndez en fase III de Nivolumab con Epaca - dostat en combinaci\u00f3n con quimioterapia (Platino + 5-Fluorouracilo) en comparaci\u00f3n con la pauta posol\u00f3gica extreme (Cetuximab + Platino + 5-Fluorouracilo) como trata - miento de primera l\u00ednea en pacientes con carcinoma de c\u00e9lulas escamosas de cabeza y cuello (CCECC) recurrente o B . Estudio de calidad de vida en pacientes con dolor irruptivo oncol\u00f3gico atendidos en los B . Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de Cemiplimab en comparaci\u00f3n con la combinaci\u00f3n de Cemiplimab m\u00e1s ISA101B en el tratamiento de sujetos con c\u00e1ncer orofar\u00edngeo (COF) VPH-16 positivo resistente . Estudio de fase III, aleatorizado y abierto para evaluar Pembro - lizumab como tratamiento neoadyuvante y en combinaci\u00f3n con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello loco - rregionalmente avanzado (CECC LA), extirpable, Fern\u00e1ndez B . Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab combinado con la quimiorradioterapia de referencia (cisplatino m\u00e1s radioterapia de - finitiva) en comparaci\u00f3n con la quimiorradioterapia de referencia en el tratamiento de primera l\u00ednea de pacientes con carcinoma epidermoide localmente avanzado de cabeza y cuello. Type: . Estudio en fase III, aleatorizado, con doble enmascaramiento y controlado con placebo, de Nivolumab o Nivolumab con Cisplatino, en combinaci\u00f3n con radioterapia en participantes con carcinoma de c\u00e9lulas escamosas de cabeza y cuello (CCEC) localmente avanzado elegibles o no para recibir tratamiento con cis - platino. Type: Clinical Castelo Fern\u00e1ndez B . Estudio sin enmascaramiento de fase II sobre Tipifarnib en neoplasias malignas no hematol\u00f3gicas avanzadas P . Estudio de fase 3, aleatorizado, controlado con placebo, de 52 sema - nas de duraci\u00f3n, para evaluar la seguridad y la eficacia de Seladelpar en sujetos con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al \u00e1cido P . Recogida de muestras de sangre para la evaluaci\u00f3n de biomarcadores en el carcinoma A . Estudio multic\u00e9ntrico espa\u00f1ol sobre la prevalencia e incidencia de la insuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del \u00e1mbito nacional. Castro Conde A . Estudio multic\u00e9ntrico, aleatorizado, abierto, de grupos paralelos para estudiar la seguridad y no inferioridad de una nueva estrategia terap\u00e9utica (polip\u00edldora cardiovascular de FUSTER-CNIC-FERRER) versus tratamiento habitual en la reduc - ci\u00f3n del CLDL y la presi\u00f3n arterial en pacientes con enfermedad cardiovascular ate - rotromb\u00f3tica. Ensayo Apolo. Type: D . Ensayo en fase III, aleatorizado y controlado con placebo de Arimo - clomol con tratamiento activo, de la segu - ridad y la eficacia extrapolada en pacientes pedi\u00e1tricos que requieren anticoagulaci\u00f3n para el tratamiento de un acontecimiento P . Investigaci\u00f3n de la mutaci\u00f3n T790M en sangre 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 49 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Grupo Espa\u00f1ol C\u00e1ncer Pulm\u00f3n. Signed date: 09/04/2018 Custodio Carretero AB . Ensayo cl\u00ednico de fase III, aleatorizado, controlado con tra - tamiento activo, con enmascaramiento parcial y con detecci\u00f3n de biomarcadores, de Pembrolizumab en monoterapia y en combinaci\u00f3n con Cisplatino + 5-Fluorouracilo frente a placebo + Cisplatino + 5-Fluorouracilo como tratamiento de primera l\u00ednea en sujetos con adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica AB . Ensayo cl\u00ednico de fase III, aleatorizado, doble ciego y con - trolado con placebo, de Pembrolizumab (MK-3475) en combinaci\u00f3n con Cisplatino y 5-Fluorouracilo frente a un placebo en combinaci\u00f3n con Cisplatino y 5-Fluorouracilo como aleatorizado, abierto, de Relatlimab (ANTI-LAG-3) m\u00e1s Nivolumab en combinaci\u00f3n con quimioterapia frente a Nivolumab en combinaci\u00f3n con quimioterapia como tratamiento de primera l\u00ednea en pacientes con adenocarcinoma g\u00e1strico o de la AB Estudio fase 3 internacional, multic\u00e9ntrico, doble ciego y aleatorizado, de la eficacia de Zolbetuximab (IMAB362) m\u00e1s Capox, en comparaci\u00f3n con placebo m\u00e1s Capox, como tratamiento de primera l\u00ednea en sujetos con adenocar - cinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica localmente avanzado irresecable o me - tast\u00e1sico, de Andr\u00e9s Ares J . Ensayo cl\u00ednico en fase III multic\u00e9ntrico, aleatorizado, doble ciego, controlado por placebo, con grupos paralelos para investigar la eficacia, seguridad y tolerabilidad de Naloxona HCL LP comprimidos en . Brigatinib en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no pe - que\u00f1as avanzado con linfoma anapl\u00e1sico cin\u00e1sico positivo (ALK+) cuyo c\u00e1ncer ha pro - durante el tratamiento con Alectinib . Ensayo cl\u00ednico de grupos paralelos, aleatorizado, de fase III de OSE2101 como tratamiento de segunda l\u00ednea o tercera l\u00ednea en comparaci\u00f3n con el tratamiento est\u00e1ndar (Docetaxel o Pemetrexed) en pacientes con HLA-A2 positivo y carcinoma broncopulmonar no microc\u00edtico metast\u00e1sico (IV) o localmente avanzado (IIIB) . Ensayo cl\u00ednico fase II, no randomizado en primera l\u00ednea de Ate - zolizumab en combinaci\u00f3n con Carboplatino y Pemetrexed en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico estadio IV con meg\u00e1stasis J . Ensayo de fase II de un \u00fanico grupo para investigar T epotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisi\u00f3n del ex\u00f3n 14 de Met (METEX14) tras fallar, como m\u00ednimo, un tratamiento activo anterior, incluido uno con doblete de platino. Type: Clinical . Ensayo fase III, randomizado, doble ciego, controlado con place - bo, multic\u00e9ntrico, internacional con Osimertinib como tratamiento de mantenimiento en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (estadio III) localmente avanzado e irresecable, con Castro Carpe\u00f1o J . Estudio abierto y aleatorizado de combinaciones de REGN2810 a dosis est\u00e1ndar y alta (Cemiplimab; anticuerpo ANTI-PD-1) e Ipilimumab (anticuerpo ANTI-CTLA-4) en el tratamiento de segunda l\u00ednea de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico metast\u00e1sico con tumores que expresan <50 . Estudio cesto, abierto, multic\u00e9ntrico, global, en fase II con En - trectinib para el tratamiento de pacientes con tumores s\u00f3lidos localmente avanzados o metast\u00e1sicos que albergan reordenaciones en los genes NTRK1/2/3, Carpe\u00f1o J. Estudio de extensi\u00f3n y observacional a largo plazo multic\u00e9ntrico, abierto en pacientes incluidos previamente en un estudio cl\u00ednico de Atezolizumab pro - mocionado por Genentech y/o F . Hoffmann-la Castro Carpe\u00f1o J . Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de Pemetrexed + quimioterapia a base de platino + Pembrolizumab (MK-3475) con o sin Lenvatinib (E7080/MK-7902) como intervenci\u00f3n 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 50 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansde primera l\u00ednea en partcicipantes con c\u00e1ncer de pulm\u00f3n de fase II/III, aleatorizado, abierto y de dos partes, de Dinutuximab e Irinotec\u00e1n versus Irinotec\u00e1n como tratamiento de segunda l\u00ednea en sujetos con c\u00e1ncer de pulm\u00f3n microc\u00edtico en recidiva o de fase III, multic\u00e9ntrico, aleatorizado, abierto de LDK378 oral frente a quimioterapia estandar en pacientes adultos con cancer de pulmon de celulas no peque\u00f1as avanzado con reordenamiento de ALK (ALK-positivo) que han sido tratados previamente con quimioterapia. J . Estudio de fase III, multic\u00e9ntrico, aleatorizado, abierto de LDK378 oral frente a quimioterapia est\u00e1ndar en pacientes adultos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque\u00f1as avanzado con reordenamiento de ALK (ALK-positivo) que han sido tratados previamente con quimioterapia. Castro Carpe\u00f1o J . Estudio de pr\u00e1ctica cl\u00ednica en condiciones reales para evaluar la toma de decisiones en el tratamiento de segunda l\u00ednea conforme a las normas asisten - ciales y basado en los perfiles de Foundation Medicine\u00ae en pacientes con c\u00e1ncer de pulm\u00f3n Carpe\u00f1o J . Estudio en fase I, abierto y no aleatorizado para evaluar el efecto de una o varias dosis orales de Osimertinib (Tagrisso) en la farmacocin\u00e9tica de un f\u00e1rmaco sonda de Glicoprote\u00edna P (Fexofenadina) en pacientes con CPNM con EGFRM avanzado que haya progresado en un tratamiento previo con TKI del EGFR. J . Estudio en fase I, abierto, no aleatorizado y multic\u00e9ntrico para evlauar la farmacocin\u00e9tica, la seguridad y la tolerabilidad de Osimertinib tras la admi - nistraci\u00f3n de una dosis oral \u00fanica de 80 mg a pacientes con tumores s\u00f3lidos avanzados y funci\u00f3n renal normal o disfunci\u00f3n renal grave. Type: Clinical Estudio en III abierto, multic\u00e9ntrico de Brigatinib (AP26113) frente a Crizotinib en pacientes con c\u00e1ncer de pulm\u00f3n avanzado positivo para ALK positiva. Type: Clinical J . Estudio en III, aleatorizado y abierto de Brigatinib (Alun - brigtm) en comparaci\u00f3n con Alectinib (Alecensa\u00ae) en pacientes con c\u00e1ncer de pul - m\u00f3n no microc\u00edtico avanzado positivo para cinasa de linfoma anapl\u00e1sico J . Estudio exploratorio de los efectos biol\u00f3gicos y los biomar - cadores de Nivolumab en combinaci\u00f3n con Ipilimumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) en estadio IV o recurrente sin tratamiento previo (Checkmate 592: evaluaci\u00f3n de la v\u00eda del punto de control y de Nivolumab en ensayos cl\u00ednicos 592. Type: . Estudio fase III, aleatorizado, abierto, de Nazartinib en mo - noterapia frente a f\u00e1rmaco a elecci\u00f3n del investigador (Erlotinib o Gefitinib) como tratamiento de primera l\u00ednea en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque - \u00f1as localmente avanzado o metast\u00e1sico con mutaciones J . Estudio internacional multic\u00e9ntrico de fase III, aleatorizado, doble ciego, controlado con placebo, de MEDI4736 como tratamiento secuencial en pacientes con c\u00e1ncer pulmonar de c\u00e9lulas no peque\u00f1as, localmente avanzado, no re - secable (estad\u00edo III) que no han progresado despu\u00e9s de la terapia de quimiorradiaci\u00f3n concurrente definitiva con base de platino (Pacific). J . Estudio multic\u00e9ntrico, abierto y de un solo grupo, del perfil molecular de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico con mutaci\u00f3n del EGFR localmente avanzado o metast\u00e1sico, Senovilla P . Estudio aleatorizado, controlado con placebo, doble ciego y multic\u00e9ntrico de la eficacia y la seguridad de LJPC-501 en pacientes pedi\u00e1tricos de > 2 a 17 a\u00f1os de edad con hipotensi\u00f3n resistente a la catecolamina asociada a Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 51 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansde La Quintana Jim\u00e9nez P. Estudio cl\u00ednico observacional postcomercializaci\u00f3n, prospec - tivo e R . Ensayo aleatorizado, abierto, multic\u00e9ntrico para evaluar la eficacia de Secukinumab subcut\u00e1neo despu\u00e9s de doce semanas de tratamiento y evaluar la seguridad, tolerabilidad y eficacia a largo plazo en pacientes de 6 a menos de 18 a\u00f1os de edad con psoriasis. Type: 27/04/2018 Laguna R . Estudio de fase 3, multic\u00e9ntrico, aleatorizado, comparativo con placebo, con enmascaramiento doble y grupos paralelos, en el que se eval\u00faa la farma - cocin\u00e9tica, la eficacia y la seguridad de Baricitinib en ni\u00f1os enfermos ambulatorios con dermatitis . Estudio de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, con - trolado con placebo y un comparador activo para evaluar la eficacia y seguridad de BMS-986165 en pacientes con psoriasis en placas de moderada a Type: R . Estudio de seguridad y eficacia preliminar de la infusi\u00f3n de c\u00e9lulas madre mesenquimales haploid\u00e9nticas derivadas de m\u00e9dula \u00f3sea para el tratamiento Biom\u00e9dica Hospital Universitario La Paz. Signed date: 09/01/2018 de Lucas Laguna R . Estudio fase 2B de b\u00fasqueda de dosis, multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia y la seguridad de Ligeli - zumab (QGE031) en pacientes adolescentes con urticaria cr\u00f3nica 18/05/2018 De Paz Arias R . Estudio cl\u00ednico de fase 2, aleatorizado, controlado y abierto para com - parar la eficacia y la seguridad de Pevonedistat m\u00e1s Azacitidina frente a Azacitidina en monoterapia en pacientes con s\u00edndromes mielodispl\u00e1sicos de alto riesgo, leucemia mie - lomonoc\u00edtica cr\u00f3nica y leucemia miel\u00f3gena aguda pobre Paz Arias R . Estudio cl\u00ednico de fase 3, abierto, aleatorizado y controlado de Pe - vonedistat m\u00e1s Azacitidina frente a Azacitidina en monoterapia como tratamiento de primera l\u00ednea en pacientes con s\u00edndromes mielodispl\u00e1sicos de alto riesgo, leucemia Paz Arias R . Estudio de extension abierto del tratamiento de Bosutinib para pa - cientes con leucemia mieloide cronica (LMC) que han participado previamente los R . Estudio fase III, prospectivo, aleatorizado, abierto, con dos brazos de tratamiento, para evaluar la tasa de remision libre de tratamiento (RLT) en pacientes con LMC cromosoma filadelfia positivo, despues de dos duraciones distintas de trata - miento de consolidaci\u00f3n con Nilotinib 300 mg Paz Arias R . Estudio multic\u00e9ntrico, de un \u00fanico brazo, de remisi\u00f3n libre de tra - tamiento de Nilotinib, en pacientes con leucemia mieloide cr\u00f3nica en fase cronica con BCR-ABL1 positivo, que han alcanzado un estado de enfermedad residual minima (ERM) duradera con tratamiento. Type: Clinical P . Estudio aleatorizado, comparativo, de no inferioridad, para evaluar la eficacia y la seguridad de Hemopatch comparado con Tachosil en la preven - ci\u00f3n o reducci\u00f3n de las fugas de aire posquir\u00fargicas tras la resecci\u00f3n FJ . Estudio piloto sobre el control del asma en pacientes con rini - tis al\u00e9rgica a polen de gram\u00edneas tratados con inmunoterapia sublingual Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, abierto, controlado con comparador activo, para evaluar la eficacia y la seguridad de Rivaroxaban a un r\u00e9gimen de dosis ajustado seg\u00fan la edad y el peso, en ni\u00f1os con tromboembolismo venoso agudo. Type: . Patrones de prescripci\u00f3n de Edoxab\u00e1n en Europa: un estudio de utilizaci\u00f3n del medicamento mediante la revisi\u00f3n retrospectiva de historias 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 52 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Daiichi-Sankyo Europe GMBH. Signed . Ensayo cl\u00ednico abierto, multic\u00e9ntrico, de un solo grupo, de Ni - volumab (BMS 936558) en sujetos con melanoma en estadio III (Irresecable) o IV confirmado mediante histolog\u00eda, en progresi\u00f3n despu\u00e9s de un tratamiento previo con un anticuerpo monoclonal E . Ensayo de extensi\u00f3n de fase III, abierto y multic\u00e9ntrico para estu - diar la seguridad y eficacia a largo plazo en participantes con tumores avanzados que actualmente est\u00e1n en tratamiento o en seguimiento en un ensayo de Pembrolizumab. Type: date: 03/05/2018 Espinosa Arranz E . Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de Pembrolizumab (MK-3475) y Lenvatinib (E7080/ MK-7902) en comparaci\u00f3n con Pembrolizumab en monoterapia como intervenci\u00f3n de primera l\u00ednea en participantes con con melanoma avanzado (LEAP-003). Type: Cli - E multic\u00e9ntrico en fase II de DS-8201A, un Anti- HER2 conjugado anticuerpo-f\u00e1rmaco (CAF) para sujetos con c\u00e1ncer de mama HER2 positivo irresecable y/o metast\u00e1sico que son resistentes o refractarios abierto y multic\u00e9ntrico en fase II de DS-8201A, un ANTI- HER2 conjugado anticuerpo-f\u00e1rmaco (CAF) para sujetos con c\u00e1ncer de mama HER2 positivo irresecable y/o metast\u00e1sico que son resistentes o refractarios aleatorizado de fase II, abierto y multic\u00e9ntrico para eva - luar la seguridad y la eficacia de IMCGP100 en comparaci\u00f3n con la elecci\u00f3n del inves - tigador en pacientes con HLA-A*0201 positivo y que no hayan recibido tratamiento previo para el melanoma maligno uveal avanzado. Type: . Estudio de fase 3, abierto y de un solo grupo para evaluar la se - guridad y la eficacia de Pembrolizumab (MK-3475) como tratamiento de primera l\u00ednea en participantes con carcinoma de c\u00e9lulas de Merkel avanzado (Keynote-913). Type: E . Estudio de fase IB multic\u00e9ntrico, sin enmascaramiento para eva - luar la seguridad y la eficacia de Ipatasertib en combinaci\u00f3n con Atezolizumab y Pa - clitaxel o Nab-Paclitaxel en pacientes con c\u00e1ncer de mama triple negativo localmente avanzado o metast\u00e1sico. Type: Arranz E . Estudio de fase IB multic\u00e9ntrico, sin enmascaramiento para eva - luar la seguridad y la eficacia de Ipatasertib en combinaci\u00f3n con Atezolizumab y Pa - clitaxel o Nab-Paclitaxel en pacientes con c\u00e1ncer de mama triple negativo localmente avanzado o metast\u00e1sico. E . Estudio en fase I/II, abierto, multic\u00e9ntrico, de la seguridad y la efica - cia de IMCGP100 usando la pauta posol\u00f3gica con aumento intrapaciente en pacientes con melanoma . Estudio observacional descriptivo sobre las caracter\u00edsticas y evo - luci\u00f3n del melanoma avanzado y Signed date: 25/06/2018 Espinosa Arranz E . Un estudio de fase IB para evaluar el uso de Cobimetinib m\u00e1s Atezolizumab en pacientes con melanoma con BRAFV600 de tipo salvaje avanzado que hayan experimentado progresi\u00f3n. Type: 08/06/2018 Espinosa Rom\u00e1n L . Carga de la enfermedad de la hipofosfatemia ligada al cromosoma X (XLH-QOL Estudio aleatorizado, multic\u00e9ntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de Bruton, Ibrutinib, en combinaci\u00f3n con Nab-Paclitaxel y Gemcitabina frente a placebo en combinaci\u00f3n con . Estudio de fase 3 aleatorizado para evaluar el uso de Eryaspase en combinaci\u00f3n con quimioterapia, comparada con quimioterapia sola como tratamiento de segunda l\u00ednea en pacientes con adenocarcinoma pancre\u00e1tico. Type: Clinical Trial, phase III. Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 53 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated de fase III, abierto y aleatorizado de Atezolizumab en combina - ci\u00f3n con Bevacizumab en comparaci\u00f3n con Sorafenib en pacientes con carcinoma he - patocelular localmente avanzado o metast\u00e1sico no Feliu Batlle J . Estudio en fase II, multic\u00e9ntrico y abierto, para investigar la eficacia, la seguridad y la farmacocin\u00e9tica del anticuerpo monoclonal ANTI-PD-1,BGB-A317, en pacientes con carcinoma . Estudio en fase III, aleatorizado, doble ciego y controlado con place - bo para evaluar la eficacia y seguridad de GS-5745 en combinaci\u00f3n con mFOLFOX6 como tratamiento de primera l\u00ednea en pacientes con adenocarcinoma g\u00e1strico avanza - do o de la . Estudio fase 1b/2 de BMS-813160 en combinaci\u00f3n con quimioterapia o Nivolumab en pacientes con tumores s\u00f3lidos avanzados. Type: multic\u00e9ntrico en adenocarcinoma de p\u00e1ncreas resecable con factores de mal pron\u00f3stico sobre la definici\u00f3n de nuevos marcadores de metilaci\u00f3n predictivos de respuesta Batlle J . Refine: date: 23/05/2018 Frank Garc\u00eda A . Estudio de extensi\u00f3n en fase III, multic\u00e9ntrico, a largo plazo sobre la seguridad y eficacia de AVP-786 (Bromhidrato de [D6]-Dextrometorfano Deuterado [D6-DM]/Sulfato de Quinidina [Q]) para el tratamiento de la agitaci\u00f3n en pacientes con demencia de tipo Alzheimer. Type: Estudio de fase IIB/III,multic\u00e9ntrico, aleatorizado, con doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de JNJ-54861911 en sujetos asintom\u00e1ticos con riesgo de desarrollar demencia de . Estudio de fase III multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo, con dise\u00f1o de grupos paralelos, para evaluar la eficacia, la seguridad y la tolerabilidad de de inmunogenicidad y seguridad de una vacuna conjugada anti - meningoc\u00f3cica tetravalente en investigaci\u00f3n administrada de forma concomitante con las vacunas pedi\u00e1tricas de rutina a ni\u00f1os peque\u00f1os y lactantes sanos en Type: Mart\u00ednez A . Estudio observacional retrospectivo para evaluar las estrategias de tratamiento en pr\u00e1ctica cl\u00ednica y la evoluci\u00f3n cl\u00ednica de los pacientes con c\u00e1ncer de ovario avanzado en Espa\u00f1a: Estudio Ovoc (evaluaci\u00f3n objetiva del c\u00e1ncer Garc\u00eda S . Ensayo cl\u00ednico de fase II de demostraci\u00f3n de viabilidad para evaluar la eficacia y la seguridad de MEDI3902 en la prevenci\u00f3n de la neumon\u00eda nosocomial causada por pseudomonas aeruginosa en pacientes Rio FJ . Caracterizaci\u00f3n de la variable \"minutos diarios de marcha\" como una medida \u00fatil de actividad f\u00edsica en pacientes FJ . Estudio observacional para la validaci\u00f3n de un cuestionario para la acti - vidad f\u00edsica de pacientes con epoc en la 28/03/2018 Garc\u00eda Rio FJ . Importancia de la evaluaci\u00f3n de la respuesta y la estandarizaci\u00f3n con prote\u00f3mica en la obstrucci\u00f3n 02/08/2018 Garc\u00eda S\u00e1nchez A . Estudio cl\u00ednico de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar la seguridad y la eficacia de Lenvatinib 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 54 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians(E7080/MK-7902) en combinaci\u00f3n con Pembrolizumab (MK-3475) frente a Lenvatinib J . Estudio cl\u00ednico de fase III, aleatorizado, doble ciego, contro - lado con placebo para evaluar la seguridad y eficacia de Selonsertib en pacientes con esteatohepatitis no alcoh\u00f3lica (EHNA) y fibrosis . Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de Selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no con . A post-market and international data Barrena E . Ensayo cl\u00ednico fase II para evaluar el efecto del HC-SVT -1001 (c\u00e9lulas mesenquimales troncales adultas aut\u00f3logas de tejido adiposo expandidas e incluidas en biomaterial de fosfato tric\u00e1lcico) en el tratamiento quir\u00fargico de pseu - doartrosis atr\u00f3ficas prospectivo, multic\u00e9ntrico para evaluar la eficacia y la seguridad de una inyecci\u00f3n \u00fanica de Hialuronato S\u00f3dico en pacientes con artrosis de rodilla. preliminary efficacy of MSCS from third party donors in the treatment of patients with osteonecrosis of Biom\u00e9dica Hospital Universitario La Paz. Signed date: 19/12/2018 G\u00f3mez Candela C . Estudio c\u00ednico nutricional en agudo para evaluar el efecto sobre la saciedad de una goma con aroma encapsulado en un colectivo de personas sanas. Type: Producto date: 03/04/2018 G\u00f3mez Candela C . Estudio cl\u00ednico nutricional para evaluar el efecto sobre la sacie - dad y el perfil lip\u00eddico del consumo habitual de un preparado de miel rico en fibra y Polifenoles en un colectivo de personas con sobrepeso/obesidad. Type: Producto C . Estudio cl\u00ednico-nutricional cruzado y aleatorizado con 3 brazos de estudio (yogur rico en fibra (dextrina, harina de avena integral y salvado de trigo); yogur rico en proteina (proteina de guisante); yogur control), para evaluar C . Estudio de intervenci\u00f3n nutricional para evaluar el efecto sobre la saciedad de una conserva de bonito en aceite de oliva enriquecida en fibra o poli - fenoles de un colectivo de personas sanas con sobrepeso. Type: C . Estudio prospectivo, observacional de una alimentaci\u00f3n por sonda con alto contenido cal\u00f3rico y proteico, con carbohidratos de liberaci\u00f3n lenta y \u00e1ci - dos grasos monoinsaturados (AGMI) en Candela C . T olerancia y eficacia de una f\u00f3rmula de nutrici\u00f3n enteral polim\u00e9rica hiperproteica/hipercal\u00f3rica, enriquecida en fibra, aceite de oliva virgen extra y omega 3 en pacientes hospitalizados. Type: Producto 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 55 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansG\u00f3mez Senent S . Estudio postcomercializaci\u00f3n observacional de cohortes en pacien - tes con enfermedad inflamatoria intestinal (EII) tratados con Inflectra (Infliximab) en Signed date: G\u00f3mez Traseira C . Efecto de la intervenci\u00f3n 'Escalera de la leche' en el desarrollo de tolerancia y en el reconocimiento de ep\u00edtopos de c\u00e9lulas B en ni\u00f1os al\u00e9rgicos a pro - te\u00ednas de leche de vaca. Type: by: Fundaci\u00f3n Biom\u00e9dica del Hospital Cl\u00ednico San Carlos. Signed date: 21/06/2018 Gonz\u00e1lez Garc\u00eda JJ . Ensayo cl\u00ednico abierto, aleatorizado y multic\u00e9ntrico para compa - rar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento TAF/FTC/DRV/ COBI cs. ABC/3TC/DTG en pacientes Gonz\u00e1lez Garc\u00eda JJ . Estudio adaptativo, aleatorizado, doble ciego (abierto para el pro - motor), controlado con placebo para investigar el efecto antiviral, la seguridad, la tole - rabilidad y la farmacocin\u00e9tica de GSK3640254 en adultos con infecci\u00f3n por VIH-1 sin . intergrupo para ni\u00f1os o adolescentes con linfoma no- Hodkin B o leucemia linfobl\u00e1stica de c\u00e9lulas B; evaluaci\u00f3n de eficacia y seguridad de Rituximab en pacientes de alto riesgo. 20/11/2018 Gonz\u00e1lez P\u00e9rez de Villar N . Registro nacional de pacientes con diabetes tipo Grac\u00eda Rio FJ . Caracterizaci\u00f3n de la variable minutos diarios de marcha como una medida \u00fatil de actividad f\u00edsica en pacientes con D . Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en comparaci\u00f3n con el placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de A . Seguridad y beneficios del dispositivo de captura de c\u00e9lulas tumorales metast\u00e1sicas en pacientes con c\u00e1ncer de ovario avanzado. P. Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multic\u00e9ntrico, de fase 3 que investiga la eficacia, la seguridad y la tolerabilidad de Tralokinumab administrado en combinaci\u00f3n con corticosteroides t\u00f3picos a pacien - . Ensayo de extensi\u00f3n a largo plazo, multic\u00e9ntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de Tralokinumab en pacientes con der - matitis at\u00f3pica que participaron previamente en ensayos cl\u00ednicos con 3, multic\u00e9ntrico, aleatorizado, doble ciego y compa - rado con placebo, para evaluar la eficacia y la seguridad de Baricitinib en pacientes con dermatitis at\u00f3pica de moderada a . Estudio de fase 3, multic\u00e9ntrico, doble ciego, en el que se eval\u00faan la seguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis . Estudio de fase 3, multic\u00e9ntrico, doble ciego, en el que se eval\u00faan la seguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis de fase 3B, multic\u00e9ntrico, aleatorizado, en doble ciego, con - trolado con principio activo de comparaci\u00f3n (Secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de Bimekizumab en adultos con psoriasis (PSO) en placas cr\u00f3nica de grado moderado o severo. Type: Clinical Estudio en fase 3, aleatorizado y abierto que eval\u00faa la eficacia de Axicabtagene Ciloleucel en comparaci\u00f3n con el tratamiento est\u00e1ndar en pacientes con linfoma difuso de c\u00e9lulas B grandes 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 56 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Kite Pharma Inc. Signed date: 02/11/2018 Herranz Pinto P . Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multic\u00e9ntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o m\u00e1s a\u00f1os de edad con dermatitis at\u00f3pica moderada o grave con la opci\u00f3n de un tratamiento de rescate para aquellos pacientes que presenten un em - peoramiento de la enfermedad. Type: Herranz P . Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multic\u00e9ntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o m\u00e1s a\u00f1os de edad con dermatitis at\u00f3pica moderada o grave con la opci\u00f3n de un tratamiento de rescate para aquellos pacientes que presenten un em - peoramiento de la enfermedad. Type: . Estudio multic\u00e9ntrico, aleatorizado, con doble enmascaramiento y controlado con placebo, para evaluar la eficacia y seguridad de Mirikizumab con Se - cukinumab y placebo en pacientes con psoriasis en placas moderada a grave - Oasis. Type: . Ensayo abierto y con un solo grupo para evaluar la farmacocin\u00e9tica, la seguridad y la eficacia de Daclatasvir (DCV) en combinaci\u00f3n con Sofosbuvir (SOF) en ni\u00f1os de entre 3 y menos de 18 a\u00f1os con infecci\u00f3n por los genotipos del 1 al 6 del virus de la hepatitis cr\u00f3nica (HCC). Type: Llanillo L . Estudio abierto de extensi\u00f3n para evaluar la eficacia y la seguridad a largo plazo de A4250 en ni\u00f1os con colestasis intrahep\u00e1tica familiar progresiva de tipo 1 y 2 . Estudio de fase 3 aleatorizado, con doble enmascaramiento, con - trolado con placebo, para demostrar la eficacia y la seguridad de A4250 en ni\u00f1os con colestasis intrahep\u00e1tica familiar progresiva de tipos 1 y 2 . Estudio de fase 3 aleatorizado, con doble enmascaramiento, con - trolado con placebo, para demostrar la eficacia y la seguridad de A4250 en ni\u00f1os con colestasis intrahep\u00e1tica familiar progresiva de tipos 1 y 2 Higuera G\u00f3mez O . Evaluaci\u00f3n de la calidad de vida de pacientes con estre\u00f1imiento inducido por opioides en tratamiento con Naloxegol. Estudio de un a\u00f1o . Paciente fr\u00e1gil con dolor irruptivo: an\u00e1lisis de la Estudio de fase III, aleatorizado, doble ciego, multic\u00e9ntrico y controlado con placebo, de Pracinostat en combinaci\u00f3n con Azacitidina en pacientes 18 a\u00f1os con leucemia mieloide aguda (LMA) de diagn\u00f3stico reciente no aptos para la quimioterapia de inducci\u00f3n habitual. Type: Clinical Estudio en fase 3, multic\u00e9ntrico, doble ciego, aleatorizado y con - trolado con placebo para evaluar AG-120 en combinaci\u00f3n con Azacitidina en sujetos de 18 a\u00f1os de edad o m\u00e1s con leucemia mieloide aguda con una mutaci\u00f3n de IDH1 sin tratamiento . Estudio observacional prospectivo sobre la supervivencia glo - bal y la calidad de vida en pacientes mayores de 60 a\u00f1os diagnosticados de leucemia mieloide aguda en Espa\u00f1a, tratados seg\u00fan la pr\u00e1ctica cl\u00ednica Ensayo multic\u00e9ntrico, aleatorizado, doble ciego, controlado con pla - cebo para investigar la eficacia y seguridad de dos concentraciones de PKB171 frente a placebo en parejas con astenozoospermia que desean Type: . Estudio aleatorizado, doble ciego, controlado con placebo, de b\u00fas - queda de dosis para evaluar la eficacia y la seguridad de Padsevonil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia C . Evaluaci\u00f3n de la consistencia cl\u00ednica y la solidez anal\u00edtica de Immu - nobiogram\u00ae como herramienta biotecnol\u00f3gica de diagn\u00f3stico in vitro para ayudar a la 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 57 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicianstoma de decisiones en el ajuste del tratamiento inmunodepresor Signed date: 13/02/2018 Jim\u00e9nez Mart\u00edn C . Impacto de los niveles de Tacr\u00f3limus en la prevenci\u00f3n del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio obser - vacional prospectivo en las condiciones de Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad de Fitusir\u00e1n en pacientes con hemofilia A o B sin anticuerpos inhibidores de los facto - res VIII o IX. Type: Clinical . Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad de Fitusir\u00e1n en pacientes con hemofilia A o B sin anticuerpos inhibidores de los facto - res VIII o IX. Type: Clinical . Atlas-INH: estudio en fase 3 para evaluar la eficacia y la seguridad de Fitusir\u00e1n en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores VIII o IX. Type: Clinical . ATLAS-INH: estudio en fase 3 para evaluar la eficacia y la seguridad de Fitusir\u00e1n en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores VIII o IX. Type: Clinical . ATLAS-PPX: estudio abierto, internacional, de cambio de trata - miento para evaluar la eficacia y la seguridad de la Profilaxis con Fitusiran en pacientes con hemofilia A y B que recibian previamente Profilaxis con factores o agentes de puenteo. Type: . Estudio abierto, multic\u00e9ntrico y no controlado de la eficacia de RFVIIIFCrfviiifc para la inducci\u00f3n de tolerancia inmune (ITI) en sujetos con hemofilia a grave con inhibidores que se someten al primer tratamiento de ITI. Type: Clinical intervencionista, prospectivo, en el que se eval\u00faan las hemorragias, las infusiones de factor VIII y los resultados percibidos por el paciente, en personas con hemofilia a grave. 5- para evaluar la eficacia y segu - ridad de la administraci\u00f3n de Concizumab en profilaxis en pacientes con hemofilia a grave sin inhibidores. Type: Clinical Alfa pegol Estudio multic\u00e9ntrico espa\u00f1ol sobre la prevalencia e incidencia de la insuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del \u00e1mbito nacional. Yague B . Estudio aleatorizado, multic\u00e9ntrico, doble ciego, para comparar la eficacia y la seguridad de Ceftobiprol Medocaril con las de la Daptomicina en el trata - miento de la bacteriemia por Aureus, Estudio en fase II, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo, en grupos paralelos, que eval\u00faa la eficacia y seguridad de MTAU9937A en pacientes con enfermedad de Alzheimer de fase prodr\u00f3mica a leve. Type: Estudio en fase II, multic\u00e9ntrico, aleatorizado, doble ciego y contro - lado con placebo, en grupos paralelos, que eval\u00faa la eficacia y seguridad de MTAU9937a en pacientes con enfermedad de Alzheimer de fase prodr\u00f3mica a leve. A . Estudio aleatorizado, controlado con placebo, doble ciego, de gru - pos paralelos, multic\u00e9ntrico, de dosis-respuesta para evaluar la eficacia y seguridad de diferentes dosis orales de BAY 1128688 en mujeres con endometriosis sintom\u00e1tica durante 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 58 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Bayer AG. Signed date: 18/09/2018 L\u00f3pez Carrasco A . Estudio aleatorizado, doble ciego, de grupos paralelos, multic\u00e9ntri - co y de fase IIB para evaluar la eficacia y seguridad de dos dosis diferentes de Vilapri - s\u00e1n (BAY 1002670) frente a placebo en mujeres L\u00f3pez La Gu\u00eda A . Estudio en fase 2, multic\u00e9ntrico, abierto y de incremento es - calonado y ampliaci\u00f3n de la dosis de Venetoclax en combinaci\u00f3n con Pomalidomida y Dexametasona en pacientes con Mieloma m\u00faltiple de La Gu\u00eda A . Estudio observacional para describir el impacto de las combi - naciones de tratamiento con Daratumumab frente a otros tratamientos alternativos en pacientes con mieloma m\u00faltiple en reca\u00edda /refractario (MMRR). Datos de europeo COOL-AMI: un ensayo multic\u00e9ntrico, prospectivo, aleatorizado y controlado en el que se eval\u00faan la seguridad y la eficacia del enfriamiento como tratamiento adyuvante en las intervenciones percut\u00e1neas de pacientes con infarto agudo. Producto Areces E . Estudio cl\u00ednico unic\u00e9ntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terap\u00e9utica con el sistema IVTM de Zoll como adjuvante de la angioplastia coronaria percut\u00e1nea en pacientes con infarto agudo de miocardio. Type: E . Estudio de fase IIB, randomizado, controlado con placebo para evaluar la seguridad y la eficacia de MEDI6012 en el infarto de miocardio agudo con elevaci\u00f3n del segmento. Type: Clinical MO . Suspensi\u00f3n de la profilaxis con Valganciclovir en trasplantados rena - les CMV-seropositivo que mantienen la inmunidad celular CD8+ Signed date: 22/10/2018 L\u00f3pez Ortego P . Ensayo cl\u00ednico fase I para establecer la seguridad del uso de c\u00e9lu - las mesenquimales alog\u00e9nicas en pacientes captopril administered prevention treatment of heart failure in paediatric patients from birth to fundamental, multic\u00e9ntrico, aleatoriza - do, doble ciego, controlado con placebo, de grupos paralelos y determinado por los epi - sodios para evaluar la eficacia y la seguridad de Vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por v\u00eda oral, en sujetos con insuficiencia card\u00edaca con fracci\u00f3n de eyecci\u00f3n disminuida (ICFED): estudio Victoria (Vericiguat Global Study in Ensayo de fase III, aleatorizado y doble ciego para eva - luar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en com - paraci\u00f3n con placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de eyecci\u00f3n Ensayo en fase III, aleatorizado y doble ciego para eva - luar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en compa - raci\u00f3n con el placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de eyecci\u00f3n Estudio aleatorizado, doble controlado con pla - cebo, de grupos paralelos, multic\u00e9ntrico, para demostrar los efectos de Sotagliflozina sobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores de riesgo cardiovascular y funci\u00f3n renal moderadamente reducida (SCORED). 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 59 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansSponsored by: Montreal Heart Institute. Signed date: 25/01/2018 Mart\u00edn . Eficacia de los bolos intravenosos de corticoides m\u00e1s tratamiento con corticoides orales en comparaci\u00f3n con corticoides orales en monoterapia para el tratamiento de la Colitis Ulcerosa). Signed date: 21/03/2018 Mart\u00cdn Arranz MD . Ensayo abierto y a largo plazo de la seguridad del tratamiento con BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado ensayos anteriores de BI Arranz MD . Estudio abierto de extensi\u00f3n y supervisi\u00f3n de la seguridad de pacientes con colitis ulcerosa de moderada a grave previamente inscritos en Estudios de fase III con Etrolizuma. Mart\u00edn Arranz MD . Estudio de ampliaci\u00f3n de fase 3, multic\u00e9ntrico, sin enmascaramien - to en el que se eval\u00faa Ozanimod por v\u00eda oral para la enfermedad de Crohn activa de moderada a grave. Type: Estudio de fase 3, aleatorizado, doble ciego, controlado con pla - cebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como tratamiento de inducci\u00f3n en sujetos con enfermedad de Crohn de moderada a grave (Carmen CD 306). Type: MD . Estudio de fase 3, aleatorizado, doble ciego, controlado con pla - cebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como tratamiento de mantenimiento en sujetos con enfermedad de Crohn de moderada a grave (Carmen CD 307). Type: Arranz MD . Estudio de fase 3, de extensi\u00f3n de seguridad a largo plazo de SHP647 en sujetos con colitis ulcerosa de moderada a grave fase 3, multic\u00e9ntrico, aleatorizado, con enmascaramien - to doble y comparativo con placebo, en el que se eval\u00faa Ozanimod por v\u00eda oral como tratamiento de mantenimiento para la enfermedad de Crohn activa de moderada a grave. Type: Estudio de fase III multic\u00e9ntrico, doble ciego y controlado con pla - cebo de la eficacia y seguridad de Etrolizumab durante la inducci\u00f3n y el mantenimiento en pacientes con colitis ulcerosa activa de moderada a grave resistentes o intolerantes a los inhibidores del FNT. MD . Estudio de fase III, aleatorizado, multic\u00e9ntrico, doble ciego, con doble simulaci\u00f3n, para evaluar la eficacia y seguridad de Etrolizumab comparado con Infliximab en pacientes con colitis ulcerosa activa entre moderada e intensa que no han recibido tratamiento previo con inhibidores del FNT. Mart\u00edn Arranz MD . Estudio de inducci\u00f3n en fase III, multic\u00e9ntrico, aleatorizado, do - ble ciego, de grupos paralelos, controlado con placebo, para evaluar Mirikizumab en pacientes con colitis ulcerosa moderada o gravemente activa sin respuesta a los trata - mientos convencionales. Type: MD . Estudio de inducci\u00f3n multic\u00e9ntrico, aleatorizado, doble ciego y comparado con placebo para evaluar la eficacia y la seguridad de Padacitinib (ABT - 494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una respuesta insuficiente o intolerancia a un tratamiento convencional pero no han pre - sentado fracaso terap\u00e9utico con f\u00e1rmacos biol\u00f3gicos. Type: Clinical . Estudio de inducci\u00f3n multic\u00e9ntrico, aleatorizado, doble ciego y comparado con placebo para evaluar la eficacia y la seguridad de Upadacitinib (ABT - 494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una respuesta insuficiente o intolerancia a un tratamiento convencional pero no han pre - sentado fracaso terap\u00e9utico con f\u00e1rmacos biol\u00f3gicos. Type: Clinical N\u00ba 1 - fase 3, multic\u00e9ntrico, aleatorizado, con enmascaramiento, doble y comparativo con placebo, en el que se eval\u00faa Ozanimod por v\u00eda oral como tratamiento de inducci\u00f3n para la enfermedad de Crohn activa de moderada a grave. Type: de mantenimiento en fase III, multic\u00e9ntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo sobre Mirikizumab en pacien - tes con colitis ulcerosa activa de moderada a grave. (LUCENT 2). Type: Clinical Trial, phase III. 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 60 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Arranz MD . Estudio en fase 1 abierto, aleatorizado, de grupos paralelos para evaluar la farmacocin\u00e9tica, la eficacia y la seguridad de CT -P13 subcut\u00e1neo y CT -P13 intravenoso en pacientes con enfermedad activa de Crohn y pacientes con colitis ulcerosa multic\u00e9ntrico aleatorizado, doble ciego y controlado con placebo de mantenimiento y de extensi\u00f3n a largo plazo, para evaluar la eficacia y la seguridad de Upadacitinib (ABT -494) en sujetos con enfermedad de Crohn que han finalizado los Estudios M1. Type: multic\u00e9ntrico de fase II/III aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia del tratamiento de inducci\u00f3n con BI 655130 en pacientes con colitis ulcerosa activa de moderada a grave que no han respondido al tratamiento previo con f\u00e1rmacos biol\u00f3gicos. Type: Clinical . Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo, prueba de concepto de Ustekinumab en pacientes con lupus eritematoso fase IIA multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de PRV-6527 (JNJ-40346527), un inhibidor del receptor del factor 1 estimulante de colonias, por v\u00eda oral, en pacientes con enfermedad de Crohn activa moderada o grave. Type: Clinical . Exploraci\u00f3n de la posible interferencia de la microbiotaintestinal en la respuesta cl\u00ednica al Vedolizumab en Mart\u00edn Arranz MD . Registro de exposici\u00f3n a largo plazo prospectivo y observacional de pacientes adultos con colitis ulceregistro de exposici\u00f3n a largo plazo prospectivo y observacional de pacientes adultos con colitis ulcerosa moderada a graverosa mode - rada Arranz MD . Un estudio de b\u00fasqueda de dosis en fase II, multic\u00e9ntrico, aleato - rizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de IMU-838 en terapia de inducci\u00f3n y mantenimiento en colitis ulcerosa de moderada a grave . Un estudio de b\u00fasqueda de dosis en fase II, multic\u00e9ntrico, aleato - rizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de IMU-838 en terapia de inducci\u00f3n y mantenimiento en colitis ulcerosa de moderada a grave de dosis fija de Bictegravir/Emtricitabina/T eno - fovir Alafenamida frente a Dolutegravir + Emtricitabina/Fumarato de Disoproxilo de T enofovir en adultos no tratados anteriormente coingectados por el VIH-1 y el virus de la hepatitis Type: M . Estudio en fase III, prospectivo, abierto, internacional y multic\u00e9ntrico sobre la eficacia y la seguridad de la Profilaxis con RVWF en la enfermedad grave de Von el tratamiento del tromboembolismo venoso en pacientes con c\u00e1ncer: un estudio prospectivo aleatorizado abierto y ciego para el evaluador - el Type: Apixab\u00e1n para el tratamiento del tromboembolismo venoso en pacientes con c\u00e1ncer: un estudio prospectivo aleatorizado abierto y ciego para el evaluador . Estudio en fase III, internacional, multic\u00e9ntrico, abierto y aleatoriza - do de BLU 285 en comparaci\u00f3n con Regorafenib en pacientes con tumor del estroma gastrointestinal (GIST) metast\u00e1sico Estudio en fase III, internacional, multic\u00e9ntrico, abierto y aleatoriza - do de BLU 285 en comparaci\u00f3n con Regorafenib en pacientes con tumor del estroma gastrointestinal (GIST) metast\u00e1sico o irresecable phase Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 61 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated neoplasia of SEOM./Estudio epidemiol\u00f3gico obser - vacional descriptivo sobre la trombosis asociada al c\u00e1ncer: registro de trombosis y JR . Estudio de recogida de datos internacional, observacional y retrospectivo en el que se eval\u00faa la eficacia de las medidas de minimizaci\u00f3n de riesgos aplicadas en pacientes quemados tratados . Seguimiento cl\u00ednico posterior a la comercializaci\u00f3n en Eruropa de Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) espec\u00edfico para la terapia neurol\u00f3gica - administraci\u00f3n de f\u00e1rmaco selectiva. Type: Pro Moreno M . Seguimiento cl\u00ednico posterior a la comercializaci\u00f3n en europa de Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) espec\u00edfico para la terapia neurol\u00f3gica - administraci\u00f3n de f\u00e1rmaco selectiva. Type: Pro tratamiento cl\u00ednico de ITUC, IIAC y NBIH/NBAV atribuibles a infecciones R . en humanos, a doble ciego, aleatorio, intraindi - vidual, controlado por placebo, con dosis m\u00faltiples de QR-313 evaluando la seguridad, prueba de mecanismo, la eficacia preliminar y la exposici\u00f3n sist\u00e9mica en sujetos con Estrategia para el mantenimiento de la supresi\u00f3n del VIH en ni\u00f1os con Elvitegravir+ Darunavir/Ritonavir multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad, la eficacia y la inmunogenecidad de una pauta de 2 y 3 dosis de V160 (Vacuna Contra el Citome - galovirus (CMV) en mujeres sanas seronegativas de 16 a 35 a\u00f1os de edad. Type: choque de cardioversi\u00f3n/desfibrilaci\u00f3n, un estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija en una poblaci\u00f3n general con desfibrilador autom\u00e1tico implantable\". Mendieta ED . Estudio multic\u00e9ntrico, observacional no intervencionista, trans - versal y retrospectivo, para evaluar el control de la actividad de la enfermedad en condiciones de pr\u00e1ctica cl\u00ednica habitual en pacientes con espondilitis anquilosante y artritis psori\u00e1sica tratados en consultas de 23/11/2018 Montes Ram\u00edrez ML . Cohorte espa\u00f1ola de pacientes con infecci\u00f3n por VIH mayores de 50 a\u00f1os para el estudio de fragildad y la . Estudio en fase 3, aleatorizdo, controlado con placebo y doble ciego para evaluar la eficiencia y la seguridad de AG-348 en sujetos adultos con deficiencia de piruvato cinasa (PK) que no reciben . Edoxab\u00e1n frente al tratamiento est\u00e1ndar y sus efectos en los re - sultados cl\u00ednicos de los pacientes que se han sometido a una implantaci\u00f3n de v\u00e1lvula a\u00f3rtica transcat\u00e9ter Cl\u00ednico aleatorizado para comparar la eficacia del Stent Angiolite frente a un stent farmacoactivo de segunda generaci\u00f3n como Xience en pa - cientes con indicaci\u00f3n de intervenci\u00f3n 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 62 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansMoreno G\u00f3mez JR . Ensayo pivotal europeo COOL-AMI: un ensayo multic\u00e9ntrico, prospectivo, aleatorizado y controlado en el que se eval\u00faan la seguridad y la eficacia del enfriamiento como tratamiento adyuvante en las intervenciones percut\u00e1neas de pacientes con infarto agudo. Producto revascularizaci\u00f3n utilizando stents liberadores de Sirolimus recubiertos de polimero biodegradable en pacientes con s\u00cdndrome coronario agudo y enfermedad coronaria multivaso. Type: Producto G\u00f3mez JR . estudio cl\u00ednico unic\u00e9ntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terap\u00e9utica con el sistema IVTM de Zoll como adjuvante de la angioplastia coronaria percut\u00e1nea en pacientes con infarto agudo de miocardio. Type: . Estudio con tomograf\u00eda de coherencia \u00f3ptica a 9 meses en stent farmacoactivo de Estudio Onyx One; un estudio aleatorizado y controlado con el Stent Resolute Onyx y tratamiento de doble antiagregaci\u00f3n plaquetaria [dapt] de un mes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario. HULP . Estudio Onyx un estudio aleatorizado y controlado con el Stent Rresolute Onyx y tratamiento de doble antiagregaci\u00f3n plaquetaria [DAPT] de un mes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario. HULP G\u00f3mez JR . Evaluaci\u00f3n de la eficacia (ACC) y la seguridad de la endopr\u00f3tesis recubierta con Biolimus A9TM Biofreedomtm de COCR en un aleatorizado en Castillo Y . Estudio de fase III, aleatorizado, abierto y multic\u00e9ntrico de Ruxo - litinib frente a la mejor terapia disponible en pacientes con enfermedad de injerto contra hu\u00e9sped aguda y refractaria a corticosteroides Registro observacional de N\u00fa\u00f1ez L\u00f3pez MC . Estudio observacional para evaluar la fragilidad de los sujetos du - rante los Estudios Zoster-006 y Zoster-022 y la eficacia frente a Hz, la inmunogeni - cidad y la seguridad de la vacuna HZ/SU seg\u00fan el estado de y doble ciego de Nivolumab adyu - vante frente a placebo para participantes con carcinoma hepatocelular que presentan un riesgo alto de reca\u00edda despu\u00e9s de la resecci\u00f3n o la ablaci\u00f3n hep\u00e1tica Estudio multic\u00e9ntrico de fase III, doble ciego, aleatorizado, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del \u00c1cido Obeti - c\u00f3lico en sujetos con esteatohepatitis Ensayo cl\u00ednico de fase 4, aleatorizado, doble ciego y controlado con comparador activo para estudiar la eficacia, la seguridad y la farmacocin\u00e9tica de Dugammadex (MK-8616) para neutralizar el bloqueo Signed date: 17/10/2018 Pascual Pascual SI . Estudio de continuaci\u00f3n, doble ciego, controlado con placebo, aleatorizado, multic\u00e9ntrico, dividido en dos partes para investigar la seguridad, tolera - bilidad, farmacocin\u00e9tica, farmacodin\u00e1mica y eficacia de RO7034067 en pacientes con atrofia muscular espinal de tipo 2 23/03/2018 Pascual Pascual SI . Estudio de extensi\u00f3n del seguimiento internacional, multic\u00e9ntrico, doble ciego de 9 meses de duraci\u00f3n para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-T ooth de Estudio de extensi\u00f3n del seguimiento internacional, multic\u00e9ntrico, doble ciego de 9 meses de duraci\u00f3n para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-T ooth de 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 63 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansPascual Pascual SI . Tratamiento de extensi\u00f3n a largo plazo y sin enmascaramiento usando fosfato s\u00f3dico de dexametasona intraeritrocitaria en pacientes con ataxia te - langiectasia que participaron en el estudio . Estudio posautorizaci\u00f3n de seguridad multic\u00e9ntrico y no interven - cionista de 6 a\u00f1os de duraci\u00f3n realizado en pacientes a los que se ha recetado Jinarc\u00ae debido Peinado Peinado R . Appraise ATP: evaluaci\u00f3n de pacientes en prevenci\u00f3n primaria previa implantaci\u00f3n de un DCI - evaluaci\u00f3n sistem\u00e1tica de la electroestimulaci\u00f3n anti - R . Estudio eficaz: Eficacia de choque de cardioversi\u00f3n/desfibrilaci\u00f3n, un estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija en una poblaci\u00f3n general con desfibrilador autom\u00e1tico implantable. date: 18/04/2018 P\u00e9rez Mart\u00ednez A . Ensayo en fase IB para evaluar Idelalisib en ni\u00f1os y adolescentes con linfoma difuso de c\u00e9lulas B grandes o linfoma mediast\u00ednico de c\u00e9lulas B recidivante o resistente en combinaci\u00f3n Type: A . Estudio aleatorizado, abierto, de seguridad y eficacia de Ibrutinib en pacientes pedi\u00e1tricos y adultos j\u00f3venes con linfoma no Hodgkin de c\u00e9lulas maduras B en reca\u00edda A . Estudio de fase 2B, abierto y de un solo grupo para evaluar la far - macocin\u00e9tica, la eficacia, la seguridad y la tolerabilidad de Letermovir en participantes pedi\u00e1tricos desde el nacimiento hasta menos de 18 a\u00f1os con riesgo de sufrir infecci\u00f3n y/o enfermedad por CMV despu\u00e9s de un trasplante alog\u00e9nico de c\u00e9lulas madre A . Estudio multic\u00e9ntrico de fase 1/2, de aumento escalonado de la dosis, para evaluar la seguridad, la farmacocin\u00e9tica, la farmacodin\u00e1mica y la eficacia de Quizartinib, en combinaci\u00f3n con quimioterapia de reinducci\u00f3n y como tratamiento de mantenimiento con un solo agente. En pacientes pedi\u00e1tricos con MLA refractaria o en reca\u00edda de entre 1 mes y 18 a\u00f1os (y adultos j\u00f3venes de hasta 21 a\u00f1os) con mutaciones de FLT3-ITD. Type: . Ensayo cl\u00ednico fase IV abierto, aleatorizado dise\u00f1ado para evaluar la reversibilidad de la neurotoxicidad asociada al uso de Abacavir/ Lamivudina /Dolute - gravir en el sistema nervioso central tras el cambio a una pauta de tratamiento anti - rretroviral basada en Alafenamida/Emtricitabina/Darunavir/Cobicistat. A . An\u00e1lisis retrospectivo de factores cl\u00ednicos asociados a un mayor bene - ficio con Axitinib en A . Estudio de fase II para la evaluaci\u00f3n del tratamiento neoadyuvante con Cabozantinib previo a la nefrectom\u00eda citorreductora en pacientes con c\u00e1ncer de c\u00e9lulas renales localmente avanzado o metast\u00e1sico. Type: Estudio de fase II, multic\u00e9ntrico, aleatorizado y abierto para evaluar la seguridad y la eficacia de Avelumab con Gemcitabina/Carboplatino frente a quimio - terapia con Gemcitabina/Carboplatino sola, en pacientes con carcinoma urotelial no resecable o metast\u00e1sico que no hayan recibido terapia sist\u00e9mica previa y que no sean aptos para la quimioterapia con cisplatino. Type: Clinical 12/03/2018 Pinto Mar\u00edn A . Estudio en fase III sobre Erdafitinib en comparaci\u00f3n con Vinflunina, Docetaxel o Pembrolizumab en sujetos con carcinoma urotelial avanzado anomal\u00edas gen\u00e9ticas . Estudio fase II, internacional, multic\u00e9ntrico, prospectivo para evaluar la eficacia, la seguridad y la calidad de vida de Pazopanib administrado diariamente por v\u00eda oral, en pacientes con carcinoma de c\u00e9lulas renales avanzado y/o metast\u00e1sico despu\u00e9s de terapia previa con tratamiento con agentes inhibidores del control de la inmunidad (Checkpoint Inhibitors). Type: Clinical Trial, phase II. 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 64 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated 06/11/2018 Pinto Mar\u00edn A . Tratamiento adyuvante del c\u00e1ncer renal con Axitinib: estudio en fase III, aleatorizado y doble ciego del tratamiento adyuvente con Axitinib frente al placebo en sujetos con alto riesgo de CCR recurrente. multic\u00e9ntrico, abierto, fase 1B/2 de Lenvatinib (E7080) m\u00e1s Pembrolizumab en sujetos con fase 1B/2 de Lenvatinib (E7080) m\u00e1s Pembrolizumab en sujetos con 05/11/2018 Prados S\u00e1nchez C . Estudio abierto en fase III para evaluar la seguridad a largo plazo y la eficacia de la Politerapia con VX-659 en pacientes con fibrosis qu\u00edstica, homocigotos C . Estudio en fase III, aleatorizado, doble ciego y controlado para evaluar la eficacia y la seguridad de la politerapia con VX-659 en pacientes con fibrosis qu\u00edstica, heterocigotos para la mutaci\u00f3n F508DEL y una mutaci\u00f3n de la funci\u00f3n m\u00ednima . Ensayo cl\u00ednico multic\u00e9ntrico, randomizado, para evaluar la eficacia y seguridad de la quimioterapia intraperitoneal hipert\u00e9rmica (HIPEC) con Mitomicina C asociada a cirug\u00eda en el tratamiento del carcinoma colorrectal localmente avanzado. Type: (FIBICO-IMIBIC). Signed date: 27/07/2018Quesadas Sim\u00f3n A . Revisi\u00f3n observacional en serie de historias cl\u00ednicas del uso de Repatha\u00ae en Registro de pacientes ME . Registro Estudio cl\u00ednico multic\u00e9ntrico, aleatorizado y abierto de S-649266 o mejor tratamiento disponible para infecciones graves provocadas por pat\u00f3genos Gram negativos resistentes a carbapenemos. en fase II, multic\u00e9ntrico, aleatorizado, doble ciego, para eva - luar la seguridad, tolerabilidad y eficacia de CD101 inyectable frente a Caspofungina intravenosa seguido de desescalado a Fluconazol oral, en el tratamiento de pacientes . Opini\u00f3n - Estudio en fase IIIB, abierto, de grupo \u00fanico y multi - c\u00e9ntrico de la monoterapia de mantenimiento con Olaparib en pacientes con c\u00e1ncer de ovario recidivante sin mutaci\u00f3n de BRCA en l\u00ednea germinal y sensible al platino que est\u00e1n en respuesta parcial o completa tras la quimioterapia con platino. Type: Redondo A . Ensayo cl\u00ednico fase II abierto de Enzalutamida en c\u00e1ncer de la granulosa ov\u00e1rica avanzado no Infrecuentes. Signed date: 21/02/2018 Redondo S\u00e1nchez A . Ensayo de fase I/II, abierto, con varios grupos, para investigar la seguridad, la tolerabilidad, la farmacocin\u00e9tica y la actividad biol\u00f3gica y cl\u00ednica de AGEN1884 en combinaci\u00f3n con AGEN2034 en sujetos con tumores s\u00f3lidos metast\u00e1 - sicos o . Ensayo fase II de Olaparib de mantenimiento tras la respuesta a 2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 65 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansTabectedina y Doxorrubicina Liposomal pegilada en c\u00e1ncer (GEICO). Signed date: 17/05/2018 Redondo S\u00e1nchez A . Ensayo fase III, aleatorizado y doble ciego de quimioterapia basa - da en platino con o sin Atezolizumab, seguida de mantenimiento con Niraparib con o sin Atezolizumab, en pacientes con c\u00e1ncer de ovario, de trompa de falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (GEICO). Signed date: 13/09/2018 Redondo S\u00e1nchez A . Ensayo internacional, con grupo \u00fanico de Tisotu - mab Vedotina (Humax\u00ae-TF-ADC) en c\u00e1ncer de cuello de - ridad, aleatorizado fase III de quimioterapia con Platino y Pacli - taxel m\u00e1s Bevacizumab y Atezolizumab frente a quimioterapia con Platino y Paclitaxel m\u00e1s Bevacizumab en el carcinoma de c\u00e9rvix metast\u00e1sico (estadio (GEICO). Signed date: 20/07/2018 Redondo S\u00e1nchez A . Estudio de en fase IB de Rucaparib (CO-338) y Atezolizumab (MPDL3280A) en pacientes con c\u00e1nceres avanzados del aparato repro - ductor femenino y c\u00e1ncer de mama triple 01/03/2018 Redondo S\u00e1nchez A . Estudio de fase 2 de Prexasertib en c\u00e1ncer de ovario resistente o recurrente refractario a derivados del platino. . Estudio de fase 2 de Prexasertib en c\u00e1ncer de ovario resistente o recurrente refractario a derivados del platino. Type: Estudio en fase III aleatorizado sobre Trabectedina (ET 743) frente a la quimioterapia elegida por el cl\u00ednico en pacientes con c\u00e1ncer ov\u00e1rico, peri - toneal primario o tub\u00e1rico con fenotipo de mutaci\u00f3n en (GEICO). Signed date: 16/02/2018 Redondo S\u00e1nchez A . Estudio fase 2 aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Farletuzumab (MORAB-003) en combinaci\u00f3n con carboplatino m\u00e1s Paclitaxel o Doxorubicina Lipos\u00f3mica Pegilada (PLD) en trial of Pembrolizumab in combination with S\u00e1nchez A . Sarcomas de partes blandas lozalizados de alto riesgo de extre - midades y pared de tronco en adultos: un enfoque integrador que incluye quimiotera - pia est\u00e1ndar tolerabilidad de T ofacitinib para el tratamiento de la artritis idiop\u00e1tica juvenil(AIJ) de curso poliarticular en sujetos ni\u00f1os y Estudio abierto, secuencial, de b\u00fasqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyecci\u00f3n subcut\u00e1nea (S.C.) a ni\u00f1os y ado - lescentes con edades comprendidas entre 2 y 17 a\u00f1os con artritis idiop\u00e1tica juvenil de curso poliarticular (AIJP), seguido de una fase . Ensayo cl\u00ednico aleatorizado, multic\u00e9ntrico, abierto, controlado, fase III, pa - ralelo, para evaluar la eficacia y seguridad de Ivabradina versus Digoxina en el control cor\u00f3nico de la frecuencia card\u00edaca en pacientes con fibrilaci\u00f3n auricular 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 66 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansRobles Marhuenda AJ . Estudio aleatorizado, doble ciego, controlado por placebo, de 52 semanas de duracion para evitar los acontecimientos adversos de especial interes en adultos con lupus eritematoso sistem\u00e1tico activo, con anticuerpos positivos, que toman Bethancourt Codes F . Caracter\u00edsticas y manejo de los pacientes diag - nosticados de s\u00edntomas del tracto urinario inferior por hiperplasia benigna de pr\u00f3stata atendidos A single arm phase I-II multicenter trial with avelumab plus auto - logus dendritic cell vaccine to determine safety and preliminary efficacy Determinaci\u00f3n del estado mutacional de ras en biopsias l\u00edquidas de sujetos con c\u00e1ncer colorrectal metast\u00e1sico ras no mutado en primera l\u00ednea: estudio Estudio abierto, aleatorizado, fase 2 que compara S95005 con Be - vacizumab frente a Capecitabina con Bevacizumab en pacientes con c\u00e1ncer colorrectal metast\u00e1sico no tratado previamente que no son candidatos a terapia intensiva. Type: Clinical N . Estudio aleatorizado de fase II para evaluar la eficacia de Folfiri +Panitumumab en el tratamiento en segunda l\u00ednea de pacientes con c\u00e1ncer colorrectal metast\u00e1sico ras no mutado que han recibido Folfox + Panitumumab en primera l\u00ednea . Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de Folfox + Panitumumab seguido por Folfiri + Bevacizumab (secuencia 1) frente a Folfox + Bevacizumab seguido por Folfiri + Panitumumab (secuencia 2) en pa - cientes con c\u00e1ncer colorrectal metast\u00e1sico no resecable, ras nativo, tumor primario en lado izquierdo, no tratado multic\u00e9ntrico, aleatorizado, controlado con placebo, de grupos paralelos en dos periodos de tratamiento para evaluar la seguridad de QAW039 a\u00f1adido al tratamiento existente en pacientes con asma no controlada con los pasos 3, 4 y 5 de la gina. Type: Clinical Fracturas de f\u00e9mur con ines - tabilidad rotacional. Estudio comparativo de la eficiencia de diferentes sistemas para incrementar la estabilidad. Type: Producto by: Fundaci\u00f3n Instituto de Estudios de Ciencias de la Salud de Castilla y Le\u00f3n. Signed date: 08/05/2018 S\u00e1enz de Pipa\u00f3n Marcos M . Estudio aleatorizado, doble ciego y controlado con placebo para evaluar el efecto de un probi\u00f3tico en ni\u00f1os prematuros. Type: MO-PED: estudio de fase 2, aleatorizado, doble ciego y con - trolado con placebo para evaluar la eficacia y la seguridad de Palovaroteno en sujetos con osteocondromas . Estudio observacional prospectivo sobre el uso de dos pautas de es - timulaci\u00f3n ov\u00e1rica con Folitropina Alfa (FSH) y Gonadotropina Menop\u00e1usica Humana (HMG) en t\u00e9cnicas de reproducci\u00f3n asistida en pacientes con potencial baja respuesta (Estudio Life). Sastre Urg\u00fcelles A . Ensayo cl\u00ednico fase 1/2 de un brazo para evaluar la seguridad y la eficacia del Mesilato de Eribulina en combinaci\u00f3n con Irinotec\u00e1n en ni\u00f1os con tumores s\u00f3lidos refractarios o recurrentes. Type: Estudio de fase I/II, multic\u00e9ntrico, abierto, a un solo brazo, de Ruxolitinib a\u00f1adido a corticosteroides en pacientes pedi\u00e1tricos con enfermedad aguda de injerto contra hu\u00e9sped de grado II-IV tras trasplante alog\u00e9nico de cl\u00ednico fase IV, abierto, de brazo \u00fanico y multic\u00e9ntrico sobre la inmunogenicidad de la vacuna nonavalente frente al virus del papiloma huma -2.6 Clinical Trials Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 67 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansno en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA Estudio de extensi\u00f3n multic\u00e9ntrico, abierto y de un solo grupo para evaluar la efectividad y la seguridad de Ocrelizumab en pacientes con esclerosis m\u00faltiple incluidos previamente en un ensayo cl\u00ednico de fase IIIB/IV de Ocrelizumab patrocinado por Esteban E . Estudio de fase 2, aleatorizado, multic\u00e9ntrico, doble-ciego, eficacia y seguridad, para la evaluaci\u00f3n de esquemas de dosis orales de Fexinidazol para el tratamiento de pacientes adultos con enfermedad de chagas cr\u00f3nica indeterminada. Type: . Estudio de fase 2, aleatorizado, multic\u00e9ntrico, doble-ciego, eficacia y seguridad, para la evaluaci\u00f3n de esquemas de dosis orales de Fexinidazol para el tratamiento de pacientes adultos con enfermedad de chagas cr\u00f3nica indeterminada. con encefalopatia con hipotermia- Sanitaria H La Fe. Signed date: 17/01/2018 Villanueva Pe\u00f1a R . Estudio de fase II, aleatorizado, doble ciego, controlado con place - bo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al d\u00eda durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia. Type: Clinical Villanueva Pe\u00f1a R . Cohorte de depresi\u00f3n en . Estudio de fase II, aleatorizado, doble ciego, controlado con place - bo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al d\u00eda durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia. Type: Clinical . Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Safinamida 100 mg una vez al d\u00eda, como tratamiento complementario, en pacientes con enfermedad de Parkinson idiop\u00e1tica (EPI) con fluctuaciones motoras y dolor cr\u00f3nico relacionado con la enfermedad de Parkinson. Type: Clinical Estudio doble controlado con placebo, de LEE011 en combinacion con Letrozol para el tratamiento de mujeres postmeno - pa\u00fasicas con c\u00e1ncer de mama avanzado con receptor hormonal positivo, HER2- negativo que no han recibido terapia previa para la enfermedad avanzada. Type: Clinical . Estudio de fase II randomizado, multic\u00e9ntrico, abierto para evaluar la eficacia y seguridad de Palbociclib en combinaci\u00f3n con Fulvestrant o Letrozol en pacientes con c\u00e1ncer de mama met\u00e1stasico HER2 negativo, ER+ (Parsifal 1). . Estudio de fase II, abierto, aleatorizado y multic\u00e9ntrico, para evaluar la seguridad y la eficacia de agentes dirigidos frente a los mecanismos de reparaci\u00f3n del ADN en combinaci\u00f3n con Olaparib, en comparaci\u00f3n con Olaparib en monoterapia, en el tratamiento de pacientes con c\u00e1ncer de mama metast\u00e1sico triple negativo con estratificaci\u00f3n en funci\u00f3n de sus alteraciones en los genes recombinantes de repara - ci\u00f3n hom\u00f3loga (incluido Estudio en fase 3 aleatorizado, abierto, de Abemaciclib en combina - ci\u00f3n con tratamiento endocrino adyuvante est\u00e1ndar frente a monoterapia con trata - miento endocrino adyuvante est\u00e1ndar, en pacientes con c\u00e1ncer de mama en estadios iniciales, de alto riesgo, con afectaci\u00f3n ganglionar, receptores hormonales 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 68 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank which works to obtain, store, manage and dis - tribute large collections of human biological samples of diseases of interest for researchers. This service is created with the collaboration of the Uni - versity Hospital La Paz, the Foundation for Biomedical Re - search of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz -IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684 The IdiPAZ Biobank belongs to the National Biobank Network (RNBB) (http://www.redbiobancos.es) to support research in science and technologies of the Strategic Health Action 2018-2020 of the Carlos III Health Institute. OBJETIVES The main objective of the IdiPAZ Biobank is to biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the Royal Decree of Biobanks 1716/2011. This guarantees the confidentiality The IdiPAZ Biobank provides researchers with an agile channel to access -ples, their products and data associated with quality assurances adaptation. is attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results. Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank favored. In the the IdiPAZ is made known and valued to society and, especially, in the field affected with society and also aims to groups with common interests both nationally and internationally. All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all (Organic Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 69 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansCOMPOSITION Scientific Director: Paloma G\u00f3mez Campelo (PhD) Coordinator: Marina Hardisson Hern\u00e1ez (MD, PhD) Francisco Arnalich Fern\u00e1ndez de C\u00e1ceres (PhD) Enrique Espinosa Arranz (MD, PhD) Eduardo L\u00f3pez Granados (MD, PhD) EQUIPMENT Eight -80\u00baC deep freezers equipped with re - mote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes Combined refrigerator of 4\u00ba C preserve tissues, blood, and cells. Printer/photocopier/scanner 3 computers and a management computer system Label printing system and a bar code reader connected to the management software PORTFOLIO OF SERVICES Technical and scientific assessment: Collection and management of new collection Work Methodology/ Methods Quality control of DNA/ARN sample treatment Expert training to use Biobank management system Training and advice on the use of Biobank management software (Bio-e-Bank) Information to the investigator on the custody, deposit, availability and transfer of samples associated with trainees (FCTs) cycles pre-existing LIB Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 70 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Paraffin/frozen and quantification to have to sample deposit (in which the terms conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject.On the other hand researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and condi - tions under which the Biobank will grant the samples. BIOBANK'S SCIENTIFIC INDICATORS In the year 2019, Biobank IdiPAZ has worked on 64 research projects funded by Spanish State aid, private foundations, industrial companies or cooperatives. The principal researchers of these projects belonged to IdiPAZ research groups and to external, national and international groups. Of these projects and together with the central node of the biobank, a total of 2,969 new samples been stored, genera - ting more than 11,549 aliquots so far this year. During the same period, the Biobank has opened several projects, so it has been dedi - cated the recruitment of samples. In allocated while maintaining the demand for samples. La Paz Central Research and Clinical Trials Unit (Unidad Central de Investigaci\u00f3n Cl\u00ednica y Ensayos Clinicos de La Paz, HULP-UCICEC), is one of the IdiPAZ suppor - ted research platforms. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UCICEC is integrated in the Spanish Clinical Research Network (SCReN). Its wide portfolio of services provides to design, set-up (including IRBs and Competent Authority data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the development research, particularly in the recruitment and follow-up of patients obtaining, processing and shipping the samples to central laboratories. (MD, 912 (MD, Garc\u00eda Garc\u00eda (MD) Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 71 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansProject Manager / Senior CRA Paloma Moraga Alapont (MSc) offices (9 work stations) 1 Meeting room (with audiovisual and teleconference systems) 1 Archive room Phase I/II Clinical Trial Unit: 2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 72 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians- A hospital ward with eight beds and four chairs (children and adults) - 1 Doctor's office - 1 Central point for sample collection - 1 Sitting room Carlos III Satellite Unit - 1 Work office and doctor\u00b4s office - 1 Laboratory EQUIPMENT 1 ECG 1 Centrifuge (Carlos III Satellite Unit) 2 Refrigerated centrifuge 1 Refrigerator 1 Room temperature chamber (Carlos III Satellite Unit) 3 -20\u00baC freezers (1 in Carlos III Satellite Unit) 2 -80\u00baC deep freezer 4 Vital signs monitors Defibrillator T emperature recording system Digital clocks synchronised by GPS 2 medical scales (1 in Carlos III Satellite Unit) Digital blood pressure monitors and pulse oximeters Digital timers Crash calling devices 4 patient surveillance cameras PORTFOLIO OF SERVICES The portfolio of services more than 80 tasks grouped OF UCICEC During more than 132 commercial clinical trials of 46 Research Groups and more than 40 independent clinical research projects. In this period, 6 audits have been conducted and have been successfully overcome. In UCICEC projects, including advice on study requirements and documentation, protocol development and design and preparation of application reports for com - petitive projects. Finally, more than 10 early phase trials have conducted in our Phase I. The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine- tunes procedures for diagnostic and therapeutic techniques that use labora - tory animals. In the teaching field, the 71 542.7.3 Experimental Surgery2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 73 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansVeterinarian: Carlota Largo Aramburu carlota.largo@salud.madrid.org Phone: (+34)91 727 71 54 Secretary: Irene Cuevas Gordo Phone: (+34) 91 727 71 54 Technicians and assistants: Javier Rubio Bol\u00edvar Sonsoles Jim\u00e9nez Mediano Isabel Rodr\u00edguez Mar\u00edn Pablo Llorente Fern\u00e1ndez Pedro Gallego Montesano Daniel Ruiz P\u00e9rez M\u00aa del Mar Barona Garcia EQUIPMENT The Section consists of two microsurgery rooms, an operating room animal facility. The microsurgery room has surgical loupes and mi as as inhalers anaesthesia systems for rodents. All experimental procedures with ro - dents are performed in this room. Its layout, with fixed and mobile posts, allows for the with and stations with performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques. The animal a total of five rooms for conventional accommodation of animals, in both the breeding phase and for experimentation. T wo of these rooms have modular en - closures for housing large species such as pigs, sheep and rabbits. The three rodents (rat, and gerbil). ventilation rats) and in shelves. It also has a sealed positive and negative FACILITY The research and teaching at IdiPAZ involving the use of laboratory animals is mana - ged via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In this department we develop biomedical research projects, training courses specific diagnostic techniques or therapies that involve the use of experimental ani - mals. In addition, the animal facility works with Wellbeing, procedures. The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental pha - ses, two rooms for animal handling and experi - mental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressurebased washing system, and several sto - rage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Sur - gery where there is a double operating theatre, a microsurgery room and various additional occasionally dogs, cats or guinea pigs. Re - cently, a fish housing unit has been established (zebra fish). T o avoid contamination and permit a good workflow, the rooms for hou - sing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the avoi cage stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects. For the cleanliness of the room and the animals, there are hot and cold water connections via a hose. 2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 74 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position. The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room. The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, glo - ves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish. There is a storeroom for feed and shavings and a room for handling and the performance of procedures. In addition to two large areas of animals, the animal facility includes: A washroom equipped with a cage washer stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it. A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray. Store room (clean material). Control room with computers for environmental control. The animal facility complies with all current legislation and is registered with number ES-280790001941. PORTFOLIO OF SERVICES Animals for experimentation (own breeding) Housing and maintenance of animals Leasing of for conducting courses (microsurgery laboratories and opera - ting room) Performance of surgical procedures on large animals (leasing space and anaesthe Learning and for and physical examination and patients, using Javier Cobas Gamallo D\u00aa. Ana Coloma Zapatero Dra. Carlota Largo Aramburu D\u00aa Elena Mart\u00edn de Castro Dr. Juan V\u00e1zquez Est\u00e9vez D\u00aa. Alicia Portas Mart\u00ednez Dr. Manuel Quintana D\u00edaz Dr. Pedro de la Oliva Senovilla Dr. Ram\u00f3n Cantero Cid Dra. Ana M\u00aa S\u00e1nchez Torres Dra. Emilia Guash Ar\u00e9valo Dr. Esteban L\u00f3pez de S\u00e1 y Areses Dr. Ignacio Zapadiel 1 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 75 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansDra. Esther Rey Cuevas Dr. Juan Jos\u00e9 R\u00edos Blanco Dra. Dolores Elorza Fern\u00e1ndez Chairman Governing Council Dr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez Dr. Manuel Quintana D\u00edaz Secretary Governing Council: D\u00aa. Ana Coloma Zapatero D\u00aa. D\u00aa. Irene Cuevas Gordo (+34) 2018, the CEASEC The platform has provided assistance and support for research 50 courses. School Courses Simulation (Summary) Course Director January, 15th, 16th, 17th Curso RCP January 31st SIMUVAD 2018 Dr. Pedro Garrido February 1st, 2nd, 3rd Curso RCP B\u00e1sico Dr. Manuel Quintana February 13th M\u00f3dulo politrauma pedi\u00e1trico Dr. Juan Jos\u00e9 V\u00e1zquez 15th Colgajos Microvasculares en la Arias Gamallo Dra. Mar\u00eda Jos\u00e9 Mor\u00e1nFebruary 19th, 23rd Accesos vasculares perif\u00e9ricos Dr. Juan Jos\u00e9 Men\u00e9ndez Suso February 28th Curso de Asistencia Inicial al Trauma Pedi\u00e1trico (AITP) Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez March 15th, 16th RCP B\u00e1sico + DESA Dr. Manuel Quintana March 19th Simulaci\u00f3n en ECMO Neonatal Dra. M\u00aa Dolores Elorza March 21stIX Curso de Ecograf\u00eda en el Paciente Pedi\u00e1trico Cr\u00edticoDr. Juan Jos\u00e9 Men\u00e9ndez Suso March 20th, 21st, 22nd RCP B\u00e1sico + DESA Dr. Manuel Quintana March 28th Shock 2018 Dr. Emilio Maseda April 6th Curso de Microcirug\u00eda Experimental y Colgajos Microvasculares RataDr. C\u00e9sar Casado S\u00e1nchez April 9th, 13th SIMUMED 2017 Dr. Pedro Garrido April 19th, 20th, 21st Soporte Vital Pedi\u00e1trico D\u00aa. Catalina Fern\u00e1ndez Carretero April 24th XXXI Curso Nacional Pr\u00e1ctico Multidisciplinario de Microcirug\u00eda Vasculo Nervioso y sus Aplicaciones Cl\u00ednicasDr. C\u00e9sar Casado S\u00e1nchez May 7th, 11th Simulaci\u00f3n en Emergencias Obst\u00e9tricas Dr. Jos\u00e9 Luis Bartha Rasero May 17th Ecograf\u00eda Pulmonar en Cardiolog\u00eda Dr. C\u00e9sar Carballo May 21st, 22nd, 23rd RCP Avanzado Dr. Manuel Quintana D\u00edaz May 21st to 25th T\u00e9cnicas de depuraci\u00f3n extracorp\u00f3rea Dra. Carlota Largo Aramburu May 29th, 30th Crisis Resource Management Radiolog\u00eda Dr. Manuel Quintana D\u00edaz June 5th RCP Avanzado Dr. C\u00e9sar Carballo June 18th, 19thScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 76 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansAtenci\u00f3n al paciente pedi\u00e1trico grave en el servicio de urgencias (CRM - Crisis resources)Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez June 19th Retos en el manejo y diagn\u00f3stico del ictusDra. Blanca Fuentes June 21st Caso cl\u00ednico laringoespasmo Dr. Francisco Reinoso Junio 21st, 22nd Curso Pr\u00e1ctico de Cirug\u00eda Laparosc\u00f3pica Dr. Ignacio Zapardiel September 17th RCP B\u00e1sica Neonatal y Ped\u00edatrica Dr. Miguel de R\u00edo September 18th, 19th Simulaci\u00f3n en Cuidados Intensivos Pedi\u00e1tricosDr. Miguel del R\u00edo September 28th Curso de Simulaci\u00f3n en Enfermer\u00eda de Atenci\u00f3n al ICTUS Dra. Blanca Fuentes October 1st, 2nd, 3rd Curso de Asistencia Inicial al Trauma Pedi\u00e1trico (AITP) Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez October 18th, 19th Curso de Ecografia en el Paciente Pedi\u00e1trico Cr\u00edticoDr. Juan Jos\u00e9 Men\u00e9ndez Suso October 8th, 9th, Canalizaci\u00f3n ecoguiada de accesos y PICCSDr. Juan Jos\u00e9 Men\u00e9ndez Suso October 22nd Curso de Instructores en RCP Pedi\u00e1trica y Neonatal Miguel de R\u00edo October 24th, 25th, 26th Crisis Resource Management en Neonatolog\u00eda Dra. Dolores Elorza Dr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez October 25th Soporte Vital Inmediato D\u00aa. Catalina Fern\u00e1ndez November 5th, 6th, Curso de simulaci\u00f3n avanzada en el manejo de paciente cr\u00edtico cardiol\u00f3gicoDr. Esteban L\u00f3pez de S\u00e1 November 12th, 13th Curso Avanzado de Instructores en Simulaci\u00f3n Cl\u00ednica Dr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez Dr. Manuel Quintana D\u00edaz November 20th, 21st Simulaci\u00f3n en de Simulaci\u00f3n en Emergencias Obst\u00e9tricas Dr. Jos\u00e9 Luis Bartha Rasero December 5th Curso de microciurg\u00eda vascular cerebral been established as a core support division integrated into the Hospital La Paz Institute for Health Research (IdiPAZ). This unit facilitates the establishment and management of in vitro model systems and experimental- related techniques for different applications and purposes including the study of biochemical processes in cells, the elucidation of the molecular and cellular me - chanisms involved in a biological process, the basis for the development of research initiatives in the field of Biomedical and Pharmacological Research and Health Sciences. The Cell Culture Unit accomplishes its mission by providing users with assistan - ce and support at scientific, technical and instrumental level through access to knowledge, equipment, material and human resources. According to IdiPAZ stra - tegic plan and other institutional guidelines, this division contributes to the trans - research groups ex - ternal institutions. It also provides dynamic and shared operational offering a convenient basis for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as the creation of researchers of various categories and disciplines. and proximity with other core as 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 77 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansTechnical Support: Beatriz Sanz Minguel EQUIPMENT AND FACILITIES The Culture Unit consists of an experimentation laboratory, cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building. laboratory II biological safety cabinet 3 Faster BIO 48 vertical laminar flow 1 TWO 30 vertical laminar a centralized and alarmed gas system, which guarantees a constant and contro - lled supply C and -20 \u00b0 C) 1 Balay refrigerator (4 \u00b0 C and -20 \u00b0 C) 1 Whirlpool refrigerator (4 \u00b0 C and -20 \u00b0 C) 1 Beko refrigerator (4 \u00b0 C and -20 \u00b0 C) Other equipment: 1 Presoclave 75 P-Selecta autoclave Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 78 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 1 Memmert thermostatic waterbath 2 6 nitrogen tank 1 10 K liquid nitrogen for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical OPERATING STANDARDS The Culture joint for biomedical including infrastructure and equipment, technical assistance and scientific consultation to researchers who request their services. With regard to facilities and equipment available, staff associated with the Unit will be responsible for their proper mainte - nance and operational guidelines and will provide support, training and supervision in order to obtain optimal utilization and exploitation. The Unit is oriented to specialized training, exchange and dissemination of scientific knowledge and an active collaboration with users to develop cell culture-related procedures and technology. This service not to meet the needs of IdiPAZ researchers but also to pro - vide adequate support to non-IdiPAZ scientists that do the Service, the established principles of prevention, health and safety, guidelines on handling and management of reagents, materials and waste disposal besides the opera - ting instructions and procedures for instruments and equipment. Users (from the IdiPAZ or other facility or institution) who request services for the first time or who demand additional information, please contact to the Head of the Platform.PORTFOLIO OF SERVICES The Cell Culture Platform activities are focused on providing users and results-oriented services in a collaborative and translational research framework. In ge - neral, this Division offers support for experimental approaches developed by IdiPAZ and laboratory assistance, training and research. The specific support provided by this Unit includes: Scientific and of results... Basic and experiments (implementation of the self-service mode) according to biosafety, waste disposal guidelines reagents and Management and supervision including good laboratory practices and work habits, cleaning and waste disposal and operation and maintenance of the equipment Performance of experimental procedures: cell separation, cell isolation for cul and Control and maintenance of cryopreserved stock cells Elaboration and management of protocols and contaminations in to these standard services, platform offers collaboration with individual researchers as an effective way to improve and to expand the port - folio of technology and services offered. Furthermore, and as part of its com - mitment to warrant users the optimal development of their research projects, the contact to other centralised equipment and affiliated facilities, infrastructu - res and common services available on the Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 79 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe main role of the Sanger sequencing laboratory is to pro - vide support for medical research in the field of Molecular Biology. The goal is to support to research groups both inside our Institute and elsewhere that require the infrastructure CE. Our laboratory is located inside INGEMM. This allows for fre - quent the hospital's various research groups, and thus allows for the laboratory members to stay up to date on state-of-the-art techniques in genetics. Therefore, the laboratory is Nowadays, the Sanger sequencing method is regarded it as the standard for validation of Next-Generation Sequencing single above, based on capillary electrophoresis. The equipment can use up to 5 simultaneous colours on the same sample when it migrates analysers. regularly involved in quality control audits on the Sanger as result homologation. EMQN). In addition, Sanger Sequencing Facility has to the ISO 9001:2015 Standard during 2018. COMPOSITION Lab Manager Mar\u00eda del Roc\u00edo Mena de la Cruz (PhD) mariarocio.mena@salud.madrid.org Phone: 91 207 10 10 (Ext. Variant Nucleic Acid Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 80 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansImage and Immunohistochemistry Unit, as a part of the network of IdiPAZ core fa - cilities, play an essential realise their in biomedical research. The laboratory mission is to provide a centralized dedicated well technical support to researchers. The Unit collaborates in creating a link between basic and clinical research to reach the translational research milestones, in addition Institute training and education plans. Therefore, Image and immunohistochemistry Unit is open researchers, inclu - provides histological and molecular technical support to the re - searchers' requirements, which in turn produces high quality data interpretation to support grant applications and national and international scientific publications. Currently a broad range of techniques ranging from molecu - lar techniques as immunohistochemistry, immunofluorescence and image and digital analysis are available at the facility. The general rules of the platform is that trained and authorized users have free access to the platform; IdiPaz staff in a Do-It-yourself manner and in a fee-for-service manner to all the rest. The Unit, located in the IdiPaz building at the La Paz University Hospital, consists of two sections, the Immunohis - tochemistry and the Microscopy laboratories. Immunohistochemistry laboratory, housed in the floor immuno-staining (Dako Autostainer). Microscopy Lab is in the -1 floor IdiPaz building and offers facilities to perform do conventional, fluorescence, confocal and high-content includes Nikon with in vivo incubation system and a microscope Nanosight with a system of tracking nanoparticles. In addition, lab offers investigacion.hulp@salud.madrid.org Phone: (+34) 91 207 15 12 RESOURCES, EQUIPMENT AND MANAGEMENT OF THE LABORATORY The laboratory staff will present the basic rules to new users for good practices and safety in the laboratory. Users should not use the equipment until the labora - personnel have checked their correct training. Users must schedule the time of work in any equipment and booking reserve it is mandatory in all the facility. Ac - cess to the Microscopy requires the magnetic individual. The services of the image core facility are available to all scientists in collaboration, Do-It-Y ourself model or in a fee model (in this case, it must be consulted the head of the laboratory, the lab will support the service depending on staff availability). Equipment of Image Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 81 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Leica EG 1150C Cold plate 2 thermostatic water Leica stirrer with Olympus NUAIRE laboratory fume hood. Dissection with manual options for Do-It-Y ourself stai - ning and cover slipping. The laboratory with shared and Anatomopathology (ESCO fume hood and - me). Permission to use must be asked to the head of these laboratories. The Microscopy laboratory equipment includes: Leica TCS SPE inverted 003 - LAB) - D gas (Bright viewing Marlin camera, an objective x20 and connected to a image analysis software. Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached) Image ProPlus 5.0 image analysis software Leica LAS AF image analysis software Analysis station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software. Nanosight NTA 3.1 analytical software. The laboratory is equipped with shared facility from Neuroscience group (Leica TCS SPE inverted confocal). RESEARCH HIGHLIGHTS In 2018, Image unit maintained their quality standards in order to support and collaborate with the groups belonging to the research areas of IdiPAZ; Neuroscien - ces, Infectious disease and system patholo - gies and Surgery, transplant and health technologies. The results of these co - llaboration are reflected in projects granted (publics or privates, national or international grants), scientific dis - semination (thesis) and high impact international publications. In the last year, we have maintained the number of users inside Hospital La Paz (HULP , clinical and basic researchers), associated IdiPaz groups (UAM), and exten - ded research groups (UCM, CSIC etc). The Operation Time in 2018 (calculated as the total time of use per year of some equipment from Microscopy lab and from immunohistochemistry) has system of quality management fo - llowing the ISO9001:2015 STANDARD. In addition, the staff of the unit assist to the SPAOM Spanish-Portuguese Meeting for Advanced Optical Microscopy orga - 2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 82 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansnized by the Spanish Network of Advanced Optical Micros - copy (REMOA) in Granada with a poster communication. This allows us to implement the collaboration with other image core platforms and the knowledge of recent advances in the field of bioimaging tech - niques. The platform maintains the training activities as tutor centre trainees of the Commu - nity of Madrid, maintaining a co - llaboration with two institutes for their students perform regulated practices. PORTFOLIO OF SERVICES Collection and processing fixing and decalcification of samples Sample processing in paraffin by hand or automatic - Complete paraffin embedding processing - Serial cut in microtome and tissue assembly Antibodies' validation Buffer preparation and consumables Sample - Preparation of freeze assembly acquisition. Viewing digital format - microscopy with biological samples (incubation system for the tem - and advice for planning projects that could require the use of microscopy 2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 83 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe IdiPAZ Flow Cytometry Laboratory is becoming consolidated as a great tool in the centre's research approach. The laboratory is dedicated to providing members Access to affordable and flow services, together with the decisive scientific expertise to utilize this technology in research. We Excel at a wide variety of flow cytometry Toledano 91 727 00 00 (ext. 2484) Secretary: Susana Garc\u00eda P\u00e9rez investigacion.hulp@salud.madrid.org T el: (+34) 912 071 512 EQUIPMENT The Flow Cytometry Laboratory Navios provides accurate measurements, especially for and monitoring. The clinical lab. - three lasers; Blue solid state Diode: 488nm, 22mwlaser - solid - form cell analysis and cell sorting in a single benchtop system. The system supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive soft - ware solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes. Each analyser has OS.9.2.2 computers is and allow to in equipment and reagents. These parallel advan - ces in optical and reagent technology allow multi-laser equipment to complement the new a deeper and more powerful insight - This analyser has BUV12: 4 / Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 84 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians(BV is connected to computer using the DIVA acquisition and analysis programme The laboratory also has an additional Mac G5 OSX analysis station with Cell - QuestPro of the platform distributed by usage hours (%) of each group. The radioactive facility of IdiPAZ laboratories is authorised by the Nuclear Safety Council (Consejo de Seguridad Nuclear, They are also responsible for the removal and management of waste products David Vicent L\u00f3pez david.vicent@salud.madrid.org Phone: (+34) 91 207 10 30 Secretary Susana Phone: (+34) 91 207 15 12EQUIPMENT Contains use of aliquot withdrawal and storage of radiolabeled equipment for exclusive use with radioac - tive material. The laboratory Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 85 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe Biostatistics Section has the mission of giving the professionals of the \"La Paz\" Universitary Hospital and, in general, to the IdiPAZ pro - fessionals, and to provide technical solutions optimization used for data analysis: SAS 9.3 (Copyright \u00a9 2012, SAS Institute Inc., Cary, NC, USA) SAS Enterprise Guide 5.1 (Copyright \u00a9 2012, SAS Institute Inc., Cary, NC, USA) R version 3.5.0 R Core T eam (2018). R: A language and environment for statis - tical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. SPSS 9 (Copyright 1999 by SPSS Inc. ) SYSTAT 11 (Copyright (c) 2004 by SYSTAT Software Inc., Richmon, CA, USA.) nQuery Advisor 5.0 (Copyright 1995-2002) PEST Planning of Sequential Trials (Medical and pharmaceu - tical Statistics Research Unit. The University of Readyng, UK) Review Manager (RevMan) Version 5.0. (Meta-an\u00e1lisis) Copenhagen: The Nor - dic Cochrane Centre, The Cochrane Collaboration, 2008. Joinpoint Regression Program, Version 4.5.0.1. June, 2017; Statistical Research and Applications Branch, National Cancer Institute. PORTFOLIO OF SERVICES Study design Creation of data collection systems (such as ms Access) T echnical support in the development of studies. Assistance in the design, analysis and interpretation of of diagnostic tests in the clinical hospital context Development of information processing systems (clinical image, readings of mea - suring devices, implementation of statistical methods ...) Analysis of results: Multi - variate Analysis (Discriminant Analysis, Correspondence Analysis, Models, develo pment for and prediction, construction of scoring systems for clinical trial methodology , methods of sequential 'Center' 14,57,813,85,259 4,853,9 5,2 17,2 4,5 11,92,2 0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit 2017 2018 34,221,2 62,213,3 34,24,5 6,7 58,4 4,518,537,85,9 14,8 0,7 0 10 TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018 69,423,2 68,7196,13,71,8 70 80Sta-feaMirAtd-due- MatronaResearcherOther 20172018 29,7109012,23,7 197,490,811,73,1 0 10 20 30 90 100DesignSample SizeData AnalysisData basesOthers 20172018 Section2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 86 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Distribution by 'Research Dissemination Objectives' 14,57,813,85,259 4,853,9 5,2 17,2 4,5 11,92,2 0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit 20172018 34,221,2 62,213,3 34,24,5 6,7 58,4 4,518,537,85,9 14,8 0,7 0 40 50 60 70 80Sta-feaMirAtd-due- MatronaResearcherOther 20172018 29,7109012,23,7 197,490,811,73,1 0 10 20 30 90 100DesignSample SizeData AnalysisData basesOthers 20172018 54,655,8 56,343,8 by 'Research Statement' 14,57,813,85,259 4,853,9 5,2 17,2 4,5 11,92,2 0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit 20172018 34,221,2 62,213,3 34,24,5 6,7 58,4 4,518,537,85,9 14,8 0,7 0 TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018 69,423,2 68,7196,13,71,8 70 80Sta-feaMirAtd-due- MatronaResearcherOther 2017 2018 29,7109012,23,7 197,490,811,73,1 0 10 20 30 90 100DesignSample SizeData AnalysisData basesOthers 20172018 54,655,8 'Required Support' 14,57,813,85,259 4,853,9 5,2 17,2 4,5 11,92,2 0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit 20172018 34,221,2 62,213,3 34,24,5 6,7 58,4 4,518,537,85,9 14,8 0,7 0 TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018 69,423,2 68,7196,13,71,8 70 80Sta-feaMirAtd-due- MatronaResearcherOther 20172018 29,7109012,23,7 197,490,811,73,1 0 10 20 30 90 100DesignSample SizeData AnalysisData basesOthers 2017 2018 50 60NOYES Pertaining to a research line 14,57,813,85,259 4,853,9 5,2 17,2 4,5 11,92,2 0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit 20172018 34,221,2 62,213,3 34,24,5 6,7 58,4 4,518,537,85,9 14,8 0,7 0 TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018 69,423,2 68,7196,13,71,8 70 80Sta-feaMirAtd-due- MatronaResearcherOther 20172018 29,7109012,23,7 197,490,811,73,1 0 10 20 30 90 100DesignSample SizeData AnalysisData basesOthers 20172018 60NOYES2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 87 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians IdiPAZ's Documentalist Platform aims to control and - duction generated through the activity of the researchers from the Institute. This control is carried out thanks to the use of different tools specifically created for this purpose and whose results are published in the bibliometric reports that appear on our website. In these reports you can observe the scientific production of each one of the research groups that form part of IdiPAZ. However, the information contained in the reports has not yet been validated by the groups, hence its provisional nature. The information supervised and validated by the directors of each group will be officially published in the Annual Research Report together with the rest of the information from the different committees and platforms that make up our Institute. The Documentation Platform also pro - vides assistance to all IdiPAZ members who need help regarding access and use of bibliographic searches, bibliometric indicators or any other related subject. As an additional service, for some time now, we have also been in charge of printing the posters that our researchers present at congresses around the world:COMPOSITION Head Ra\u00fal Rom\u00e1n Ca\u00f1izares documentalista@idipaz.es Phone: (+34) 91 207 15 12 PORTFOLIO OF SERVICES Draw up of IdiPAZ's Annual Research Report Support to researchers in their access and use of databases, literature searches, etc. Design and creation of tools to control the scientific production Development of Bibliometric Reports Evaluation of researchers Bibliometric assessment of Research Groups Advice on literature search tools Advice on the use of techniques The PAIN Platform-Early-Stage Researches Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ that aims to promote the design and development of research projects in several health areas, with high methodolo - gical quality, to enable our professionals mission of the PAIN Platform is to promote the training and development of early career researchers COMPOSITION Head 15 12PORTFOLIO OF SERVICES Methodological and epidemiological support to the study design of the professionals in early-stage research T echnical and methodological support in developing a research protocol for a study Analysis of the grounds for refusal of rejected projects Methodological support to write proposals to access all available funding programs T 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 88 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe IdiPAZ Internationalisation Platform constitutes a service who wish either to increase their influence or to keep being reference in the Health Research international arena, with particular focus in the European funding schemes and framework programmes. The main objective is to promote the different research groups of IdiPAZ at in - ternational level. Thus, identifying possible as well as 17 90 of international funding programs for Research & T flag and disseminate relevant opportunities and calls IdiPAZ research and actively participate in international networks of interest for the centre. T o introduce and disseminate the capabilities of the centre and its research groups. T o recognise, define, validate and develop project ideas that emerge in the centre. T o support and encourage participation in information events. T o organise and host information and training sessions on specific required areas. T o advise on the proposal preparation and the negotiation phase with the European Commission T o manage the approved projects. PROGRAMMES Horizon 2020 H2020 is the leading European program for funding research and innovation pro - jects in various subject areas. For the 2014-2020 it accounts with a budget of nearly are managed by the following figure:2.7.13 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 89 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansHorizon Europe The future framework programme for R&I will come into force in 2021 and last until the end of 2027. The EC ambitions a budget of \u20ac 100,000 million a instrument of Research Missions. EU Health Programme The Health Program of the EU is the main instrument available to the European Commission to carry out its Health Strategy for the Union. It is implemented through annual work plans, in which the criteria and funding priorities are esta - blished. The total budget of the third program is 449.4 million euros for the period 2014- 2020. IMI The Innovative Medicines Initiative (IMI) is the world's biggest public-private part - nership in the life sciences. It joins the European Union (represented by the Eu - ropean Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through its \u20ac 3,300 million budget for 2014-2020, IMI facilitates open collabora - tion in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need. COST COST is the oldest (established in 1971) and widest European intergovernmental framework for transnational Cooperation in Science and echnology. Its aim is to enable breakthrough scientific developments leading Actions, represent the main the program for its implementation. The calls are continuously open with two INTERREG-SUDOE DOCUMENTATION Webs Funding entry point for electronic administration of EU- funded research Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense. Eshorizonte2020: it is the H2020 Spanish portal. EURAXESS: it is a unique pan-European initiative providing access to a com - plete range of information and support services to researchers wishing to pursue their research careers in Europe connected to European IPR Helpdesk: it offers free of first-line support IP and IPR matters to beneficiaries of EU funded research SMEs involved in transnational partnership especially within (EEN). EATRIS: European Infrastructure for Translational Medicine, it provides a new development pathway, open to researchers and companies in need of support for advancing biomedical innovations. ECRIN: European Clinical Research Infrastructure Network, it is a public, non- profit organisation that links scientific partners and networks across Europe to facilitate multinational clinical Agreement - AMGA December 2018 version 2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 90 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansCURRENT ACTIVE PROJECTS 2.7 Platforms Acronym TitleLink to project (CORDIS Network on transplantation in childrenhttp://www.transplantchild. com/ EU Health Systems G\u00f3mez BarrenaScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 91 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansqMARQuantification of the intestinal load of a targeted set of resistance genes MINECO Europa Redes y GestoresJos\u00e9 Ram\u00f3n November the the call \"Europa Redes y Gestores 2017\". The final aim of the project H2020PAZ is to encourage and facilitate the jects that improve the rates of success and return of the institute. In this sense, the H2020PAZ project has two main objectives: to consolidate and current structure of Platform of IdiPAZ and to encourage the participation of the research groups of the institute in international research programs - especially H2020-, technological development and innovation, by the different tasks and activities defined in this proposal. In order to achieve these main objectives, the project is structured into four groups with directly and Project Management. H2020PAZ will of 2 years, beginning on January 1st, 2017 but the ending date has been extended December 31st, 2019.Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 92 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansPORTFOLIO OF SERVICES Participation in international networks of interest of funding and project opportunities sessions and courses Preparation and dissemination of scientific and technological profiles of the research groups Advice on the definition of the project idea and the preparation of proposals Identification of project proposals under preparation in which the centre can be involved Identification of partners for projects coordinated or participated by resear - chers at the centre Support in the negotiation phase with the European Commission - EC before the signing of the grant agreement - GA Management of funded Platforms The and 3D promote - jresearch and solutions based on tissue engineering and bioprinting and offer different services as 3D printing technologies, computer ima - ging, virtual planning and computer aided design to the bioprinting of tissues and organs development a skin model Establishment of a live organoid biobank from patients' samples Lab on a Chip (LOC) and Organ on a Chip (OOC) devices Tissue engineering approaches to develop tissue models and organs Development of medical devices (biomodels, surgical guides, prosthesis and implants) based printing Computer imaging, virtual planning and 3D printing to plan surgeries COMPOSITION Director Ram\u00f3n Cantero Cid Scientific advisor Maria P . De Miguel Gonz\u00e1lez Lab manager Daniel Cerme\u00f1o Pampliega PITI3D@idipaz.es Research assistant Mario Ju\u00e1rez Rodr\u00edguezEntrepreneur Carlos Biec Amigo info.piti3d@gmail.com (+34) REGEMAT SERVICES Bioprinting of meshes materials Development of biofabrication processes Development of Lab on a Chip (LOC) and Organ on a Chip (OOC) devices Computer imaging and tissue segmentation from TAC and MRI 3D virtual planning Computer processing and manufacturing Education and training in the areas of activities2.7.14 Tissue Engineering and 3D Printing PlatformScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 93 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansThe IdiPAZ Food, Nutrition and created to provide scientific-technical service and support in Human Research and Specialized Advice in Nutrition and Food issues. The Platform provide service of Specialized Advice in Nutrition and Food at 3 levels: 1. Industries (agro-food or pharmaceutical sector) interesting in the new products development with an improved 2. of guidelines and healthy habits (web, app, etc.) and 3. Individual interested in knowing their nutritional status through a precision and individualized nutritional human nutrition, in order to validate the activity and efficacy compounds, artificial ted products. Institutions/government agencies with an interest in expanding knowledge in the area of nutrition for the generation/implementation of political measures in Pu - blic Health. Public or private institutions that want to develop computer applications, or in - formation or communication programs in the field of consumers interest in the variables in their research projects. Individuals interested in obtain information about their nutritional health and wish to receive precision of foods or nutritional formulas Scientific-technical support of Human Create well designed Project Plan for and other human studies - Management and Submission of applications to the Ethics Committee: The platform prepares management all execution are carried out by members of the platform team with consolidated qualifications in the area) - Dietary studies: through the use of validated tools (Food records (24h, 3-7 2.7.15 Food, Nutrition and Health Platform2.7 Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 94 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Cliniciansdays), Food Frequency Questionnaires, Weighted food trition Universal Screening T - Quality of life studies: through the use of valida - ted questionnaires - Gastrointestinal T olerance Studies: through the use of validated questionnaires - Nutrigenetics and Metabo - lic Studies with our colla - borating centers - Production of scientific and te- chnical report Development of computer applications for websites or mobile apps in the nutri - tion / food area and pro Platforms Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 95 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.8 Scientific Production Journal ISSNTotal of documentsImpact AMERICAN HUMAN JOURNAL OF MEDICAL GENETICS AMERICAN JOURNAL OF MEDICINE AnalysisScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 96 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansAMERICAN JOURNAL OF OPHTHALMOLOGY 0002-9394 Q1 OF RESPIRATORY AND Q1 AMERICAN JOURNAL CARDIOLOG\u00cdA DE M\u00c9XICO 1405-9940 1 Not Indexed ARCHIVOS DE LA SOCIEDAD ESPA\u00d1OLA DE OFTALMOLOG\u00cdA1989-7286 1 Not Indexed ARCHIVOS ESPANOLES DE UROLOG\u00cdA HISTORIA DE LA MEDICINA Y DE LA CIENCIA0210-4466 1 Not Indexed ASIAN JOURNAL OF Production Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 97 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansBONE & JOINT JOURNAL 2049-4394 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 98 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansCYTOTHERAPY 1465-3249 14.297 Q1 DATA FAILURE 2055-5822 13.407 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 99 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansFRONTIERS 2 2 CARE MEDICINE 0342-4642 5 JOURNAL OF ANTIMICROBIAL JOURNAL OF CANCER INSTITUTE0027-8874 2 13.757 Q12.8 Scientific Production Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 100 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansJOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY0021-8561 1 3.571 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE1582-4934 JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM0271-678X Q1 JOURNAL OF Production Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 101 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansJOURNAL OF PEDIATRIC PSYCHOPHARMACOLOGY 0269-8811 JOURNAL OF RHEUMATOLOGY OF THE AMERICAN COLLEGE OF CARDIOLOGY0735-1097 6 18.639 Q1 JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION0731-5724 12.08 JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 0002-8614 JOURNAL OF THE AMERICAN HEART ASSOCIATION 2047-9980 JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION1525-8610 Q1 JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA0004-5772 1 Not Indexed JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY0926-9959 3 5.113 59.102 INTENSIVA 0210-5691 1 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 102 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF (TECAMACHALCO, PUEBLA, M\u00c9XICO: 1 Not REVISTA CL\u00cdNICA DE GASTROENTEROLOG\u00cdA DE M\u00c9XICO 0375-0906 1 Not Indexed2.8 Scientific Production Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 103 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansREVISTA DE NEUROLOG\u00cdA 0210-0010 50.485 Q4 REVISTA DE PSIQUIATR\u00cdA 12.927 Q2 REVISTA ESPA\u00d1OLA DE ANESTESIOLOG\u00cdA Y REANIMACI\u00d3N0034-9356 Indexed REVISTA ESPA\u00d1OLA DE CARDIOLOG\u00cdA 0300-8932 275.126 Q1 REVISTA ESPA\u00d1OLA DE CIRUG\u00cdA ORTOP\u00c9DICA Y TRAUMATOLOG\u00cdA1988-8856 2 Not Indexed REVISTA ESPA\u00d1OLA DE ENFERMEDADES DIGESTIVAS 1130-0108 91.858 Q4 REVISTA ESPA\u00d1OLA DE GERIATR\u00cdA Y GERONTOLOG\u00cdA1578-1747 8 Not Indexed REVISTA ESPA\u00d1OLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR2253-654X 40.928 Q4 REVISTA ESPA\u00d1OLA DE PATOLOG\u00cdA 1988-561X 2 Not Indexed REVISTA ESPA\u00d1OLA DE QUIMIOTERAPIA 0214-3429 30.76 Q4 REVISTA ESPA\u00d1OLA DE SALUD 1 Not 1 Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 104 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.8.2 High Impact Publications2.8 Scientific Production Neuroscience Area Area Wenzel Diaconu Cors Position on the Manda G, Hassan A, Alcaraz MJ, Barbas C, Daiber A, Ghezzi P , Leon R, L\u00f3pez MG, Oliva B, Pajares M, Rojo AI, Robledinos-Anton N, Valverde AM, Guney E, Schmidt HHHW. Transcription factor NRF2 as a , Rojo AI, Arias E, D\u00edaz-Carretero A, Cuervo AM, Cuadrado A. Transcription factor Garc\u00eda-Yag\u00fce AJ, Buend\u00eda I, Van Leuven F , Yamamoto M, L\u00f3pez MG, Cuadrado A . Deficiency in the transcription factor NRF2 A, Uribarri A, Garc\u00eda-Acuna JM, Villa P , P\u00e9rez PJ, L\u00f3pez-Send\u00f3n JL . A multicentre randomized Jarr\u00edn I, Moreno A, Dom\u00ednguez L, Montes M, Ald\u00e1miz-Echevarr\u00eda T, T\u00e9llez MJ, Santos I, Ben\u00edtez L, Sanz J, Ryan P, Gaspar G, \u00c1lvarez B, Losa JE, T orres-Perea R, Barros C, San Mart\u00edn JV, Arponen S, de Guzm\u00e1n MT, Monsalvo R, Vegas A, Garc\u00eda-Benayas MT, Serrano R, Gotuzzo L, Men\u00e1ndez MA, Belda C, Richette P, van der Heijde D. In patients with axial spondyloarthritis inflammation on disease acti- vity Briones AC, Moreno AB, Mate AD, Do - m\u00ednguez-Soto A, Merino MJB, Molina LD, R, C\u00e1rdenas PP , Polo LC D\u00edaz MC, Vales-G\u00f3mez M, Santiago ER, Cerd\u00e1n AF, Blanco JN, Corbi AL, Reyburn HT, Regueiro E, Gorostidi M, de la Cruz JJ, Ruiz-Hurtado G, Segura J, Rodr\u00edguez-Artalejo F, Williams B. Relationship clinic and ambulatory blood-pressure Armada E, S\u00e1nchez-Salado JC, S\u00e1nchez PL, Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 105 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.8 Scientific Production Large System Pathologies Area Surgery, Transplant and Health Technologies Area Cancer and Human Molecular Genetics Area V, Nuno-Nuno L, Peiteado D, Villalba A, JP , Lobo VJSA, Megias D, Felipe I, del Pozo N, Millan I, Thommesen L, Bruland T, Olson SH, Smith Worsley-Hunt N, Garc\u00eda-R\u00edo F, Mole D, Ratcliffe P, Wasser - man WW, Jim\u00e9nez B, SIN3A , Lasocki S, Les - T, Dupont Castillo-Mafla A, Montero-Feijoo A, Salgado P , Arruebo M, R, IF: Large congenital coronary fistula. Editorial Material. 2018; KE. a Afonso R, Alonso V, Astudillo A, Capdevila J, Garc\u00eda-Carbonero R, Grande E, Jim\u00e9nez-Fonseca P , Marazuela M, V\u00e1zquez-Naharro Santos V, Morales S, Yuste L, Peinado H, Garc\u00eda-Gomez A, Portillo F , Her - nando E, Cano A. Lysyl oxidase-like 3 E, Ortega S, JF Agra N, Vallesp\u00edn E, Fern\u00e1ndez-Montano VE, Mart\u00edn-Arenas R, del Pozo A, Gonz\u00e1lez-Pecellin H, Mena R, Rueda-Arenas I, G\u00f3mez MV, Villaverde C, Bustamante A, Ayuso C, Ruiz-P\u00e9rez VL, Nevado J, of the Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 106 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians 2.9 CIBERs and RETICs Acronym Center Biomaterials and Garc\u00eda-Samaniego Rey, Javier Clinician 31/12/2019 CIBERerNetworked Biomedical Rare Trascasa, MargaritaDiagnosis and Treatment Research Center for Public Health and EpidemiologyCarlos III Health Institute Rodr\u00edguez Artalejo, Fernando Cardiovascular Epidemiology 31/12/2018 CIBERnedNetworked Biomedical Research AntonioNeuroprotective Strategies Diseases31/12/2018 CIBERcvNetworked Biomedical Research Center for DiseasesCarlos III Mercedes Vascular Physiology 31/12/2022 CIBERonc Research Garc\u00eda, Amparo Mechanisms of T umour Progression CenterScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 107 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.9 CIBERs and PT17/0005/0025 ITEMAS Biomarkers in Cancer31/12/2020 PT17/0015/0025 Innate Immune Response 31/12/2020 PT17/0017/0013 SCReNPlataforma de Unidades Investigaci\u00f3n Cl\u00ednica y Ensayos Cl\u00ednicosCarlos III Health Institute Fr\u00edas Iniesta, PLUSVascular Tejedor, ExuperioNeurology and Cerebrovascular Diseases31/12/2021 S2013/MIT-2862 MULTIMATMateriales multifuncionales para los D\u00edaz, Nuria RIS Research Network for AIDS Carlos III Health Institute Gonz\u00e1lez Garc\u00eda, Juan Jos\u00e9 Julio Associated Clinician 31/12/2021 RD16/0022/0006 SAMIDResearch Network for Maternal and Child Health and DevelopmentCarlos III Health Institute Mart\u00ednez 31/12/2021 Guti\u00e9rrez, Rafael Nephrology 31/12/2021 RD16/0022/0004 SAMIDResearch Network for Maternal and Child Health and DevelopmentCarlos III Health Institute Caba\u00f1as Gonz\u00e1lez, Fernando Congenital REDTResearch Network NRF2 as Node Diseases31/12/2019 SAF2017-90604- REDTNuRCaMeInRed de Receptores Nucleares en C\u00e1ncer, Metabolismo e Inflamaci\u00f3nMinisterio de Ciencia, Innovaci\u00f3n y UniversidadesMu\u00f1oz T 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 108 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians Karolinska Lund Hospital (Skane Univ Hospital) Vilnius UH Santariskiu Klinikos Children's Memorial Health Institute Hannover Medical School Papa Giovanni XXIII Bambino Gesu Ospiedaliera di Podova ISMETT H Sta Mar\u00eda Hospital de Coimbra Centro Hospitalario do Porto EPE (CHP) Hospital Universitario la Paz Paris Necker Bicetre Whilhelmina Children Hospital Saint Luc KCH (King's College Hospital NHS foundation Trust) 2.10 Institutional European Reference Network (ERN) TransplantChild (www.transplantchild.eu) was accredited by the European Commission in 2017 to tackle a low prevalence complex procedure and condition as the paediatric transplantation of kind solid Data shows that more than 5.000 children receive some kind of transplant in Europe each year. Regardless the type of transplant, all transplanted children share a common life-long medical to prevent rejection. The secondary effects malignancy in adolescents, can impact in the quality of life of these patients and their families and eventually could lead to chronic and re-transplantation. Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 109 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansStrategic areas La Paz University Hospital-IdiPAZ, coordinates the resources and existing knowledge from the 18 hospitals from 11 European Member States, involved in the ERN TransplantChild in order generate disseminate the its participation in the activities of the network, ease access to information, dissemination of experience, re- search, exchange of necessary knowledge gaps transplant patient care through society stakeholders, and activities). IdiPAZ Added Value La Paz University Hospital has one of the most highly specialized multidisciplinary transplant teams in Europe and is the only one in Spain accredited to do all kind of paediatric transplants with survival and quality indicators comparable to the hospitals in the world. IdiPAZ-La Paz University Hospital' commitment to this network is significant, not only for the members of the Executive Operating Committee, but the groups and involved in the activities developed by the network: Participation in the screening of publications for the elaboration of the Clinical Practice Guideline in Immunosuppression Management Sharing and participation information of the existing registries development of the first European Registry on Paediatric Transplantation (PETER) Participation as speakers on Paediatric - sharing Value advice all EU providing to patients access to the best available diagnosis and treatment procedures, bearing in mind the quality of life of patients and their families. The members of TransplantChild are working together to improve the life of these children in different ways, but we would like to highlight the following: consultation technology, responding to the most advanced EU standards in terms of security and data protection.. Creation of the first European Registry for paediatric transplanted patients (PETER). This will increase transplantation scientific evidence is scarce. Putting together the effort and cases from all the members of the net - work, will allow developing Clinical Practice Guidelines based even more important in since the network is Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 110 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.11 Internationalization AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIA AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIAArgentina Brazil Canada Chile Ecuador Honduras Mexico United States of America AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIA Bangladesh China India Israel Japan Lebanon Philippines Singapore South Korea Taiwan Thailand Turkey AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIAUganda AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIA Australia AMERICA AMERICA EUROPA AFRICA ASIA OCEANIA EUROPE AFRICA ASIA OCEANIAAustria Belgium Bulgaria Croatia Czech Republic England Estonia Greece Hungary Ireland Italy Netherlands Norway Poland Portugal Romania Scotland Serbia Sweden Switzerland Ukraine United Kingdom WalesScientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 111 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated Clinicians2.12 Comunication Communication and another scientific dissemination activity IdiPAZ was present in different media (journals, magazines, webs, radio, TV., etc.), which contributed to highlight the activity developed by the Institute throughout 2018. A number of our researchers have been interviewed by the mains mass media to broadcast all the knowledge generated in our institute. Besides, the presence of our news in popular platforms such as: Twitter, Instagram and Facebook help us to expand our research work to society via the most commonly used means today. Along these lines, the scientific direction of our institute is extraordinarily active in social networks and the media, which has made our center one of the best known by society. IdiPAZ appear in a total of 216 publications of written press, and in our website, \"Idi- PAZ in the media\" it is included a coverage of 394 digital press mentions of this year: http://www.idipaz.es/PaginaDinamica.aspx?IdPag=650&Lang=ES. Also, eight own news were published at the website of the Insitute (www.idipaz.es), and the Community of Madrid at the website of Consejer\u00eda de Sanidad included six news from IdiPAZ researchers (https://www.comunidad.madrid/actualidad): 2018/09/06- Presentado estudio sobre reinfecciones en pacientes con He- patitis C y VIH en la Comunidad de Madrid . \"El estudio titulado \"Reinfecci\u00f3n por el VHC despu\u00e9s del tratamiento eficaz con antivirales de acci\u00f3n directa frente al VHC en individuos coinfectados por VIH en la 22\u00aa Confe - rencia Internacional sobre el SIDA celebrada en \u00c1msterdam del 23 al 27 de julio de 2018. Han participado 21 hospitales del Servicio Madrile\u00f1o de Salud con experiencia en el tratamiento de pacientes con coinfecci\u00f3n VIH/VHC.\" 2018/08/03- Contamos con la primera unidad de Terapias Avanzadas para tratar el c\u00e1ncer en ni\u00f1os y adolescentes . \"El Hospital Universitario La Paz acaba de poner en marcha la Unidad CRIS de T erapias Avanzadas para C\u00e1ncer Infantil. Esta unidad, pionera en la Comunidad de Madrid, est\u00e1 situada en la octava planta del Hospital Materno-Infantil y viene a completar al servicio de Hemato- Oncolog\u00eda actual con diez nuevas habitaciones: seis para adolescentes y ensayos cl\u00ednicos y cuatro dise\u00f1adas con aislamiento de \u00faltima generaci\u00f3n para pacientes inmunodeprimidos y tratamientos complejos. Estas habitaciones se suman a las 16 ya existentes, cuatro de ellas para trasplante de progenitores hematopoy\u00e9ti - cos. Adem\u00e1s, cuenta con un espacio para ensayos cl\u00ednicos ubicado en los labora - torios de IdiPAZ, del Instituto de Gen\u00e9tica M\u00e9dica y Molecular (INGEMM) y en la Unidad de Ensayos Cl\u00ednicos del hospital, UCICEC. 2018/08/03- IdiPAZ participa en el Programa Healthstart con dos de los doce proyectos seleccionados . \"El Hospital La Paz, a trav\u00e9s del IdiPAZ, partici - par\u00e1 con dos proyectos en el Programa Healthstart organizado por la Fundaci\u00f3n para el Conocimiento madri+d junto con la Plataforma de Innovaci\u00f3n en Tec- nolog\u00edas M\u00e9dicas y Sanitarias (ITEMAS) para impulsar emprendimiento y crea- ci\u00f3n de spin-offs basadas en tecnolog\u00edas sanitarias. Dos de los doce proyectos seleccionados en esta III Edici\u00f3n del Programa est\u00e1n liderados por personal de IdiPAZ.\" 2018/06/26- El presente y el futuro de la tecnolog\u00eda 3D, a debate en el Hospital La Paz . \"La Plataforma de Innovaci\u00f3n del Hospital Universitario La Paz ha celebrado la tercera edici\u00f3n de sus jornadas de innovaci\u00f3n. Bajo el t\u00edtulo \"La Paz 3.D: gesti\u00f3n de la tridimensionalidad\" el objetivo ha sido reunir a los pro- fesionales sanitarios y la industria para debatir sobre el presente y futuro de la tridimensionalidad y su gesti\u00f3n en el sector sanitario contrastando experiencias, conocimiento e innovaci\u00f3n.\" 2018/06/11- El IdiPAZ coordina el Registro Nacional de Pacientes con Frac- tura de Cadera . \"El IdiPAZ (Instituto de Investigaci\u00f3n de La Paz) coordina el Registro Nacional de Fracturas de Cadera (RNFC) por fragilidad en el anciano. El registro cuenta ya con los datos de m\u00e1s de 7.000 pacientes procedentes de 54 hospitales de la mayor\u00eda de las comunidades aut\u00f3nomas de Espa\u00f1a. El princi - pal objetivo de este registro es mejorar la calidad asistencial. Los resultados se comparan con otros centros tanto nacionales como internacionales.\" - 2018/02/12- Se presenta en el Hospital La Paz-IdiPaz un sello dedicado a la investigaci\u00f3n biom\u00e9dica \"La Sociedad Estatal de Correos y Tel\u00e9grafos presenta en La Paz una colecci\u00f3n filat\u00e9lica dedicada a la investigaci\u00f3n biom\u00e9dica en Espa\u00f1a, que incluye un sello de 35 x 24.5 mm. y un matasellos. El acto ha contado con la presencia del presidente de Correos, la Secretaria General T\u00e9cnica del Ministe - rio de Fomento, la directora general de Investigaci\u00f3n de la Consejer\u00eda de Sanidad y el director cient\u00edfico del Instituto de Investigaci\u00f3n de la Paz.\"Scientific Report 1 2 3 4Executive summary 2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and 2.5 Quality Committe 2.10 Institutional Projects 2.11 Internationalization 2.12 Comunication 112 1 2 3 4Introduction 1 2 3 4 Information Groups by Area 1 2 3 4 Associated CliniciansIn the website, the activity has been improving year after year since its implementa - tion in 2011, so at the end of 2018, it exceeded 240,000 visits. News that includes the work of our researchers, data about courses, grants, and other news of interest to the public, are published in the main social networks, whe - re IdiPAZ has @IdipazScience Currently, the number of followers was 851 on Twitter, 76 on Facebook, and 237 on Instragram. Regarding to Scienbtific communication, more than symposiums, workshop, etc. organized Scientific Seminars of IdiPAZ was cer- tified by \"Acreditaci\u00f3n de Actividades de Formaci\u00f3n Continuada de las Profesiones Sanitarias\" by the Comunity of Madrid (07-AFOC-003327.1/2018). In 2018, 20 se- minars were celebrated. Coordinators: Laura Date 12/01/2018 Jaime la polaridad del hepatocito en la respuesta inflamatoria del h\u00edgado 19/01/2018 Carlos Ram\u00edrez La cuarta R de la experimentaci\u00f3n animal 26/01/2018 Anee Miren Andr\u00e9sTrasplante intestinal y rechazo: estudio experimental con c\u00e9lulas troncales mesenquimales derivadas de tejido adiposo para su prevenci\u00f3n y perspectivas cl\u00ednicas futuras en la b\u00fasqueda de la tolerancia inmunol\u00f3gica 09/02/2018Jos\u00e9 Luis L\u00f3pez Send\u00f3n Amesty Medicina regenerativa aplicada a la urolog\u00eda23/02/2018 Daniel Ortega Ponce Hipertermia magn\u00e9tica y su aplicaci\u00f3n en biomedicina 02/03/2018 Silvia Mart\u00edn PuigHypoxia and Cardiovascular System: New Mouse Models to investigate Human Diseases 09/03/2018Elena futuro ya en Cirug\u00eda Pl\u00e1stica, una realidad 06/04/2018Miguel Gonz\u00e1lez, M\u00aa PazHacia el desarrollo de una c\u00f3rnea humanizada por medio de ingenier\u00eda celular 13/04/2018 Francisco Garcia RioCausas y consecuencias del s\u00edndrome de apnea del sue\u00f1o 20/04/2018 Mar\u00eda Luisa Toribio Leucemia linfobl\u00e1stica aguda de c\u00e9lulas T 27/04/2018Miguel \u00c1ngel Rico DazaMedicamento NC1 de terapias avanzadas. Requisitos para su fabricaci\u00f3n y aplicaci\u00f3n en el HUPHM 18/05/2018Santiago Rodr\u00edguez prote\u00f3mica funcional en biomedicina. El caso del h\u00edgado 19/10/2018 Rafael Correa RochaTerapia celular con c\u00e9lulas Treg obtenidas de tejido t\u00edmico (thyTreg) para prevenir el rechazo en ni\u00f1os trasplantados de coraz\u00f3n. Un nuevo paradigma en el tratamiento de enfermedades inmunol\u00f3gicas 26/10/2018 Arancha Llama PalaciosEstudio de las bacterias periodontales mediante herramientas prote\u00f3micas 23/11/2018 Jes\u00fas Mingorance CruzAn\u00e1lisis cuantitativo de colonizaci\u00f3n multirresistentes 30/11/2018 Almudena Val BlascoRole of nucleotide-binding oligomerization domain type 1 (nod1) in human and experimental heart failure 21/12/2018 Laetitia PereiraPapel de nuevos mediadores reguladores del calcio intracelular en la enfermedad metab\u00f3licaScientific Report Hospital Universitario La Paz Fundaci\u00f3n para la "}